Thiazolylpiperidine derivatives, processes for the preparation thereof, pharmaceutical compositions comprising same, and applications thereof in the treatment of hypertriglyceridaemia, hypercholesterolaemia and dyslipidaemia

5

10

15

20

25

30

[0001] The invention relates to compounds that are inhibitors of microsomal triglyceride transfer protein (MTP), to pharmaceutical compositions comprising same, and to the use thereof in medicine.

[0002] MTP (microsomal triglyceride transfer protein) is a transfer protein located in the reticulum of hepatocytes and enterocytes, which catalyses the assembly of biomolecules that transport triglycerides, the apo B lipoproteins.

[0003] The term apo B more particularly denotes apoprotein 48 of the intestine and apoprotein 100 of the liver.

[0004] Mutations in MTP or in the B apoproteins are reflected in man by very low levels or even an absence of apo B lipoproteins. The lipoproteins containing apo B (chylomicrons, very low density lipoproteins) and their metabolic residues (chylomicron remnants, low density lipoproteins) are recognized as being a major risk factor in the development of atherosclerosis, a major cause of death in industrialized countries. It is observed that, in individuals who are heterozygous for these mutations, levels reduced on average by a half are associated with a low cardiovascular risk (C.J. Glueck, P.S. Gartside, M.J. Mellies, P.M. Steiner, *Trans. Assoc. Am. Physicians*, 90, 184 (1977)). This suggests that modulation of the secretions of triglyceride-rich lipoproteins by means of MTP antagonists and/or of secretion of apo B might be useful in the treatment of atherosclerosis and more broadly of pathologies characterized by an increase in apo B lipoproteins.

[0005] Molecules that inhibit MTP and/or the secretion of apo B might thus be useful for the treatment of hypertriglyceridaemia, hypercholesterolaemia and

dyslipidaemia associated with diabetes, and also for the prevention of and treating obesity.

[0006] It has now been discovered that certain compounds of thiazolylpiperidine structure have inhibitory properties towards MTP and/or apoB secretion.

[0007] As a result of this activity, these compounds have an entirely advantageous possible application in the treatment of hypertriglyceridaemia, hypercholesterolaemia and dyslipidaemia associated with diabetes, and also with the prevention and treatment of obesity.

[0008] Thus, the present invention relates firstly to compounds of thia-zolylpiperidine structure of the general formula (I):

$$R^{1}$$
 G R^{5} R^{4} R^{5}

15

10

in which:

A represents a radical chosen from radicals a1 and a2 below:


$$\begin{array}{cccc}
 & & & & R^2 \\
 & & & & N \\
 & & & & R^3
\end{array}$$
a1 ; a2

10

15

20

 G represents a divalent bond or radical chosen from groups g1, g2 and g3 below:



- R¹ is chosen from hydrogen and an alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkylcarbonyl or alkoxycarbonyl radical;
- R², R^{2'} and R³, which may be identical or different, are chosen, independently of each other, from a hydrogen atom, an alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl radical and a radical -NRR'; or
- R² and R³ together form, with the nitrogen atom that bears them, a heterocycle;
- R⁴ and R⁵, which may be identical or different, are chosen, independently of each other, from a hydrogen atom, an alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl radical and a radical -NRR':
- R and R', which may be identical or different, represent, independently
 of each other, a hydrogen atom or a radical chosen from alkyl, alkenyl,
 alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl;
 or together form, with the nitrogen atom that bears them, a heterocycle,
 or together form the double bond of an alken-1-yl radical;
- · Y represents an oxygen or sulfur atom; and
- Z represents -NH- or an oxygen atom;
- the possible geometrical and/or optical isomers, epimers and various tautomeric forms, and possible oxidized forms, especially amine oxides, thereof, the solvates and the hydrates of these compounds;

and also the possible pharmaceutically acceptable salts thereof with an acid or a base, or the pharmaceutically acceptable prodrugs of these compounds.

[0009] The definitions that follow specify the natures of the various groups and radicals defined above. Unless otherwise mentioned, these definitions apply for all the terms of the present invention thus explained.

[0010] The term "halogen atom" denotes a fluorine, chlorine, bromine or iodine atom.

10

15

20

25

The term "alkyl" denotes a linear or branched alkyl radical containing from 1 to 12 carbon atoms, optionally substituted by one or more chemical species, which may be identical or different, chosen from a halogen atom, an oxo, thioxo, hydroxyl, thiol, -NRR' (where R and R', which may be identical or different, are as defined above), cyano, nitro or carboxyl group, and an alkoxy, alkenyloxy, alkynyloxy, alkylthio, alkyldisulfanyl (alkyl-S-S-), alkylsulfinyl (alkyl-S(=O)-), alkylsulfonyl (alkyl-S(=O)₂-), alkenylthio, alkynylthio, alkylcarbonyl, alkoxycarbonyl, alkylcarbonylamino, alkoxycarbonylamino, arylcarbonyl, arylcarbonylamino, (di)alkylaminocarbonyl, cycloalkyl, cycloalkoxy, cycloalkylthio, heterocycloalkyl, heterocycloalkoxy, heterocycloalkylthio, aryl, aryloxy, arylthio, heteroaryl, heteroarylcarbonyl, heteroaryloxy or heteroarylthio radical.

[0012] Examples of alkyl radicals, which may be optionally substituted as indicated above, are methyl, ethyl, propyl, isopropyl, butyl, isobutyl, *tert*-butyl, pentyl, isopentyl, neopentyl, 2-methylbutyl, 1-ethylpropyl, hexyl, isohexyl, neohexyl, 1-methylpentyl, 3-methylpentyl, 1,1-dimethylbutyl, 1,3-dimethylbutyl, 1-ethylbutyl, 1-methyl-1-ethylpropyl, heptyl, 1-methylhexyl, 1-propylbutyl, 4,4-dimethylpentyl, octyl, 1-methylheptyl, 2-methylhexyl, 5,5-dimethylhexyl, nonyl, decyl, 1-methylnonyl, 3,7-dimethyloctyl and 7,7-dimethyloctyl.

10

15

20

25

30

[0013] The term "alkenyl" denotes a linear or branched alkyl radical comprising at least one unsaturation in double bond form and containing from 2 to 12 carbon atoms, optionally substituted by one or more chemical species, which may be identical or different, chosen from a halogen atom, an oxo, thioxo, hydroxyl, thiol, -NRR' (in which R and R', which may be identical or different, are as defined above), cyano, nitro or carboxyl group, and an alkoxy, alkenyloxy, alkynyloxy, alkylthio, alkyldisulfanyl (alkyl-S-S-), alkylsulfinyl (alkyl-S(=O)-), alkylsulfonyl (alkyl-S(=O)₂-), alkenylthio, alkynylthio, alkylcarbonyl, alkoxycarbonyl, alkylcarbonyl, and an alkoxycarbonyl, alkylcarbonyl, alkoxycarbonyl, alkylcarbonyl, alkoxycarbonyl, alkylcarbonyl, alkoxycarbonyl, alkylcarbonyl, arylcarbonyl, arylcarbonyl, heterocycloalkyl, cycloalkoxy, cycloalkylthio, heterocycloalkyl, heterocycloalkyl, aryloxy, arylthio, heteroaryl, heteroarylcarbonyl, heteroaryloxy or heteroarylthio radical.

[0014] Examples of alkenyl radicals, which may be optionally substituted as indicated above, are ethylenyl, propenyl, propadienyl, butenyl, butadienyl, pentenyl, pentadienyl, hexadienyl, heptenyl, heptadienyl, octenyl, octadienyl, nonenyl, nonadienyl, decenyl and decadienyl, and also the branched isomers thereof, the absence of indication of the position of the double bond(s) being necessarily understood as meaning that no limitation is placed on the double bond(s). For example, the "pentenyl" radical includes, without preference, the pent-1-en-1-yl, pent-2-en-1-yl and pent-3-en-1-yl radicals, but also the pent-1-en-2-yl, pent-2-en-2-yl and pent-3-en-2-yl radicals, as well as the pent-1-en-3-yl, pent-2-en-3-yl and pent-3-en-3-yl radicals.

[0015] The term "alkynyl" denotes a linear or branched alkyl radical comprising at least one unsaturation in triple bond form and containing from 2 to 12 carbon atoms, optionally substituted by one or more chemical species, which may be identical or different, chosen from a halogen atom, an oxo, thioxo, hydroxyl, thiol, -NRR' (in which R and R', which may be identical or different, are as defined above), cyano, nitro or carboxyl group, and an alkoxy, alkenyloxy, alkylyloxy, alkylthio, alkyldisulfanyl (alkyl-S-S-), alkylsulfinyl (alkyl-S(=O)-), alkylsulfonyl

10

15

20

25

30

(alkyl-S(=O)₂-), alkenylthio, alkynylthio, alkylcarbonyl, alkoxycarbonyl, alkylcarbonylamino, alkoxycarbonylamino, arylcarbonyl, arylcarbonylamino, (di)alkylaminocarbonyl, cycloalkyl, cycloalkoxy, cycloalkylthio, heterocycloalkyl, heterocycloalkylthio, aryl, aryloxy, arylthio, heteroaryl, heteroarylcarbonyl, heteroaryloxy or heteroarylthio radical.

[0016] Examples of alkynyl radicals, which may be optionally substituted as indicated above, are ethynyl, propynyl, propadiynyl, butynyl, butadiynyl, pentynyl, pentadiynyl, hexynyl, hexadiynyl, heptynyl, heptadiynyl, octynyl, octadiynyl, nonynyl, nonadiynyl, decynyl and decadiynyl, and also the branched isomers thereof, the absence of indication of the position of the double bond(s) being necessarily understood as meaning that no limitation is placed on the double bond(s). For example, the "pentynyl" radical includes, without preference, the pent-1-yn-1-yl, pent-2-yn-1-yl and pent-3-yn-1-yl radicals, but also the pent-1-yn-2-yl, pent-2-yn-2-yl and pent-3-yn-2-yl radicals, as well as the pent-1-yn-3-yl, pent-2-yn-3-yl and pent-3-yn-3-yl radicals.

The term "cycloalkyl" denotes a monocyclic, bicyclic or tricyclic, [0017] bridged or unbridged cycloalkyl radical containing from 3 to 13 carbon atoms, optionally comprising one or more double bonds, also including spirane compounds, and optionally substituted by one or more chemical species, which may be identical or different, chosen from a halogen atom, an oxo, thioxo, hydroxyl, thiol, -NRR' (in which R and R', which may be identical or different, are as defined above), cyano, nitro or carboxyl group, and an alkyl, especially substituted by one or more halogen atoms, in particular perhaloalkyl, for instance trifluoromethyl, alkynyl, alkoxy, alkenyloxy, alkynyloxy, alkylthio, alkyldisulfanyl alkenyl. (alkyl-S-S-), alkylsulfinyl (alkyl-S(=O)-), alkylsulfonyl (alkyl-S(=O)₂-), alkenylthio, alkynylthio, alkylcarbonyl, alkoxycarbonyl, alkylcarbonylamino, alkoxycarbonylamino. arylcarbonyl, arylcarbonylamino, (di)alkylaminocarbonyl, cycloalkoxy, cycloalkylthio, heterocycloalkyl, heterocycloalkoxy, heterocycloalkylthio, aryl, aryloxy, arylthio, heteroaryl, heteroarylcarbonyl, heteroaryloxy or heteroarylthio radical.

[0018] Examples of cycloalkyl groups, which are optionally substituted as indicated above, are especially cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl and cyclodecyl, adamantyl, diamantyl, norbornyl and bornyl groups.

The term "heterocycloalkyl" denotes a monocyclic, bicyclic or tricyclic [0019] radical containing a total of from 3 to 13 atoms, among which 1, 2, 3 or 4 are chosen, independently of each other, from nitrogen, oxygen and sulfur, the other atoms being carbon atoms, the said heterocyclic radical also optionally comprising 1, 2, 3 or 4 double bonds, also including spirane compounds, and being optionally substituted by one or more chemical species, which may be identical or different, chosen from a halogen atom, an oxo, thioxo, hydroxyl, thiol, -NRR' (in which R and R', which may be identical or different, are as defined above), cyano, nitro or carboxyl group, and an alkyl, especially substituted by one or more halogen atoms, in particular perhaloalkyl, for instance trifluoromethyl, alkenyl, alkynyl, alkoxy, alkenyloxy, alkynyloxy, alkylthio, alkyldisulfanyl (alkyl-S-S-), alkylsulfinyl (alkyl-S(=O)-), alkylsulfonyl (alkyl-S(=O)₂-), alkenylthio, alkynylthio, alkylcarbonyl, alkoxycarbonyl, alkylcarbonylamino, alkoxycarbonylamino, arylcarbonyl, arylcarbonylamino, (di)alkylaminocarbonyl, cycloalkyl, cycloalkoxy, cycloalkylthio, heterocycloalkyl, heterocycloalkoxy, heterocycloalkylthio, aryl, aryloxy, arylthio, heteroaryl, heteroarylcarbonyl, heteroaryloxy or heteroarylthio radical.

25

30

10

15

20

[0020] In particular, saturated or partially unsaturated, monocyclic heterocycles of 5 to 8 atoms are saturated, or partially unsaturated, derivatives of the heteroaryls defined later. More particularly, among the heterocycloalkyl radicals that may be mentioned are morpholino, morpholinyl, piperidyl, thiazolidinyl, oxazolidinyl, tetrahydrothienyl, tetrahydrofuryl, tetrahydropyranyl, pyrrolidinyl, isoxazolidinyl, imidazolidinyl and pyrazolidinyl radicals.

15

20

25

30

[0021] The term "aryl" denotes a monocyclic, bicyclic or tricyclic aryl radical containing from 6 to 14 carbon atoms, optionally substituted by one or more chemical species, which may be identical or different, chosen from a halogen atom, an oxo, thioxo, hydroxyl, thiol, -NRR' (in which R and R', which may be identical or different, are as defined above), cyano, nitro or carboxyl group, and an alkyl, especially substituted by one or more halogen atoms, in particular perhaloalkyl, for instance trifluoromethyl, alkenyl, alkynyl, alkoxy, alkenyloxy, alkynyloxy, alkylthio, alkyldisulfanyl (alkyl-S-S-), alkylsulfinyl (alkyl-S(=O)-), alkylsulfonyl $(alkyl-S(=O)_2-),$ alkenylthio, alkynylthio, а phosphoric acid derivative [(alkyl-O)₂-P-O-alkyl], alkylcarbonyl, alkoxycarbonyl, alkylcarbonylamino, alkoxycarbonylamino, arylcarbonyl, arylcarbonylamino, (di)alkylaminocarbonyl, cycloalkyl, cycloalkoxy, cycloalkylthio, heterocycloalkyl, heterocycloalkoxy, heterocycloalkylthio, aryl, aryloxy, arylthio, heteroaryl, heteroarylcarbonyl, heteroaryloxy or heteroarylthio radical.

[0022] Aryl radicals that may be mentioned, in a non-limiting manner, include phenyl, naphthyl, anthryl and phenanthryl radicals.

The term "heteroaryl" denotes a monocyclic, bicyclic or tricyclic aromatic radical containing a total of from 3 to 13 atoms, among which 1, 2, 3 or 4 are chosen, independently of each other, from nitrogen, oxygen and sulfur, optionally in oxidized form (in the case of nitrogen and sulfur), the other atoms being carbon atoms, the said heteroaryl radical being optionally substituted by one or more chemical species, which may be identical or different, chosen from a halogen atom, an oxo, thioxo, hydroxyl, thiol, -NRR' (in which R and R', which may be identical or different, are as defined above), cyano, nitro or carboxyl group, and an alkyl, especially substituted by one or more halogen atoms, in particular perhaloalkyl, for instance trifluoromethyl, alkenyl, alkynyl, alkoxy, alkenyloxy, alkynyloxy, alkylthio, alkyldisulfanyl (alkyl-S-S-), alkylsulfinyl (alkyl-S(=O)-), alkylsulfonyl (alkyl-S(=O)-), alkenylthio, alkynylthio, alkylcarbonyl, alkoxycarbonyl, alkyl-

carbonylamino, alkoxycarbonylamino, arylcarbonyl, arylcarbonylamino, (di)alkylaminocarbonyl, cycloalkyl, cycloalkoxy, cycloalkylthio, heterocycloalkyl, heterocycloalkylthio, aryl, aryloxy, arylthio, heteroaryl, heteroarylcarbonyl, heteroaryloxy or heteroarylthio radical.

5

[0024] Preferably, at least one of the monocycles constituting the heterocycle contains from 1 to 4 endocyclic hetero atoms and more preferably from 1 to 4 endocyclic hetero atoms. According to the invention, the heterocyclic polycyclic nucleus consists of one or more monocycles each containing from 5 to 8 atoms included in the ring.

10

15

[0025] Examples of heteroaryl radicals, optionally substituted as has just been described, are radicals derived from heteroaromatic compounds, such as pyridine, furan, thiophene, pyrrole, imidazole, thiazole, isothiazole, isoxazole, furazane, pyridazine, pyrimidine, pyrazine, thiazines, oxazole, pyrazole, oxadiazole, triazole and thiadiazole. Among the preferred heteroaryls that may be mentioned are pyridyls, pyrimidinyls, triazolyls, thiadiazolyls, oxazolyls, thiazolyls and thienyls.

20

[0026] Examples of bicyclic heteroaryl radicals in which each monocycle contains from 5 to 8 endocyclic atoms are derived from aromatic compounds chosen from indolizine, indole, isoindole, benzofuran, benzothiophene, indazole, benzimidazole, benzothiazole, benzofurazane, benzothiofurazane, purine, quinoline, isoquinoline, cinnoline, phthalazine, quinazoline, quinoxaline, naphthyridines, pyrazolotriazines, pyrazolopyrimidine and pteridine.

25

[0027] Among the heteroaryls defined above, quinolyl, pyridyl, benzotriazolyl, triazolyl, acridyl, phenazinyl and carbazolyl radicals are preferred.

30

[0028] When the radicals R² and R³ form, together with the nitrogen atom that bears them, a heterocycle, the said heterocycle is a monocycle, bicycle or

tricycle containing a total of from 3 to 13 atoms including the nitrogen atom, among which 1, 2, 3 or 4 are chosen, independently of each other, from nitrogen, oxygen and sulfur, the other atoms being carbon atoms, the said heterocycle also optionally comprising 1, 2, 3 or 4 double bonds, also including spirane compounds, and being optionally substituted by one or more chemical species, which may be identical or different, chosen from a halogen atom, an oxo, thioxo, hydroxyl, thiol, -NRR' (in which R and R', which may be identical or different, are as defined above), cyano, nitro or carboxyl group, and an alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkyldisulfanyl (alkyl-S-S-), alkenyloxy, alkynyloxy, alkylsulfinyl (alkyl-S(=O)-), alkylsulfonyl (alkyl-S(=O)₂-), alkenylthio, alkynylthio, alkylcarbonyl, alkoxycarbonyl, alkylcarbonylamino, alkoxycarbonylamino, arylcarbonylamino, (di)alkylaminocarbonyl, cycloalkyl, cycloalkoxy, cycloalkylthio, heterocycloalkyl, heterocycloalkoxy, heterocycloalkylthio, aryl, aryloxy, arylthio, heteroaryl, heteroaryloxy or heteroarylthio radical.

15

20

25

30

10

5

[0029] For the compounds of the formula (I) presented above, the term "geometrical isomer" means a cis/trans or E/Z isomerism. More particularly, the possible double bond(s) present in the various substituents of the compounds of the general formula (I) can be of E or Z configuration. These pure or impure geometrical isomers, alone or as a mixture, form an integral part of the compounds of the formula (I).

[0030] The term "optical isomer" includes all the isomeric forms, alone or as mixtures, resulting from the presence of one or more axes and/or centres of symmetry in the molecule, and resulting in the rotation of a beam of polarized light. The term "optical isomer" more particularly includes enantiomers and disastero-isomers, in pure form or as a mixture.

[0031] The acids capable of forming pharmaceutically acceptable salts with the compounds of the formula (I) above are organic or mineral acids. Non-limiting examples that may be mentioned include hydrochloric acid, hydrobromic acid,

phosphoric acid, sulfuric acid, tartaric acid, citric acid, maleic acid, acetic acid, fumaric acid, alkanesulfonic acid, naphthalenesulfonic acid, para-toluenesulfonic acid, bis-trifluoroacetic acid and camphoric acid.

[0032] The bases capable of forming pharmaceutically acceptable salts with the compounds of the formula (I) above are mineral or organic bases. Among these bases, non-limiting examples that may be mentioned include sodium hydroxide, potassium hydroxide, ammonia, diethylamine, triethylamine, ethanolamine, diethanolamine, piperidine, piperazine, morpholine, basic amino acids, such as arginine and lysine, osamines, for example meglumine, and amino alcohols, such as 3-aminobutanol and 2-aminobutanol.

[0033] The invention especially covers the pharmaceutically acceptable salts, as indicated above, but also salts allowing a suitable separation or crystallization of the compounds of the formula (I), such as the salts obtained with chiral amines.

[0034] The compounds of the formula (I) above also comprise the prodrugs of these compounds.

20

5

10

15

[0035] The term "prodrugs" means compounds which, once administered to the patient, are chemically and/or biologically converted by the living body into compounds of the formula (I).

25 [0036] Among the compounds of the formula (I) according to the invention that are preferred are those for which the radical R⁵ represents hydrogen, the possible geometrical and/or optical isomers, epimers and various tautomeric forms, and optional oxidized forms, especially amine oxides, thereof, and the sol-

vates and hydrates of these compounds;

and also the possible pharmaceutically acceptable salts thereof with an acid or a base, or the pharmaceutically acceptable prodrugs of these compounds.

20

25

30

[0037] Preference is also given to the compounds of the formula (I) according to the invention for which the radical R⁴ represents hydrogen,

the possible geometrical and/or optical isomers, epimers and various tautomeric forms, and optional oxidized forms, especially amine oxides, thereof, and the solvates and hydrates of these compounds;

and also the possible pharmaceutically acceptable salts thereof with an acid or a base, or the pharmaceutically acceptable prodrugs of these compounds.

10 [0038] Another preferred group of compounds according to the present invention consists of compounds of the formula (I) in which the thiazolyl radical is branched in position 3 or in position 4 of the piperidine nucleus, preferably in position 4 of the piperidine nucleus.

15 [0039] Another preferred group of compounds according to the present invention consists of compounds of the general formula (I) in which G represents the radical g1, preferably in which Y represents an oxygen atom,

the possible geometrical and/or optical isomers, epimers and various tautomeric forms, and optional oxidized forms, especially amine oxides, thereof, and the solvates and hydrates of these compounds;

and also the possible pharmaceutically acceptable salts thereof with an acid or a base, or the pharmaceutically acceptable prodrugs of these compounds.

[0040] Another preferred group of compounds according to the present invention consists of compounds of the general formula (I) in which the radical R⁴ represents hydrogen, the radical R⁵ represents hydrogen, the thiazolyl radical is branched in position 4 of the piperidine nucleus, and G represents the radical g1 in which Y represents an oxygen atom,

the possible geometrical and/or optical isomers, epimers and various tautomeric forms, and optional oxidized forms, especially amine oxides, thereof, and the solvates and hydrates of these compounds;

and also the possible pharmaceutically acceptable salts thereof with an acid or a base, or the pharmaceutically acceptable prodrugs of these compounds.

[0041] Another preferred group of compounds of the invention consists of compounds of the general formula (I) in which R¹ represents an aryl radical, especially phenyl, substituted by one or more aryl and/or alkyl radicals. The compounds of the general formula (I) in which R¹ represents a biphenyl radical, optionally substituted by one or more alkyl radicals, preferably methyl, ethyl or propyl, and/or with a perhaloalkyl or perhaloalkoxy radical, are most particularly preferred. The compounds of the general formula (I) in which R¹ represents a substituted biphenyl radical, for example a trifluoromethylbiphenyl or methyltrifluoromethoxy-biphenyl radical, are more particular preferred.

[0042] Among the compounds of the general formula (I), another preferred group of compounds consists of those for which A represents a2, the other substituents having the same definitions as those given above, the possible geometrical and/or optical isomers, epimers and various tautomeric forms, and optional oxidized forms, especially amine oxides, thereof, and the solvates and hydrates of these compounds; and also the possible pharmaceutically acceptable salts thereof with an acid or a

[0043] Among the above compounds, the ones most particularly preferred

base, or the pharmaceutically acceptable prodrugs of these compounds.

are those for which a2 represents a radical of the formula a2' below:

$$R^6$$
 R^7
 R^3

25

10

15

20

in which R⁶ and R⁷, which may be identical or different, and independently of each other, have the same definitions as the radicals R² and R³ defined above, the other substituents having the same definitions as those given above,

10

15

20

the possible geometrical and/or optical isomers, epimers and various tautomeric forms, and optional oxidized forms, especially amine oxides, thereof, and the solvates and hydrates of these compounds;

and also the possible pharmaceutically acceptable salts thereof with an acid or a base, or the pharmaceutically acceptable prodrugs of these compounds.

[0044] A preferred sub-group of compounds consists of compounds of the general formula (I) in which G represents the radical g1, with Y representing an oxygen atom, R¹ represents a biphenyl radical, optionally substituted by one or more alkyl radicals, preferably methyl, ethyl or propyl, and/or a trifluoromethyl or trifluoromethoxy radical, and A represents a2,

the other substituents being as defined above,

the possible geometrical and/or optical isomers, epimers and various tautomeric forms, and optional oxidized forms, especially amine oxides, thereof, and the solvates and hydrates of these compounds;

and also the possible pharmaceutically acceptable salts thereof with an acid or a base, or the pharmaceutically acceptable prodrugs of these compounds.

In this sub-group, the compounds that are more particularly preferred are those of the general formula (I) in which G represents the radical g1, with Y representing an oxygen atom, R¹ represents a biphenyl radical, optionally substituted by one or more alkyl radicals, preferably methyl, ethyl or propyl, and/or a trifluoromethyl or trifluoromethoxy radical, and A represents a2' as defined above, the other substituents being as defined above,

the possible geometrical and/or optical isomers, epimers and various tautomeric forms, and optional oxidized forms, especially amine oxides, thereof, and the solvates and hydrates of these compounds;

and also the possible pharmaceutically acceptable salts thereof with an acid or a base, or the pharmaceutically acceptable prodrugs of these compounds.

10

15

20

25

[0046] Particularly preferred examples of compounds according to the present invention are chosen from:

- N-ethyl-N-(1-methyl-2-oxo-2-phenylethyl) 2-[1-(4'-trifluoromethyl-biphenyl-2-carbonyl)piperid-4-yl]thiazole-4-carbamate;
- N-ethyl-N-(1-methyl-2-oxo-2-pyrid-3-ylethyl) 2-[1-(4'-trifluoromethyl-biphenyl-2-carbonyl)piperid-4-yl]thiazole-4-carbamate;
- N-ethyl-N-(1-methyl-2-oxo-2-phenylethyl) 2-[1-(6-methyl-4'-trifluoro-methoxybiphenyl-2-carbonyl)piperid-4-yl]thiazole-4-carbamte;
- N-ethyl-N-(1-methyl-2-oxo-2-pyrid-2-ylethyl) 2-[1-(6-methyl-4'-trifluoromethoxybiphenyl-2-carbonyl)piperid-4-yl]thiazole-4-carbamate.
- N-[cyano(4-fluorophenyl)methyl]-N-phenyl-2-[1-(4'-trifluoromethyl-biphenyl-2-carbonyl)piperid-4-yl]thiazole-4-carboxamide;
- N-(α-cyanobenzyl)-N-ethyl-2-[1-(4'-trifluoromethylbiphenyl-2-carbonyl)piperid-4-yl]thiazole-4-carboxamide;
- 2-{1-{4'-(trifluoromethyl)-1,1'-biphenyl-2-yl]carboxyl}piperid-4-yl}-1,3-thiazole-4-carboxylic acid
- 1-(4-{4-(3-hydroxypiperid-1-yl)methanoyl]thiazol-2-yl}piperid-1-yl)-1-(4'-trifluoromethylbiphenyl-2-yl)methanone
- N-methyl-N-(1-methyl-2-oxo-2-phenethyl)-2-[1-(4'-trifluoromethylbi-phenyl-2-carbonyl)piperid-4-yl]thiazole-4-carboxamide
- N-methyl-N-(1-methyl-2-oxo-2(*S*)-phenethyl)-2-[1-(4'-trifluoromethyl-biphenyl-2-carbonyl)piperid-4-yl]thiazole-4-carboxamide
- N-(7-oxo-7H-thieno[3,2-b]pyran-6-yl)-2-[1-(4'-trifluoromethylbiphenyl-2-carbonyl)piperid-4-yl]thiazole-4-carboxamide
- N-(2-methyl-4-oxo-4H-chromen-3-yl)-2-[1-(6-methyl-4'-trifluoro-methoxybiphenyl-2-carbonyl)piperid-4-yl]thiazole-4-carboxamide
- N-(α-cyanobenzyl)-N-isopropyl-2-[1-(4'-trifluoromethylbiphenyl-2-carbonyl)piperid-4-yl]thiazole-4-carboxamide; and
- N-[1-cyano-1-(pyrid-4-yl)methyl)-N-isopropyl-2-[1-(4'-trifluoromethyl-30 biphenyl-2-carbonyl)piperid-4-yl]thiazole-4-carboxamide;

10

15

20

the optical isomers thereof, oxidized forms, solvates and hydrates of these compounds;

and also the possible pharmaceutically acceptable salts thereof with an acid, or the pharmaceutically acceptable prodrugs of these compounds.

[0047] The compounds of the present invention can be prepared from the compounds of the formula (II):

in which T represents a labile protecting group, for example *tert*-butoxy-carbonyl (BOC), and R⁵ is as defined above,

which is reacted with ethyl R⁴-bromopyruvate, generally in equimolar proportions, in a polar solvent, for example dimethylformamide, in the presence of an excess of base, preferably an organic base, such as triethylamine, at a suitable temperature, for example at room temperature, for a time ranging from 1 to 40 hours and preferably between 4 and 18 hours,

so as to form the thiazolyl ring and give the compound of the formula (III):

in which T, R⁴ and R⁵ are as defined above,

which compound of the formula (III) is then saponified with a base, of alkali metal or alkaline-earth metal hydroxide type, for example sodium hydroxide, in polar medium, for instance tetrahydrofuran and/or water, especially a 2:1 tetrahydrofuran/water mixture, at room temperature, for a time ranging from 1 to 12 hours, so as to form the salt of the formula (IV):

$$T-N$$
 S
 R^4
 (IV)

in which T, R⁴ and R⁵ are as defined above, and M⁺ represents the alkali metal or alkaline-earth metal cation derived from the base that is useful for the saponification reaction,

which compound of the formula (IV) is next hydrolysed and then/or esterified to a compound of the formula (V1):

in which R⁴, R⁵, a1 and T are as defined above,

or converted into the corresponding amide of the formula (V2):

10

15

5

in which R², R³, R⁴, R⁵ and T are as defined above,

via the action of an amine of the formula HNR²R³, generally in equimolar proportions, in the presence of a base, preferably an organic base, such as disopropylethylamine (DIPEA), and a catalyst, for example O-benzotriazol-1-yl-N,N,N',N'-tetraethyluronium hexafluorophosphate (HBTU), in a polar aprotic solvent, such as dimethylformamide, at room temperature, for a time that can range from 1 to 50 hours and generally from 4 to 20 hours,

10

15

20

the compounds of the formulae (V1) and (V2) together forming the compound of the formula (V):

$$T-N$$
 S
 R^4
 (V)

in which R⁴, R⁵, A and T are as defined above,

which compound of the formula (V) is then used in a reaction for deprotection of the amine function of the piperidine ring, via the action of an organic or mineral acid, for example hydrochloric acid or trifluoroacetic acid, in dichloromethane (DCM) or dioxane medium, at room temperature, for a time ranging from a few minutes to a few hours, generally ranging from five minutes to 12 hours, to give the compound of the formula (VI):

which is a special case of the compounds of the formula (I), in which R¹ represents hydrogen, G represents a bond, A, R⁴ and R⁵ being as defined above,

which is then subjected to the action of a compound chosen from:

in which X represents a halogen atom, preferably chlorine, R¹, Y and Z being as defined above,

in the presence of a base, preferably an organic base, such as disopropylethylamine (DIPEA), and a catalyst, for example O-benzotriazol-1-yl-N,N,N',N'-tetraethyluronium hexafluorophosphate (HBTU), in a polar aprotic solvent, such as dimethylformamide, at room temperature, for a time that can range from 1 to 50 hours and generally from 4 to 20 hours,

to give the compound of the formula (I) as defined above.

5 **[0048]** According to one variant, the compounds of the formula (I) can also be prepared by reacting a compound of the formula chosen from:

$$R^1$$
-OH ; R^1 OH ; R^1 OH and R^1 -S-OH

in which R1, Y and Z are as defined above, with a compound of the formula (VII):

10

15

20

in which R⁵ is as defined above,

in the presence of an acyl chloride, such as oxalyl chloride, in basic medium, for example triethylamine, and in an apolar aprotic solvent, for example dichloromethane, at room temperature, for a time ranging from 1 to 50 hours and generally from 4 to 20 hours,

to give the compound of the formula (VIII):

$$R^{1/3} = N + NH_2$$
 (VIII),

in which G, R¹ and R⁵ are as defined above,

which is then converted into the corresponding thioamide of the formula (IX) via the action of Lawesson's reagent, in a polar solvent, for example dimethyl ether, at a temperature of about 50°C, for a time generally of about 2.5 hours:

15

$$R^{1}$$
 $G-N$ NH_{2} $(IX),$

in which G, R¹ and R⁵ are as defined above,

the thiazole ring then being formed in a manner similar to that presented above for the formation of the compound of the formula (III), via the action of ethyl R⁴-bromopyruvate, to give the compound of the formula (X):

$$G$$
 R^1
 G
 R^5
 R^5
 R^4
 R^5
 R^5
 R^4
 R^5
 R^5

in which G, R¹, R⁴ and R⁵ are as defined above,

which compound of the formula (X) is then saponified, in a manner similar to that for the formation of the compound of the formula (IV), to give the acid of the formula (I_{OH}):

which is a special case of the compound of the formula (I) in which A represents $-O-R^{2'}$, $R^{2'}$ representing a hydrogen atom,

which compound of the formula (I_{OH}) is then optionally used in an esterification reaction, or subjected to the action of an amine of the formula HNR²R³, in order to give the compounds of the formula (I) in which A represents, respectively, a1, with R^{2'} other than hydrogen, and a2.

[0049] In the processes described above, it should be understood that the operating conditions can vary substantially as a function of the different substituents G, R¹, R², R^{2'}, R³, R⁴, R⁵, R⁶ and R⁷ present in the compounds of the formula (I) that it is desired to prepare. Such variations and adaptations are readily accessible to a person skilled in the art, for example from scientific reviews, the patent literature, Chemical Abstracts, and computer databases, including the Internet.

[0050] For the compounds of the general formula (I) for which A represents a2', the intermediate amine H-a2' below:

$$R^6$$
 R^7 R^3

10

15

5

in which R³, R⁶ and R⁷ are as defined above,

which will be reacted with the compounds of the formulae (V2) and (I_{OH}) defined above,

can advantageously be prepared according to one of the synthetic routes presented in the following scheme, and in which the various substituents are as defined in the present invention:

[0051] The present invention also relates to pharmaceutical compositions comprising an effective pharmaceutical amount of a compound of the formula (I), as defined above, in combination with one or more pharmaceutically acceptable vehicles.

5

[0052] These compositions can be administered orally in the form of immediate-release or controlled-release tablets, gel capsules or granules, intravenously in the form of an injectable solution, transdermally in the form of an adhesive transdermal device, or locally in the form of a solution, cream or gel.

10

[0053] A solid composition for oral administration is prepared by adding to the active principle a filler and, where appropriate, a binder, a disintegrating agent, a lubricant, a colorant or a flavour enhancer, and by forming the mixture into a tablet, a coated tablet, a granule, a powder or a capsule.

15

[0054] Examples of fillers include lactose, corn starch, sucrose, glucose, sorbitol, crystalline cellulose and silicon dioxide, and examples of binders include poly(vinyl alcohol), poly(vinyl ether), ethylcellulose, methylcellulose, acacia, gum tragacanth, gelatin, Shellac, hydroxypropylcellulose, hydroxypropylmethylcellulose, calcium citrate, dextrin and pectin.

20

[0055] Examples of lubricants include magnesium stearate, talc, polyethylene glycol, silica and hardened plant oils. The colorant can be any colorant permitted for use in medicaments.

25

[0056] Examples of flavour enhancers include cocoa powder, mint in herb form, aromatic powder, mint in oil form, borneol and cinnamon powder. It should be understood that the tablet or granule may be suitably coated with sugar, gelatin or the like.

[0057] An injectable form comprising the compound of the present invention as active principle is prepared, where appropriate, by mixing the said compound with a pH regulator, a buffer agent, a suspension agent, a solubilizer, a stabilizer, a tonicity agent and/or a preserving agent, and by converting the mixture into a form for intravenous, subcutaneous of intramuscular injection, according to a conventional process. Where appropriate, the injectable form obtained can be lyophilized via a conventional process.

[0058] Examples of suspension agents include methylcellulose, polysorbate 80, hydroxyethylcellulose, acacia, powdered gum tragacanth, sodium carboxymethylcellulose and polyethoxylated sorbitan monolaurate.

[0059] Examples of solubilizers include castor oil solidified with polyoxyethylene, polysorbate 80, nicotinamide, polyethoxylated sorbitan monolaurate and the ethyl ester of castor oil fatty acid.

[0060] In addition, the stabilizer includes sodium sulfite, sodium metasulfite and ether, while the preserving agent includes methyl *para*-hydroxybenzoate, ethyl *para*-hydroxybenzoate, sorbic acid, phenol, cresol and chlorocresol.

20

15

10

[0061] A subject of the present invention is also a use of a compound of the formula (I) of the invention for the preparation of a medicament for the treatment of hypertriglyceridaemia, hypercholesterolaemia and dyslipidaemia associated with diabetes, and also for the prevention of and treating obesity.

25

[0062] The examples that follow illustrate the present invention without limiting it in any way.

10

15

20

Examples of thiazolylpiperidine compounds according to the invention

Example 1:

2-[1-(6-Methyl-4'-trifluoromethoxybiphenyl-2-carbonyl)piperid-4-yl]thiazol-4-carbonyl[N-ethyl-N-(1-methyl-2-oxo-2-phenylethyl)]amide Step a)

tert-Butyl 4-(4-ethoxycarbonylthiazol-2-yl)piperidine-1-carboxylate

tert-Butyl 4-(aminocarbothioyl)tetrahydropyridine-1(2H)-carboxylate (Maybridge) (85 mmol; 20.8 g) is dissolved in 250 ml of dimethylformamide and placed at 5°C. Ethyl bromopyruvate (1 eq.; 85 mmol; 16.6 g) dissolved in 50 ml of dimethylformamide is added dropwise. The reaction medium is stirred overnight and excess triethylamine is then added dropwise. The reaction medium is evaporated and the residual brown oil is taken up in ethyl acetate and washed with water (twice) and then with saturated sodium chloride solution (twice). The organic phase is dried over sodium sulfate and evaporated to dryness. The crude product is chromatographed on silica, eluting with dichloromethane to dichloromethane/3% methanol, to give 20.5 g of the expected product in the form of oily crystals. TLC: 1/1 ethyl acetate/hexane: Rf = 0.55

Yield = 71 %.

Step b)

tert-Butyl 4-(4-carboxythiazol-2-yl)piperidine-1-carboxylate

tert-Butyl 4-(4-ethoxycarbonylthiazol-2-yl)piperidine-1-carboxylate (60 mmol; 20.4 g) is dissolved in 225 ml of a mixture of tetrahydrofuran and water (2/1), and 1N sodium hydroxide (2 eq.; 120 mmol; 120 ml) is added dropwise. The reaction medium is stirred at room temperature overnight. The reaction medium is washed with ether and the aqueous phase is then acidified with saturated nitric acid solution. The precipitate is filtered off, washed with water and dried to give 15.5 g of cream-coloured crystals.

TLC: 1/1/1 CH₂Cl₂/EtOAc/MeOH: Rf = 0.6.

Yield: 83%.

Step c)

10

15

20

25

<u>tert-Butyl</u> 4-{4-[ethyl(1-methyl-2-oxo-2-phenylethyl)carbamoyl]thiazol-2-yl}-piperidine-1-carboxylate

tert-Butyl 4-(4-carboxythiazol-2-yl)piperidine-1-carboxylate (6.5 mmol; 2.03 g) is dissolved in 40 ml of anhydrous dimethylformamide and placed under an inert atmosphere, and 2-(ethylamino)propiophenone hydrochloride (1 eq.; 6.5 mmol; 1.39 g), HBTU (1 eq.; 6.5 mmol; 2.47 g) and N-ethyldiisopropylamine (3.5 eq.; 22.75 mmol; 3.97 ml) are then added. The reaction medium is stirred at room temperature overnight. The reaction medium is evaporated to dryness and then taken up in dichloromethane and washed with saturated potassium carbonate (K_2CO_3) solution, citric acid solution and water (twice). The organic phase is dried over sodium sulfate and then evaporated to dryness. The crude product is chromatographed on silica, using a 1/1 ethyl acetate/hexane mixture as eluent (Rf = 0.55) to give 2.6 g of expected product in the form of an oil.

Yield: 85%.

Step d)

4-{4-[Ethyl(1-methyl-2-oxo-2-phenylethyl)carbamoyl]thiazol-2-yl}piperidinium chloride

tert-Butyl 4-{4-[ethyl(1-methyl-2-oxo-2-phenylethyl)carbamoyl]thiazol-2-yl}-piperidine-1-carboxylate (5.5 mmol; 2.59 g) is dissolved in 13.75 ml of a 4M solution of hydrochloric acid in dioxane. The reaction medium is stirred at room temperature overnight and is then evaporated to dryness to give 2.24 g of a white solid.

Yield = quantitative.

10

Step e)

2-[1-(6-Methyl-4'-trifluoromethoxybiphenyl-2-carbonyl)piperid-4-yl]thiazol-4-carbonyl[N-ethyl-N-(1-methyl-2-oxo-2-phenylethyl)]amide

The title compound was obtained according to a procedure similar to that used for the preparation of *tert*-butyl 4-{4-[ethyl(1-methyl-2-oxo-2-phenylethyl)car-bamoyl]thiazol-2-yl}piperidine-1-carboxylate.

TLC: $1/1 CH_2Cl_2/EtOAc$: Rf = 0.47

LC-MS: (ES+) 650.4 (M+H)

Yield: 88%.

20

25

30

15

Example 2:

1-(4-{4-(1-morpholin-4-yl)methanoyl]thiazol-2-yl}piperid-1-yl)-1-(4'-trifluoromethylbiphenyl-2-yl)methanone

Step a)

1-{[4'-(trifluoromethyl)-1,1'-biphenyl-2-yl]carbonyl}piperidine-4-carbox-amide

4'-(Trifluoromethyl)-2-biphenylcarboxylic acid (20.5 g; 77 mmol) is dissolved in 340 ml of dimethylformamide and 200 ml of dichloromethane. The reaction medium is placed at 0°C and oxalyl chloride (1.8 eq.; 138.6 mmol; 12 ml) is added. The reaction medium is stirred at room temperature for 3 hours and then evaporated to dryness. The crude product is taken up in 270 ml of dichloro-

methane, followed by addition of a solution of isonipecotamide (0.97 eq.; 74.7 mmol; 9.57 g) and triethylamine (2.7 eq.; 207.9 mmol; 29 ml) in 270 ml of dichloromethane, placed at 0°C. The mixture is allowed to warm to room temperature over 12 hours, saturated aqueous sodium hydrogen carbonate solution is then added (in a 1/1 proportion) and the resulting mixture is stirred for 30 minutes. The organic phase is washed with 1M sodium hydroxide solution and then with water, dried over sodium sulfate and evaporated to dryness. The crude product is dispersed in diisopropyl ether and then filtered off and dried to give 23.09 g of coupling product.

Yield: 79.6 %.

Step b)

10

15

20

25

30

1-{[4'-(trifluoromethyl)-1,1'-biphenyl-2-yl]carbonyl}piperidine-4-carbothioamide

1-{[4'-(Trifluoromethyl)-1,1'-biphenyl-2-yl]carboxyl}piperidine-4-carbox-amide (11.29 g; 30 mmol) is dissolved in a mixture of Lawesson's reagent (1 eq.; 30 mmol; 12.13 g), dimethyl ether (100 ml) and chloroform (40 ml). The reaction medium is heated at 50°C for 2 hours 30 minutes and then evaporated to dryness and taken up in ethyl acetate. The organic phase is washed with saturated potassium carbonate solution and then with water, dried over sodium carbonate and evaporated to dryness. The yellow solid is dispersed in diisopropyl ether and then filtered off and dried to give 10.5 g of product.

Yield: 89 %.

Step c)

Ethyl 2-{1-{[4'-(trifluoromethyl)-1,1'-biphenyl-2-yl]carbonyl}piperidine-4-yl}-1,3-thia-zole-4-carboxylate

1-{[4'-(Trifluoromethyl)-1,1'-biphenyl-2-yl]carbonyl}piperidine-4-carbothio-amide (10.5 g; 26.75 mmol) is dissolved in 100 ml of dimethylformamide and placed at 0°C. 90% [lacuna] bromopyruvate (1 eq.; 26.75 mmol; 3.73 ml) is added, the mixture is left at 0°C for 30 minutes and is then allowed to warm to room temperature over 12 hours, followed by addition of 10 ml of triethylamine. The reaction

medium is evaporated and the crude product is then extracted three times with ethyl acetate. The organic phase is washed with saturated aqueous sodium chloride solution (three times), with water (once) and again with sodium chloride, and is then dried over sodium sulfate and evaporated to dryness. The residue is chromatographed on silica (eluent: 97/3 dichloromethane/methanol) to give 10.33 g of the expected product.

Yield: 79 %.

Step d)

10

15

20

25

2-{1-{4'-(Trifluoromethyl)-1,1'-biphenyl-2-yl]carboxyl}piperid-4-yl}-1,3-thiazole-4-carboxylic acid

The title compound was obtained according to a procedure similar to that used for the preparation of *tert*-butyl 4-(4-carboxythiazol-2-yl)piperidine-1-carboxylate.

Yield: quantitative.

Step e)

1-(4-{4-(1-Morpholin-4-yl)methanoyl]thiazol-2-yl}piperid-1-yl)-1-(4'-trifluoromethyl-biphenyl-2-yl)methanone

The title compound was obtained according to a procedure similar to that used for the preparation of *tert*-butyl 4-{4-[ethyl(1-methyl-2-oxo-2-phenylethyl)car-bamoyl]thiazol-2-yl}piperidine-1-carboxylate.

Yield: 87%.

As an additional example, the procedure below shows a synthetic route that can be used for the preparation of an amine of the formula H-a2':

Preparation of 2-ethylamino-1-pyrid-2-ylpropan-1-one in the form of the acid salt with bis-trifluoroacetic acid

Step a)

5

10

15

20

Methyl 2-(2-nitrobenzenesulfonylamino)propionate

DL-Alanine methyl ester hydrochloride (13.96 g; 0.1 mol) is dissolved in 800 ml of dichloromethane and placed at 0°C. Triethylamine (2.3 eq.; 230 mmol; 32 ml) is added dropwise, along with portionwise addition of 2-nitrobenzene-sulfonyl chloride (1 eq.; 100 mmol; 22.16 g), and the reaction medium is allowed to return to room temperature overnight. The reaction medium is washed with water and then dried over sodium sulfate, filtered through silica and evaporated to dryness to give 25.3 g of solid corresponding to the title compound.

Yield: 88 %.

Step b)

Methyl 2-[ethyl(2-nitrobenzenesulfonyl)amino]propionate

Methyl 2-(2-nitrobenzenesulfonylamino)propionate (17 g; 59 mmol) is dissolved in 600 ml of dimethylformamide, and caesium carbonate (1.5 eq.; 88 mmol; 28.6 g) is then added. The reaction medium is stirred for 30 minutes at room temperature, followed by dropwise addition of ethyl bromide (4 eq.; 236 mmol; 17.6 ml) and the resulting mixture is stirred overnight at room temperature. The reaction medium is evaporated to dryness, taken up in dichloromethane, filtered and evaporated to dryness. The crude product is chromatographed on silica (eluting with dichloromethane) to give 17.1 g of the expected product.

Yield: 92 %.

25

30

Step c)

Methyl 2-ethylaminopropionate

Methyl 2-[ethyl(2-nitrobenzenesulfonyl)amino]propionate (8.07 g; 25.5 mmol) is dissolved in 250 ml of acetonitrile, and thiophenol (1.12 eq.; 28.7 mmol; 2.93 ml) and K_2CO_3 (3.25 eq.; 82.9 mmol; 11.45 g) are then added. The reaction medium is stirred overnight at room temperature. The crude product

is evaporated to dryness and then taken up in ether. The organic phase is acidified with 1N hydrochloric acid and then washed with water. The aqueous phases are combined and then washed with ether and basified with potassium carbonate. The basic aqueous phase is extracted with ether three times. The three ether phases are washed with water and then with saturated aqueous sodium chloride solution, dried over sodium sulfate and evaporated to dryness to give 1.04 g of the expected product.

Yield: 31 %.

10 Step d)

15

20

25

Methyl 2-(tert-butoxycarbonylethylamino)propionate

Methyl 2-ethylaminopropionate (0.96 g; 7.3 mmol) is dissolved in 10 ml of dichloromethane, and triethylamine (1 eq.; 7.3 mmol; 1 ml) and Boc-O-Boc (1.1 eq.; 8 mmol; 1.75 g) are added. The reaction medium is stirred for 12 hours at room temperature and then washed with water, dried over sodium sulfate and evaporated to dryness to give 1.28 g of the expected product.

Yield: 76 %.

Step e)

2-(tert-Butoxycarbonylethylamino)propionic acid

Methyl 2-(*tert*-butoxycarbonylethylamino)propionate (1.27 g; 5.5 mmol) is dissolved in 5 ml of methanol, and potassium hydroxide (1.2 eq.; 6.6 mmol; 0.37 g) dissolved in 1.6 ml of water is then added. The reaction medium is left at room temperature for 12 hours and then evaporated to dryness, taken up in water and washed with ether. The aqueous phase is acidified by adding 1N hydrochloric acid and extracted three times with ether. The organic phases are combined, dried over sodium sulfate and evaporated to dryness to give 0.88 g of a white solid.

Yield: 74 %.

Step e bis): Alternative route:

DL-2-Bromopropionic acid (76.5 g; 0.5 mol) is dissolved in 250 ml of water and 70% ethylamine (4.7 eq.; 2.3 mol; 150 g) is added dropwise. The reaction medium is stirred at room temperature for 12 hours and then evaporated to dryness and taken up in 400 ml of water comprising 40 g of sodium hydroxide (1.0 mol). The reaction medium is again evaporated to dryness.

The crude product is dissolved in 500 ml of water and 250 ml of dioxane. The reaction medium is placed at 0°C and di(*tert*-butyl) carbonate (1.1 eq.; 0.55 mol; 120 g) dissolved in 200 ml of dioxane is added dropwise. The pH is maintained at 10 by adding sodium hydroxide. The reaction medium is stirred at room temperature for 24 hours and then filtered. The filtrate is concentrated and then taken up in 700 ml of water and acidified to pH 2-3 with citric acid. The precipitate is filtered off and dried (108.6 g).

Yield: 62 %.

15

20

25

10

5

Step f)

Dimethyl ethyl eth

2-(*tert*-Butoxycarbonylethylamino)propionic acid (40 mmol; 873 mg) is dissolved in 5 ml of dimethylformamide, and N,O-dimethylhydroxylamine hydrochloride (1.25 eq.; 5.0 mmol; 490 mg), HOBT (1.25 eq.; 5.0 mmol; 676 mg), triethylamine (1.25 eq.; 5.0 mmol; 0.7 ml) and EDC (1.25 eq.; 5.0 mmol; 960 mg) are added. The reaction medium is stirred for 12 hours and then evaporated to dryness. The crude product is extracted with ether, washed successively, twice with aqueous 4% citric acid solution, twice with aqueous 4% sodium hydrogen sulfite solution, with water and then with saturated sodium chloride solution. The organic phase is dried over sodium sulfate, evaporated to dryness and chromatographed on silica (eluent: 1/2 ethyl acetate/hexane; Rf = 0.45) to give 795 mg of a colourless product.

Yield: 76 %.

Step g)

tert-Butyl ethyl(1-methyl-2-oxo-2-pyrid-2-ylethyl)carbamate

2-Bromopyridine (7.0 mmol; 667 μ L) is dissolved in 40 ml of anhydrous tetrahydrofuran and placed at -100°C, followed by dropwise addition of a 1.6M solution of n-butyllithium in hexane (1 eq.; 7.0 mmol; 4.375 ml). The reaction medium is stirred for 30 minutes and dimethyl ethyl ethyl[1-(methoxymethyl-carbamoyl)ethyl]carbamate (1 eq.; 7.0 mmol; 1.822 g) dissolved in 20 ml of anhydrous tetrahydrofuran is added dropwise. The reaction medium is stirred at -100°C for 1 hour 30 minutes. The reaction medium is then removed from the ice bath, 200 ml of saturated aqueous sodium chloride solution are added and the mixture is then extracted with ether. The organic phase is dried over sodium sulfate, evaporated to dryness and chromatographed on silica (eluent: 1/2 ethyl acetate/heptane; Rf = 0.23) to give 1.04 g of the expected product.

Yield: 53 %.

15

20

25

30

10

5

Step h)

2-Ethylamino-1-pyrid-2-ylpropan-1-one – acid salt with bis-trifluoroacetic acid

tert-Butyl ethyl(1-methyl-2-oxo-2-pyrid-2-ylethyl)carbamate (1.03 g; 3.7 mmol) is dissolved in 30 ml of a 1/1 dichloromethane/trifluoroacetic acid mixture. The reaction medium is stirred for one hour at room temperature and then evaporated to dryness to give 1.5 g of the expected salt.

Yield: quantitative.

The compounds of the general formula (I) presented in the table below were prepared according to procedures similar to those described above.

Other examples of compounds included in the scope of the present invention are presented in Table 1 below. All these compounds are obtained according to procedures similar to those presented above.

TABLE 1

No.	FORMULA	NMR or mass
1	F F O S	(CDCl3): 1.27-1.22 (19H, m); 1.25-1.23 (1H, m); 1.27-1.24 (1H, m); 1.25-1.27 (13H, m).
2	F F O Z O S	(CDCl3): 1.29-1.24 (16H, m); 1.29-1.24 (1H, m); 1.29-1.26 (9H, m).
2d	F F O OH OH S	(DMSO-d6): 1.23-1.29 (8H, m); 1.23-1.28 (1H, m); 1.21-1.20 (8H, m); 1.28-1.20 (1H, m); 11.29 (1H, s large).

No.	FORMULA	NMR or mass
3		(CDCI3): 1.29-,129 (3H, m); 1.29-1.25 (3H, m); 1.29-1.27 (7H, m); 1.21-1.22 (4H, m); 1.28-1.27 (1H, m); 1.20-1.25 (14H, m).
4	F F O O O O O O O O O O O O O O O O O O	(CDCl3): 1.20-1.25 (3H, d, J = 1.2 Hz); 1.27- 1.28 (12H, m); 1.27-1.29 (1H, m); 1.28-1.20 (14H, m).
5	F F O O O O O O O O O O O O O O O O O O	(CDCl3) 1.23- 1.24 (3H, d, J = 1.2 Hz); 1.26-1.20 (11H, m); 1.21-1.20 (1H, m); 1.21-1.23 (1H, m); 1.29-1.20 (14H, m).

No.	FORMULA	NMR or mass
6		(CDCl3): 1.23-1.24 (16H, m); 1.28-1.22 (1H, m); 1.21-1.24 (1H, m); 1.21-1.28 (13H, m).
7	N-(7-oxo-7H-thieno[3,2-b]pyran-6-yl)-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]-carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	LC-MS: (ES+) 701.2 (M+H)
8	F F S S S S S S S S S S S S S S S S S S	LC-MS : (ES+) 661.2 (M+H)

No.	FORMULA	NMR or mass
9		
10		
11		
12	F O N O N O	LC-MS : (ES+) 651.2 (M+H)

No.	FORMULA	NMR or mass
13	F L O N N N N N N N N N N N N N N N N N N	(CDCl3): 1.25-1.21 (14H, m); 1.27-1.25 (1H, m); 1.29-1.24 (1H, m); 1.20-1.21 (9H, m); 1.23-1.25 (2H, m); 1.20-1.29 (1H, m).
14	F F S S S S S S S S S S S S S S S S S S	(DMSO-d6): 1.27 (3H, t, J = 1.2 Hz); 1.21-1.22 (4H, m); 1.22-1.27 (4H, m); 1.26 (4H, q, J = 1.2 Hz); 1.26- 1.26 (1H, m); 1.20-1.28 (8H, m); 1.29 (1H, s).
15	F F O N N N N O O	(CDCl3): 1.28 (3H, d, J) = 1.2 Hz); 1.26-1.24 (4H, m); 1.21-1.23 (5H, m); 1.25-1.28 (1H, m); 1.28-1.29 (1H, m); 1.23-1.27 (1H, m); 1.29-1.26 (14H, m); 1.22 (1H, s).

No.	FORMULA	NMR or mass
16	F F O N HN O	(CDCl3): 1.27-1.24 (2H, m); 1.20-1.27 (6H, m); 1.21-1.20 (4H, m); 1.20-1.23 (1H, m); 1.27-1.26 (7H, m); 1.26-1.26 (7H, m); 1.27-1.28 (1H, m).
17	F F S S S S S S S S S S S S S S S S S S	(CDCl3): 1.26-1.26 (2H, m); 1.22-1.28 (4H, m); 1.22-1.28 (8H, m); 1.29-1.24 (1H, m); 1.20-1.23 (5H, m); 1.21-1.23 (8H, m).
18	F F F	(CDCl3): 1.21 (3H, s); 1.23 (3H, s); 1.24-1.24 (7H, m); 1.25-1.26 (1H, m) 1.26- 1.28 (3H, m); 1.23-1.21 (14H, m)

No.	FORMULA	NMR or mass
19	F F O O O O O O O O O O O O O O O O O O	(CDCl3); 1.25-1.20 (3H, m); 1.23-1.22 (10H, m); 1.23-1.21 (1H, m); 1.26-1.23 (1H, m); 1.23-1.26 (2H, m); 1.28-1.26 (14H, m).
20	F F S N N N N N N N N N N N N N N N N N	(CDCl3): 1.20-1.28 (12H, m); 1.28-1.25 (1H, m); 1.20-1.27 (8H, m); 1.27-1.24 (1H, m); 1.29-1.26 (3H, m); 1.21-1.25 (9H, m).
21	F F F S O S O S O S O S O S O S O S O S	(CDCl3); 1.27-1.27 (4H, m); 1.21-1.21 (6H, m); 1.23-1.22 (3H, m); 1.21-1.27 (2H, m); 1.24-1.26 (1H, m); 1.29-1.28 (5H, m); 1.22-1.26 (8H, m); 1.29-1.22 (1H, m).

No.	FORMULA	NMR or mass
22	F F O O O O O O O O O O O O O O O O O O	(CDCI3): 1.24-1.21 (4H, m); 1.20-1.24 (6H, m); 1.29-1.26 (3H, m); 1.29-1.24 (1H, m); 1.24-1.20 (1H, m); 1.24-1.28 (2H, m); 1.20-1.26 (2H, m); 1.22-1.25 (9H, m); 1.21-1.20 (1H, m).
23	F F O O O O O O O O O O O O O O O O O O	(CDCl3): 1.27-1.28 (4H, m); 1.29-1.26 (2H, m); 1.26 (3H, s); 1.24- 1.26 (4H, m); 1.28-1.22 (2H, m); 1.21-1.28 (3H, m); 1.26-1.29 (14H, m).
24		(CDCl3): 1.26-1.28 (7H, m); 1.22-1.25 (10H, m);: 1.21-1.25 (3H, m); 1.21-1.24 (7H, m); 1.25-1.25 (7H, m).

No.	FORMULA	NMR or mass
25	F F O O O O O O O O O O O O O O O O O O	(DMSO-d6): 1.28-1.27 (3H, m); 1.20-1.24 (8H, m); 1.21-1.28 (3H, m); 1.27-1.26 (8H, m); 1.24-1.22 (1H, m).
26	F F O N N N N N N N N N N N N N N N N N	(DMSO-d6): 1.24-1.22 (4H, m); 1.24-1.22 (4H, m); 1.29-1.20 (1H, m); 1.29-1.24 (8H, m); 1.23-1.22 (1H, m); 11.27 (1H, s large).
27	F F S	(DMSO-d6): 1.24-1.25 (6H, m); 1.23-1.25 (10H, m); 1.20-1.24 (1H, m); 1.28-1.26 (1H, m); 1.23-1.27 (14H, m).
28	F F S	(CDCl3): 1.29-1.23 (6H, m); 1.27-1.21 (10H, m); 1.23-1.28 (3H, m); 1.24-1.24 (1H, m large); 1.22-1.22 (14H, m).

No.	FORMULA	NMR or mass
29		(DMSO-d6): 1.22-1.26 (18H, m); 1.23-1.28 (1H, m); 1.20-1.22 (1H, m); (15H, m).
	N-[2-(diethylamino)-2-oxo-1-phenylethyl]-2-(1-{[4'-(trifluoromethyl)-biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	
30		(CDCl3): 1.20-1.21 (8H, m); 1.26-1.27 (1H, m); 1.28-1.27 (1H, m); 1.27-1.27 (8H, m); 1.20-1.25 (3H, m); 1.22 (1H, s); 1.24- 1.29 (10H, m).
31		(CDCl3): 1.22-1.25 (3H, m); 1.27-1.27 (7H, m); 1.24-1.20 (1H, m); 1.28-1.21 (1H, m); 1.25-1.22 (9H, m); 1.22-1.28 (1H, m).

No.	FORMULA	NMR or mass
32		(CDCI3): 1.21-1.26 (3H, m); 1.23-1.27 (6H, m); 1.26-1.24 (2H, m); 1.29-1.21 (1H, m); 1.22-1.24 (1H, m); 1.26-1.22 (1H, m); 1.24-1.20 (15H, m); 1.28-1.21 (1H, m).
33	F F O O O O O O O O O O O O O O O O O O	(CDCl3): 1.23-1.25 (9H, m); 1.29-1.29 (4H, m); 1.29-1.24 (2H, m); 1.28-1.29 (3H, m); 1.23-1.27 (10H, m).
34	F F O N N N N N N N N N N N N N N N N N	(CDCI3): 1.24-1.28 (7H, m); 1.20-1.29 (3H, m); 1.26-1.22 (1H, m); 1.26-1.25 (1H, m); 1.29-1.26 (20H, m).

No.	FORMULA	NMR or mass
35	F F S	(CDCl3): 1.29-1.24 (8H, m); 1.25-1.23 (7H, m); 1.26-1.25 (1H, m); 1.27-1.27 (13H, m); 1.28-1.22 (1H, m).
36	N-(2-oxo-2,3-dihydro-1H-indol-3-yl)-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	(CDCl3): 1.22-1.29, (7H, m); 1.291.26 (2H, m); 1.26-1.21 (1H, m); 1.28-1.25 (15H, m).
37	N-[2-(4-fluorophenyl)-1,1-dimethylethyl]-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	(CDCl3): 1.21 (6H, s); 1.20-1.23 (7H, m); 1.26-1.20 (2H, m); 1.22-1.23 (1H, m); 1.22-1.20 (1H, m); 1.26-1.24 (13H, m); 1.23 (1H, s).

No.	FORMULA	NMR or mass
38	F F O N O NH ₂	(CDCl3): 1.21-1.23 (7H, m); 1.26-1.28 (1H, m); 1.20-1.28 (1H, s large); 1.29 (1H, s large); 1.27 (8H, m); 1.26-1.22 (1H, m).
39	F F O N N	(CDCI3): 1.24-1.24 (6H, m); 1.24-1.24 (7H, m); 1.24-1.23 (1H, m); 1.28-1.25 (1H, m); 1.21-1.25 (9H, m).
40	1-(1-phenylethyl)-4-{[2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}-piperidin-4-yl)-1,3-thiazol-4-yl]carbonyl}piperazine	(CDCl3): 1.27-1.24 (3H, m); 1.26-1.21 (11H, m); 1.28-1.23 (2H, m); 1.23-1.27 (4H, m); 1.20-1.24 (1H, m); 1.24-1.26 (14H, m).

No.	FORMULA	NMR or mass
41	F F O N N N N N N N N N N N N N N N N N	(CDCl3): 1.23-1.22 (17H, m); 1.29-1.27 (2H, m); 1.22-1.29 (2H, m); 1.22-1.21 (2H, m); 1.23-1.20 (12H, m).
42	F F O N N N N N N N N N N N N N N N N N	(CDCl3): 1.25-1.26 (7H, m); 1.26-1.22 (5H, m); 1.25-1.26 (1H, m); 1.23-1.20 (13H, m); 1.28-1.22 (2H, m).
43	F F S S S S S S S S S S S S S S S S S S	(CDCl3): 1.28-1.27 (14H, m); 1.291.21 (4H, m); 1.22-1.24 (14H, m).

No.	FORMULA	NMR or mass
44	F F O N N N N N N N N N N N N N N N N N	
45	F F S N N N S N N N N N N N N N N N N N	-
46	F F O N N N N N N N N N N N N N N N N N	

No.	FORMULA	NMR or mass
47	1-(4-methoxyphenyl)-4-{[2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}-piperidin-4-yl)-1,3-thiazol-4-yl]carbonyl}piperazine	
48	F F O D D D D D D D D D D D D D D D D D	
49	N-heptyl-N-(2,3,4,5-tetrahydro-1-benzoxepin-5-yl)-2-(1-{[4'-(trifluoromethyl)-biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
50	N-(2,4-dioxoimidazolidin-1-yl)-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]-carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	
51	T-{[2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazol-4-yl]carbonyl}proline	
52	2-{[2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazol-4-yl]carbonyl}hydrazinecarbothioamide	

No.	FORMULA	NMR or mass
53		
	N-(cyanomethyl)-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	
54	N-prop-2-yn-1-yl-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	
55	H N N O F F F	

No.	FORMULA	NMR or mass
56	N-(2-hydroxyethyl)-N-methyl-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]-carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	
57	N-pyrimidin-2-yl-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
58	4-{4-[(5-methyl-1H-pyrazol-1-yl)carbonyl]-1,3-thiazol-2-yl}-1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidine	
59	4-[4-(pyrrolidin-1-ylcarbonyl)-1,3-thiazol-2-yl]-1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidine	

No.	FORMULA	NMR or mass
60	4-[4-(piperidin-1-ylcarbonyl)-1,3-thiazol-2-yl]-1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidine	
61	N-(pyridin-3-ylmethyl)-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}-piperidin-4-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
62	N-cyclohexyl-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	
63	N-benzyl-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
64	ethyl 4-{[2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazol-4-yl]carbonyl}piperazine-1-carboxylate	
65	S N N N F F F	
66	N-(3-methylbenzyl)-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}-piperidin-4-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
67	N-[2-(4-hydroxyphenyl)ethyl]-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]-carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	
68	N-(2-hydroxyethyl)-N-phenyl-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]-carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
69	ethyl 1-{[2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazol-4-yl]carbonyl}piperidine-4-carboxylate	
70	N-(1,5-dimethylhexyl)-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}-piperidin-4-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
71	N-benzyl-N-(2-hydroxyethyl)-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]-carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	
72	1-phenyl-4-{[2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazol-4-yl]carbonyl}piperazine	

No.	FORMULA	NMR or mass
73	4-(4-chlorophenyl)-1-{[2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}-piperidin-4-yl)-1,3-thiazol-4-yl]carbonyl}piperidin-4-ol	
74	4-phenyl-1-{[2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazol-4-yl]carbonyl}piperidine	· · · · · · · · · · · · · · · · · · ·

No.	FORMULA	NMR or mass
75	4-phenyl-1-{[2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazol-4-yl]carbonyl}piperidin-4-ol	
76	N-(1-phenylethyl)-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
77	2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-N-[4-(trifluoromethyl)phenyl]-1,3-thiazole-4-carboxamide	
78	1-{[2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazol-4-yl]carbonyl}azepane	

No.	FORMULA	NMR or mass
79	1-(2-phenylpropyl)-4-{[2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}-piperidin-4-yl)-1,3-thiazol-4-yl]carbonyl}piperazine	
80	N-1,3-thiazol-2-yl-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
81	N-1,3-benzothiazol-2-yl-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}-piperidin-4-yl)-1,3-thiazole-4-carboxamide	
82	N-(3-morpholin-4-ylpropyl)-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}-piperidin-4-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
83	N-methyl-N-(pyridin-3-ylmethyl)-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]-carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	
84	N-methyl-N-(2-pyridin-2-ylethyl)-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]-carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
85	N-(tert-butyl)-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	
86	N-(3-methoxypropyl)-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}-piperidin-4-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
87		
	N-[3-(diethylamino)propyl]-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}-piperidin-4-yl)-1,3-thiazole-4-carboxamide	
88	N-(2,3-dihydro-1,4-benzodioxin-6-ylmethyl)-2-(1-{[4'-(trifluoromethyl)-biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
89	N-cyclohexyl-N-methyl-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}-piperidin-4-yl)-1,3-thiazole-4-carboxamide	
90	N,N-diallyl-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
91	N-(4-isopropylphenyl)-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}-piperidin-4-yl)-1,3-thiazole-4-carboxamide	
92	N-(2-hydroxy-1,1-dimethylethyl)-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]-carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
93	N-[2-hydroxy-1-(hydroxymethyl)-1-methylethyl]-2-(1-{[4'-(trifluoromethyl)-biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	
94	N-(2-hydroxy-1-phenylethyl)-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]-carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
95	N-[3-(trifluoromethyl)benzyl]-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]-carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	
96	N-(1-methyloctyl)-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
97	N-cyclobutyl-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	
98	diethyl 4-({[2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazol-4-yl]carbonyl}amino)benzyl phosphite	

No.	FORMULA	NMR or mass
99	ethyl 4-({[2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazol-4-yl]carbonyl}amino)piperidine-1-carboxylate	
100	6-ethoxy-2,2,4-trimethyl-1-{[2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}-piperidin-4-yl)-1,3-thiazol-4-yl]carbonyl}-1,2-dihydroquinoline	

No.	FORMULA	NMR or mass
101	FFF F N N S N S 2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-N'-[4-(trifluoromethyl)pyrimidin-2-yl]-1,3-thiazole-4-carbohydrazide	
102	N-isopropyl-N-methyl-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}-piperidin-4-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
103	1-[bis(4-fluorophenyl)methyl]-4-{[2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]-carbonyl}piperidin-4-yl)-1,3-thiazol-4-yl]carbonyl}piperazine	
104	N-(2-piperidin-1-ylethyl)-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}-piperidin-4-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
105	N-(1,2,3,4-tetrahydronaphthalen-1-yl)-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	
106	1-[bis(4-chlorophenyl)methyl]-4-{[2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]-carbonyl}piperidin-4-yl)-1,3-thiazol-4-yl]carbonyl}piperazine	

No.	FORMULA	NMR or mass
107	N-[3-(2-oxopyrrolidin-1-yl)propyl]-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]-carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	
108	N-[3-(1H-imidazol-1-yl)propyl]-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]-carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
109	N-[3-(2-methylpiperidin-1-yl)propyl]-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]-carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	
110	N-[2-(1-methylpyrrolidin-2-yl)ethyl]-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]-carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
111	N-[2-(2-thienyl)ethyl]-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}-piperidin-4-yl)-1,3-thiazole-4-carboxamide	
112	N-(2-phenoxyethyl)-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}-piperidin-4-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
113	N-(4-methoxyphenyl)-N-methyl-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]-carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	
114	ethyl (2E)-3-(4-fluorophenyl)-3-({[2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]-carbonyl}piperidin-4-yl)-1,3-thiazol-4-yl]carbonyl}amino)acrylate	

No.	FORMULA	NMR or mass
115	N-{(1E)-1-cyclopentyl-3-oxo-3-[4-(trifluoromethyl)phenyl]prop-1-en-1-yl}-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	
116	N-{1,3-dimethyl-4-[4-(methylthio)phenyl]-1H-pyrazol-5-yl}-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
117	8,9-dimethoxy-1-{[2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazol-4-yl]carbonyl}-1,2,5,6-tetrahydro-3H-imidazo[2,1-b][1,3]-benzodiazepin-3-one	
118	4-(4-{[3-(3,4-dimethoxyphenyl)pyrrolidin-1-yl]carbonyl}-1,3-thiazol-2-yl)-1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidine	

No.	FORMULA	NMR or mass
119	1-(4-{[2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazol-4-yl]carbonyl}piperazin-1-yl)-2,6-naphthyridine	
120	N-[2-(2-chlorophenyl)imidazo[1,2-a]pyridin-3-yl]-2-(1-{[4'-(trifluoromethyl)-biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
121	N-(4-chloroquinolin-3-yl)-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}-piperidin-4-yl)-1,3-thiazole-4-carboxamide	
122	N'-[(1E)-3-cyanopropylidene]-N-pyridin-2-yl-2-(1-{[4'-(trifluoromethyl)-biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazole-4-carbohydrazide	

No.	FORMULA	NMR or mass
123	6-(4-methoxyphenyl)-1-{[2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}-piperidin-4-yl)-1,3-thiazol-4-yl]carbonyl}-1,2,5,6-tetrahydro-3H-imidazo[2,1-b][1,3]benzodiazepin-3-one	
124	4-{4-[(2-phenylpyrrolidin-1-yl)carbonyl]-1,3-thiazol-2-yl}-1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidine	

No.	FORMULA	NMR or mass
125	N-({1-[4-(2-hydroxyethyl)benzyl]-3,3-dimethylcyclobutyl}methyl)-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	
126	N-[1-methyl-4-(methylthio)-1H-pyrazol-3-yl]-2-(1-{[4'-(trifluoromethyl)-biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
127	4-(4-{[2-(methylthio)-4,5-diphenyl-1H-imidazol-1-yl]carbonyl}-1,3-thiazol-2-yl)-1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidine	
128	F F F	

No.	FORMULA	NMR or mass
129	N-{1-tert-butyl-4-[4-(methylthio)phenyl]-1H-pyrazol-5-yl}-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	
130	N-(1-{[2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazol-4-yl]carbonyl}piperidin-4-yl)benzamide	

No.	FORMULA	NMR or mass
131	N N O N O F F F	
132	phenyl(1-{[2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazol-4-yl]carbonyl}-1H-benzimidazol-2-yl)acetonitrile	
133	2-(1-{[2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazol-4-yl]carbonyl}piperidin-4-yl)isoindolin-1-one	

No.	FORMULA	NMR or mass
134	3-(3-{[2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazol-4-yl]carbonyl}-1,3-thiazolidin-2-yl)pyridine	
135	3-[(4-{[2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazol-4-yl]carbonyl}piperazin-1-yl)methyl]-2H-chromen-2-one	

No.	FORMULA	NMR or mass
136	N-(3-hydroxy-2,2-diphenylpropyl)-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]-carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	
137	tert-butyl [(1-{[2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazol-4-yl]carbonyl}piperidin-3-yl)methyl]carbamate	

No.	FORMULA	NMR or mass
138	N-[2-(3-methoxyphenyl)ethyl]-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]-carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	
139	N-benzyl-N-(2-hydroxy-1-phenylethyl)-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
140	6-methyl-4a-phenyl-1-{[2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}-piperidin-4-yl)-1,3-thiazol-4-yl]carbonyl}decahydro-1,6-naphthyridine	
141	N-(2,6-dimethylphenyl)-2-(4-{[2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]-carbonyl}piperidin-4-yl)-1,3-thiazol-4-yl]carbonyl}piperazin-1-yl)acetamide	

No.	FORMULA	NMR or mass
142	N-(2H-chromen-3-ylmethyl)-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}-piperidin-4-yl)-1,3-thiazole-4-carboxamide	
143	methyl 4-[2-({[2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazol-4-yl]carbonyl}amino)ethoxy]benzoate	

No.	FORMULA	NMR or mass
144	N-{[1-(1-benzofuran-3-yl)cyclopentyl]methyl}-2-(1-{[4'-(trifluoromethyl)-biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	
145	O H N O F F F	

No.	FORMULA	NMR or mass
146	N-{[1-(1-methyl-1H-indol-3-yl)cyclopentyl]methyl}-2-(1-{[4'-(trifluoromethyl)-biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	
147	N-(3,3-diphenylpropyl)-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}-piperidin-4-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
148	N-(8-bromo-4-hydroxy-3,3-dimethyl-2,3,4,5-tetrahydro-1-benzoxepin-5-yl)-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	
149	1-{[2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazol-4-yl]carbonyl}-4-(3,4,5-trimethoxybenzyl)piperazine	

No.	FORMULA	NMR or mass
150	N-ethyl-N-(3-hydroxybenzyl)-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]-carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	
151	3-(4-methoxyphenyl)-4-{[2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}-piperidin-4-yl)-1,3-thiazol-4-yl]carbonyl}piperazin-2-one	

No.	FORMULA	NMR or mass
152	N-(6-cyano-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-chromen-4-yl)-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	
153		

No.	FORMULA	NMR or mass
154		
155	methyl 1-{[2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazol-4-yl]carbonyl}-1H-indazole-3-carboxylate	
156	N-{[1-(1-benzothien-3-yl)cyclopentyl]methyl}-2-(1-{[4'-(trifluoromethyl)-biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
157	N-[3-chloro-4-(nitroacetyl)phenyl]-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]-carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	
158	N-({3-(benzyloxy)-1-[4-(2-hydroxyethyl)benzyl]cyclobutyl}methyl)-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
159	7-(4-methoxyphenyl)-5-{[2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}-piperidin-4-yl)-1,3-thiazol-4-yl]carbonyl}-5,6,7,8-tetrahydro-4H-thieno[3,2-c]azepine	
160	3-phenyl-1-{[2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazol-4-yl]carbonyl}-1H-pyrrolo[2,3-b]pyridine	

No.	FORMULA	NMR or mass
161	N-benzyl-N-pyridin-2-yl-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}-piperidin-4-yl)-1,3-thiazole-4-carboxamide	
162	N-[2-(2-methoxyphenoxy)ethyl]-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]-carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	
163	S N-NO N-NO N-F F	

No.	FORMULA	NMR or mass
164	S NNNO S FFF	
165	N-(4-cyano-1,3-dimethyl-1H-pyrazol-5-yl)-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	
166	S N O F F F	

No.	FORMULA	NMR or mass
167	S N-N O	
168	4-chlorophenyl 4-({[2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazol-4-yl]carbonyl}amino)benzoate	
169	N-{1-methyl-4-[4-(methylsulfinyl)phenyl]-1H-pyrazol-3-yl}-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
170	S P F F	
	N-[4-(4-methoxyphenyl)-1-methyl-1H-pyrazol-3-yl]-2-(1-{[4'-(trifluoromethyl)-biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	
171	N N N O F F F	,
172	S TO	

No.	FORMULA	NMR or mass
173	N-(2-pygrolidin-1-ylethyl)-2-(1-/[4]-(trifluoromethyl)binbenyl-2-yllcarbonyl-	
	N-(2-pyrrolidin-1-ylethyl)-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}-piperidin-4-yl)-1,3-thiazole-4-carboxamide	
174	N-[(1-ethylpyrrolidin-2-yl)methyl]-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]-carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
175	N-[(3R)-1-benzylpyrrolidin-3-yl]-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]-carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	
176	N-[3-(4-methylpiperazin-1-yl)propyl]-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]-carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
177	N-[(4R,5R)-7-bromo-4-hydroxy-3,3-dimethyl-2,3,4,5-tetrahydro-1-benz-oxepin-5-yl]-2-(1-[[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	
178		

No.	FORMULA	NMR or mass
179	N'-[(1H-benzimidazol-2-ylthio)acetyl]-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]-carbonyl}piperidin-4-yl)-1,3-thiazole-4-carbohydrazide	
180		
181	N-(2,2,2-trifluoroethyl)-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}-piperidin-4-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
182	N-(2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-5-yl)-2-(1-{[4'-(trifluoro-methyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	
183	3-(benzyloxy)-2-methyl-1-{[2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}-piperidin-4-yl)-1,3-thiazol-4-yl]carbonyl}pyridin-4(1H)-one	

No.	FORMULA	NMR or mass
184	benzyl 4-{[2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazol-4-yl]carbonyl}piperazine-1-carboxylate	
185	N-isopropyl-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-N-[4-(trifluoromethyl)phenyl]-1,3-thiazole-4-carboxamide	
186		

No.	FORMULA	NMR or mass
187	N-(2-methyl-4-oxo-4H-chromen-3-yl)-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]-carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	
188	N-[(7-bromo-3,3-dimethyl-2,3-dihydro-1-benzoxepin-5-yl)methyl]-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
189	2-({[2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazol-4-yl]carbonyl}amino)ethyl (2E)-3-phenylacrylate	
190	2-(4-{[2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazol-4-yl]carbonyl}piperazin-1-yl)phenol	

No.	FORMULA	NMR or mass
191	N-quinolin-6-yl-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	
192	N-{1-[(6-fluoroquinolin-2-yl)methyl]piperidin-4-yl}-2-(1-{[4'-(trifluoromethyl)-biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
193	4-[4-({2-[(benzyloxy)methyl]-2,5,5-trimethyl-1,3-thiazolidin-3-yl}carbonyl)-1,3-thiazol-2-yl]-1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidine	
194	4-pyrrolidin-1-yl-1-{[2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazol-4-yl]carbonyl}piperidine	

No.	FORMULA	NMR or mass
195	1-{[2-(1-{[4'-(trifluoromethyl)biphenyl-2-yi]carbonyl}piperidin-4-yl)-1,3-thiazol-	
196	1-{[2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazol-4-yl]carbonyl}piperidine-4-carboxamide F F F N N N-[4-(trifluoromethoxy)benzyl]-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]-arrboxyllpiperidin 4 yl) 1,3 thiazolo 4 parboxymide	
196	F F N S	

No.	FORMULA	NMR or mass
197	N-isoxazol-3-yl-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	
198	N-cyclohexyl-N-isopropyl-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}-piperidin-4-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
199	ethyl N-(4-methoxyphenyl)-N-{[2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]-carbonyl}piperidin-4-yl)-1,3-thiazol-4-yl]carbonyl}norvalinate	
200	3,5-dimethyl-1-{[2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazol-4-yl]carbonyl}piperidine	

No.	FORMULA	NMR or mass
201	1'-{[2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazol-4-yl]carbonyl}-1,4'-bipiperidine	
202	methyl 1-{[2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazol-4-yl]carbonyl}piperidine-4-carboxylate	

No.	FORMULA	NMR or mass
203	2-{[2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazol-4-yl]carbonyl}decahydroisoquinoline	
204	HO N S (1-{[2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazol-4-yl]carbonyl}piperidin-4-yl)methanol	

No.	FORMULA	NMR or mass
205	3-(2-pyridin-3-ylethyl)-5-({[2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}-piperidin-4-yl)-1,3-thiazol-4-yl]carbonyl}amino)benzyl pentanoate	
206	N-(2,2-difluoro-1,3-benzodioxol-5-yl)-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]-carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
207	2-(1-{[2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazol-4-yl]carbonyl}piperidin-4-yl)ethanol	Ŋ:
208	N-(1,3-benzodioxol-5-ylmethyl)-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]-carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
209	N-(2-mercaptoethyl)-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}-piperidin-4-yl)-1,3-thiazole-4-carboxamide	
210	N-(4-hydroxyphenyl)-N-methyl-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]-carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
211	ethyl N-methyl-N-{[2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazol-4-yl]carbonyl}glycinate	
212	methyl N-{[2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazol-4-yl]carbonyl}alaninate	

No.	FORMULA	NMR or mass
213	1-(2-methylphenyl)-4-{[2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}-piperidin-4-yl)-1,3-thiazol-4-yl]carbonyl}piperazine	
214	N-(1-methylhexyl)-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
215	N-1-azabicyclo[2.2.2]oct-3-yl-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]-carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	
216	N-[2-(3,4-dihydroxyphenyl)ethyl]-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]-carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
217	N-[(3s,5s,7s)-1-adamantyl]-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]-	
	carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	
218	N-(2-oxotetrahydro-3-thienyl)-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]-carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	
219	1-(2-chlorophenyl)-4-{[2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}-piperidin-4-yl)-1,3-thiazol-4-yl]carbonyl}piperazine	

No.	FORMULA	NMR or mass
220	1-{[2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazol-4-yl]carbonyl}-4-[3-(trifluoromethyl)phenyl]piperazine	
221	N-1-naphthyl-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	
222	N,N-bis(1-phenylethyl)-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}-piperidin-4-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
223	ethyl (2E)-3-ethoxy-3-({[2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}-piperidin-4-yl)-1,3-thiazol-4-yl]carbonyl}amino)acrylate	
224	OH N S (1-{[2-(1-{[4'-(trifluoromethyl))biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazol-4-yl]carbonyl}-1H-imidazol-4-yl)methanol	

No.	FORMULA	NMR or mass
225	N-{2-[4-(4-fluorophenyl)spiro[chromene-2,1'-cyclopentan]-3-yl]ethyl}-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	
226	N-[2-(3,4-dimethoxyphenyl)ethyl]-N-(1,2-diphenylethyl)-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
227	H S N O F F	
228	5-(3-methoxyphenyl)-2-(methylthio)-3-{[2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazol-4-yl]carbonyl}-4,5-dihydro-3H-1,3-benzodiazepine	
229	N-heptyl-N-(1-methyl-1,2,3,4-tetrahydroquinolin-4-yl)-2-(1-{[4'-(trifluoro-methyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
230	N-(5-tert-butyl-2-hydroxybenzyl)-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]-carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	
231	N-[(3,5-dimethyl-1H-pyrazol-1-yl)(imino)methyl]-2-(1-{[4'-(trifluoromethyl)-biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
232	4-phenyl-2-{[2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazol-4-yl]carbonyl}-1,2,3,4-tetrahydroisoquinoline	
233	6-methoxy-2-phenyl-3-{[2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}-piperidin-4-yl)-1,3-thiazol-4-yl]carbonyl}-3,4-dihydroquinazoline	

No.	FORMULA	NMR or mass
234	N-[(1-benzylcyclopentyl)methyl]-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]-carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	
235	1'-{[2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazol-4-yl]carbonyl}-3,4-dihydrospiro[chromene-2,4'-piperidin]-4-ol	

No.	FORMULA	NMR or mass
236	N-{3-[4-(4-fluorobenzoyl)piperidin-1-yl]-2-hydroxypropyl}-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	
237	N-{[1-(4'-fluorobiphenyl-4-yl)cyclopentyl]methyl}-2-(1-{[4'-(trifluoromethyl)-biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
238	ethyl 3-octyl-4-{[2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazol-4-yl]carbonyl}-3,4-dihydro-2H-1,4-thiazine-6-carboxylate	
239	N-[imino(2-naphthyl)methyl]-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]-carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
240	N-[biphenyl-4-yl(imino)methyl]-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]-carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	
241	methyl N-{[2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazol-4-yl]carbonyl}serinate	

No.	FORMULA	NMR or mass
242	N-[(3-chloro-2-thienyl)methyl]-N-[2-(2-thienyl)ethyl]-2-(1-{[4'-(trifluoro-methyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	
243	N-[(2-hydroxy-1-naphthyl)methyl]-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]-carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
244	ethyl 2-[(N-{[2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazol-4-yl]carbonyl}glycyl)amino]benzoate	
245	1-(1-naphthyl)-4-{[2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazol-4-yl]carbonyl}piperazine	

No.	FORMULA	NMR or mass
246	N-{[2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazol-4-yl]carbonyl}glycine	
247	HO O S NO	

No.	FORMULA	NMR or mass
248		
	1-{[2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazol-4-yl]carbonyl}piperidine-4-carboxylic acid	
249	N-{[2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-	
	N-{[2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazol-4-yl]carbonyl}leucine	

No.	FORMULA	NMR or mass
250	HO O H S N O F F F	
251	3-phenyl-3-({[2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazol-4-yl]carbonyl}amino)propanoic acid	

No.	FORMULA	NMR or mass
252	N-{[2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazol-4-yl]carbonyl}phenylalanine	
253	N-methyl-N-{[2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazol-4-yl]carbonyl}glycine	

No.	FORMULA	NMR or mass
254	1-{[2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazol-4-yl]carbonyl}piperidine-2-carboxylic acid	
255	S-methyl-N-{[2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazol-4-yl]carbonyl}cysteine	

No.	FORMULA	NMR or mass
256		
257	1-{[2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazol-	
258	4-yl]carbonyl}-1H-pyrazole-4-carboxylic acid F	

No.	FORMULA	NMR or mass
259	N-[(7-hydroxy-4-methyl-2-oxo-2H-chromen-8-yl)methyl]-N-{[2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazol-4-yl]-carbonyl}glycine	
260	HO O S N O F F F	

No.	FORMULA	NMR or mass
261	{2-[(benzyl{[2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazol-4-yl]carbonyl}amino)methyl]-6-methoxyphenoxy}acetic acid	
262	{4-[2-({[2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazol-4-yl]carbonyl}amino)ethyl]phenoxy}acetic acid	

No.	FORMULA	NMR or mass
263	2-[4-({[2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazol-4-yl]carbonyl}amino)phenyl]propanoic acid	
264	(3R)-8-methyl-4-{[2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazol-4-yl]carbonyl}-1-thia-4,8-diazaspiro[4.5]decane-3-carboxylic acid	

No.	FORMULA	NMR or mass
265	HO S N O F F F	
266	2-(3,4-dichlorophenyl)-3-{[2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}-piperidin-4-yl)-1,3-thiazol-4-yl]carbonyl}-1,3-thiazolidine-4-carboxylic acid	

No.	FORMULA	NMR or mass
267	2-[(N-methyl-N-{[2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazol-4-yl]carbonyl}glycyl)amino]benzoic acid	
	yl)-1,3-thiazol-4-yl]carbonyl}glycyl)amino]benzoic acid	
268	(4R)-5,5-dimethyl-2-pyridin-3-yl-3-{[2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]-carbonyl}piperidin-4-yl)-1,3-thiazol-4-yl]carbonyl}-1,3-thiazolidine-4-carboxylic acid	

No.	FORMULA	NMR or mass
269	(2E)-3-(1-{[2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazol-4-yl]carbonyl}-1H-imidazol-5-yl)acrylic acid	
270	CHIRAL F F (2R)-cyclohexa-1,4-dien-1-yl({[2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]-carbonyl}piperidin-4-yl)-1,3-thiazol-4-yl]carbonyl}amino)acetic acid	

No.	FORMULA	NMR or mass
271	N-{[2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazol-4-yl]carbonyl}-D-valine	
272	N-[2-amino-1-(4-fluorophenyl)-2-oxoethyl]-N-phenyl-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
273	N-methyl-N-[12-oxo-1,2,3,4,9,9a-hexahydro-4a,9-(epiminoethano)xanthen-2-yl]-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	
274	N-benzyl-N-(2-hydroxy-2-phenylethyl)-2-(1-{[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
275	HN N N O F F F	
276	F F O N O N O N O N O N O N O N O N O N	
277	F F S S S S S S S S S S S S S S S S S S	(CDCl3): 1.27-1.21 (16H, m); 1.27-1.26 (1H, m); 1.24-1.26 (1H, m); 1.21-1.27 (13H, m).
278	F F O N N N N N N N N N N N N N N N N N	(CDCI3): 1.23-1.29 (19H, m); 1.28-1.27 (1H, m); 1.27-1.27 (1H, m); 1.20-1.25 (12H, m).

No.	FORMULA	NMR or mass
279	N-(4-methoxybiphenyl-2-yl)-2-{1-[(2-pyridin-2-ylethyl)sulfonyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	
280		
281		

No.	FORMULA	NMR or mass
282	2-(1-pent-4-enoylpiperidin-4-yl)-N-[2-pyrrolidin-1-yl-5-(trifluoromethyl)-phenyl]-1,3-thiazole-4-carboxamide	E. c.
283		,
284		

No.	FORMULA	NMR or mass
285		
286		
287		

No.	FORMULA	NMR or mass
288	DE LOS DEL LOS DEL LOS DELLOS	
289	HZ COCC	
290		

No.	FORMULA	NMR or mass
291	O N N O N O N O N O N O N O N O N O N O	
292		
293		

No.	FORMULA	NMR or mass
294	methyl N-({4-[4-({[2-pyrrolidin-1-yl-5-(trifluoromethyl)phenyl]amino}-carbonyl)-1,3-thiazol-2-yl]piperidin-1-yl}carbonothioyl)-beta-alaninate	
295		
296	NH S	

No.	FORMULA	NMR or mass
297	NH NN NN NN NN NN NN NN NN NN NN NN NN N	
298	NH NN NN S	
299		
300	NH NH NH NH NH	

No.	FORMULA	NMR or mass
301		
302		
303		
304	NH NH S	

No.	FORMULA	NMR or mass
305	NH S NH S	
306	but-3-en-1-yl 4-[4-({[2-pyrrolidin-1-yl-5-(trifluoromethyl)-phenyl]amino}-carbonyl)-1,3-thiazol-2-yl]piperidine-1-carboxylate	
307	N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)pyridin-3-yl]-2-(1-{[(2-furylmethyl)amino]-carbonothioyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
308	NH S	
309	NH S	
310		
311		

No.	FORMULA	NMR or mass
312	N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)pyridin-3-yl]-2-[1-(ethylsulfonyl)piperidin-4-yl]-1,3-thiazole-4-carboxamide	
313	NH NH NH NH NH NH NH NH NH NH NH NH NH N	
314	O NH S	

No.	FORMULA	NMR or mass
315	N-(2-morpholin-4-ylphenyl)-2-[1-(propylsulfonyl)piperidin-4-yl]-1,3-thiazole-4-carboxamide	
316	NH S	
317	ethyl N-({4-[4-({[2-pyrrolidin-1-yl-5-(trifluoromethyl)phenyl]amino}carbonyl)-1,3-thiazol-2-yl]piperidin-1-yl}carbonothioyl)glycinate	

No.	FORMULA	NMR or mass
318		
319		
320		

No.	FORMULA	NMR or mass
321	2-{1-[(4-chlorophenoxy)acetyl]piperidin-4-yl}-N-(2-morpholin-4-ylphenyl)-1,3-thiazole-4-carboxamide	
322		
323	N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)pyridin-3-yl]-2-[1-(2-phenoxypropanoyl)-piperidin-4-yl]-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
324		
325	O NH NH S	
326	O NH S	

No.	FORMULA	NMR or mass
327	O ZH O N O N O N O N O N O N O N O N O N O	
328		
329	methyl N-({4-[4-({[2-pyrrolidin-1-yl-5-(trifluoromethyl)phenyl]amino}-carbonyl)-1,3-thiazol-2-yl]piperidin-1-yl}carbonothioyl)glycinate	

No.	FORMULA	NMR or mass
330	N S S S S S S S S S S S S S S S S S S S	
331	S N N N N N N N N N N N N N N N N N N N	
332	NH S N S	
333		

No.	FORMULA	NMR or mass
334		
335	NH NH NH N	
336	NH NH S	
337	NH N N S	

No.	FORMULA	NMR or mass
338	NH NN NN S	
339	NH NO	
340	O NH	
341		

No.	FORMULA	NMR or mass
342		
343		
344	ZH S ZH Z	

No.	FORMULA	NMR or mass
345	NH NH S	
346		
347	S N HZ C	

No.	FORMULA	NMR or mass
348		
349	O N NO	
350	S N- N- O HN	

No.	FORMULA	NMR or mass
351	methyl N-({4-[4-({[2-(3,5-dimethyl-1H-pyrazol-1-yl)pyridin-3-yl]amino}-carbonyl)-1,3-thiazol-2-yl]piperidin-1-yl}carbonothioyl)-beta-alaninate	
352	NH NH NH S	
353	2-{1-[(butylamino)carbonothioyl]piperidin-4-yl}-N-[2-pyrrolidin-1-yl-5-(trifluoromethyl)phenyl]-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
354	S N HN F	
355		
356	ON NO N	
357	NH NN NN NN NN NN NN NN NN NN NN NN NN N	

No.	FORMULA	NMR or mass
358		
359	O Z W	
360		·
361	O NH	

No.	FORMULA	NMR or mass
362	2-{1-[(ethylamino)carbonothioyl]piperidin-4-yl}-N-[2-pyrrolidin-1-yl-5-(trifluoromethyl)phenyl]-1,3-thiazole-4-carboxamide	
363	N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)pyridin-3-yl]-2-(1-{[(2-methylbutyl)amino]-carbonothioyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	
364		

No.	FORMULA	NMR or mass
365	O NH NH S	
366	2-{1-[(allylamino)carbonothioyl]piperidin-4-yl}-N-[2-pyrrolidin-1-yl-5-(trifluoromethyl)phenyl]-1,3-thiazole-4-carboxamide	
367	O N S	

No.	FORMULA	NMR or mass
368	NH S	
369	O NH NH NN NN NN O	
370	O N N O N O N O N O N O N O N O N O N O	

No.	FORMULA	NMR or mass
371	O NH S	
372	NH ON NH NH NH NH NH NH NH NH NH NH NH NH NH	
373	ethyl N-({4-[4-({[2-pyrrolidin-1-yl-5-(trifluoromethyl)phenyl]amino}carbonyl)-	

No.	FORMULA	NMR or mass
374	2-(1-{[(2-methylbutyl)amino]carbonothioyl}piperidin-4-yl)-N-[2-pyrrolidin-1-yl-5-(trifluoromethyl)phenyl]-1,3-thiazole-4-carboxamide	
375	NH N	
376	NH O N O N O N O N O N O N O N O N O N O	

No.	FORMULA	NMR or mass
377		
378		
379	O NH S	

No.	FORMULA	NMR or mass
380	O NH S	
381		
382	O NH S	

No.	FORMULA	NMR or mass
383	2-[1-(3-phenylpropanoyl)piperidin-4-yl]-N-[2-pyrrolidin-1-yl-5-(trifluoro-methyl)phenyl]-1,3-thiazole-4-carboxamide	
384	2-[1-(ethylsulfonyl)piperidin-4-yl]-N-(2-morpholin-4-ylphenyl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
385	N-ethyl-4-[4-({[2-pyrrolidin-1-yl-5-(trifluoromethyl)phenyl]amino}carbonyl)-1,3-thiazol-2-yl]piperidine-1-carboxamide	
386	NH ON	
387	O N N N N N N N N N N N N N N N N N N N	

No.	FORMULA	NMR or mass
388		
389	ON NO N	
390	ethyl N-({4-[4-({[2-pyrrolidin-1-yl-5-(trifluoromethyl)phenyl]amino}carbonyl)-1,3-thiazol-2-yl]piperidin-1-yl}carbonyl)glycinate	

No.	FORMULA	NMR or mass
391	O N N O N O N O N O N O N O N O N O N O	
392	O NH S	
393	NH O	
394	D N N O N O N O N O N O N O N O N O N O	

No.	FORMULA	NMR or mass
395	N-butyl-4-[4-({[2-pyrrolidin-1-yl-5-(trifluoromethyl)phenyl]amino}carbonyl)-1,3-thiazol-2-yl]piperidine-1-carboxamide	
396	2-{1-[(isobutylamino)carbonothioyl]piperidin-4-yl}-N-[2-pyrrolidin-1-yl-5-(trifluoromethyl)phenyl]-1,3-thiazole-4-carboxamide	
397	(Initidorometriyi)-1,3-trilazole-4-carboxamide	

No.	FORMULA	NMR or mass
398	SH S	
399	EL S ZH Z ZH Z	
400		

No.	FORMULA	NMR or mass
401		
402	2-[1-(buty sulfonyl)piperidin-4-yl]-N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)pyridin-3-yl]-1,3-thiazole-4-carboxamide	
403		

No.	FORMULA	NMR or mass
404	N N N N N N N N N N N N N N N N N N N	
405	DH S S S S S S S S S S S S S S S S S S S	
406		·
407	NH S	

No.	FORMULA	NMR or mass
408		
409	2-(1-{[(cyclopropylmethyl)amino]carbonothioyl}piperidin-4-yl)-N-[2-pyrrolidin-1-yl-5-(trifluoromethyl)phenyl]-1,3-thiazole-4-carboxamide	
410	NH NH NN NS NH NS	

No.	FORMULA	NMR or mass
411	2-{1-[(pentylamino)carbonothioyl]piperidin-4-yl}-N-[2-pyrrolidin-1-yl-5-(trifluoromethyl)phenyl]-1,3-thiazole-4-carboxamide	
412	NH NH O	
413	N-propyl-4-[4-({[2-pyrrolidin-1-yl-5-(trifluoromethyl)phenyl]amino}carbonyl)-1,3-thiazol-2-yl]piperidine-1-carboxamide	

No.	FORMULA	NMR or mass
414		
415		
416	2-(1-{[(2-furylmethyl)amino]carbonothioyl}piperidin-4-yl)-N-[2-pyrrolidin-1-yl-5-(trifluoromethyl)phenyl]-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
417	2-(1-{[(cyclopropylmethyl)amino]carbonothioyl}piperidin-4-yl)-N-(2-piperidin-1-ylphenyl)-1,3-thiazole-4-carboxamide	
418		
419	O ZH	

No.	FORMULA	NMR or mass
420		
421		
422		
423		

No.	FORMULA	NMR or mass
424	O N O N O N O N O N O N O N O N O N O N	
425	NH N S	
426	N-(2-tert-butylphenyl)-2-(1-{[(cyclopropylmethyl)amino]carbonothioyl}-piperidin-4-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
427	NH S	
428	NH S	
429	NH S	

No.	FORMULA	NMR or mass
430	NH S NH S	
431	NH NH NH S	
432		
433	O NH NH S	

No.	FORMULA	NMR or mass
434	O NH S	
435	NH S	
436		

No.	FORMULA	NMR or mass
437	2-(1-{[(cyclopropylmethyl)amino]carbonothioyl}piperidin-4-yl)-N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)pyridin-3-yl]-1,3-thiazole-4-carboxamide	
438		
439	O NH S N S	

No.	FORMULA	NMR or mass
440	NH S	
441	N-pentyl-4-[4-({[2-pyrrolidin-1-yl-5-(trifluoromethyl)phenyl]amino}carbonyl)-1,3-thiazol-2-yl]piperidine-1-carboxamide	
442	N-allyl-4-[4-({[2-pyrrolidin-1-yl-5-(trifluoromethyl)phenyl]amino}carbonyl)-1,3-thiazol-2-yl]piperidine-1-carboxamide	

No.	FORMULA	NMR or mass
443	NH NH NH NH NH NH NH NH NH NH NH NH NH N	
444	O NH S	
445	O N O N O N O N O N O N O N O N O N O N	

No.	FORMULA	NMR or mass
446	NH S	
447		
448	S Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z	

No.	FORMULA	NMR or mass
449	O NH H S	
450	2-(1-{[(3-methoxypropyl)amino]carbonothioyl}piperidin-4-yl)-N-[2-pyrrolidin-4-yl]	
451	1-yl-5-(trifluoromethyl)phenyl]-1,3-thiazole-4-carboxamide HN S N HN CI	

No.	FORMULA	NMR or mass
452	DH NO NH	
453	NH S	
454	O Z H S	

No.	FORMULA	NMR or mass
455	2-(1-{[(2-methoxyethyl)amino]carbonothioyl}piperidin-4-yl)-N-[2-pyrrolidin-1-yl-5-(trifluoromethyl)phenyl]-1,3-thiazole-4-carboxamide	
456		
457	DE LA CONTRACTION OF THE CONTRAC	

No.	FORMULA	NMR or mass
458		
459	S E HN	
460		
461	S N N N N N N N N N N N N O	

No.	FORMULA	NMR or mass
462	NH NH S	
463	O NH S	
464	HN S N O HN	
465	O NH NH S	

No.	FORMULA	NMR or mass
466	O NHOO	
467	NH S S S S S S S S S S S S S S S S S S S	
468	N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)pyridin-3-yl]-2-[1-(propylsulfonyl)-piperidin-4-yl]-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
469	ON O	
470	NH S	
471		
472	ON NO N	

No.	FORMULA	NMR or mass
473	O N S	
474	HN S N O F HN F	
475	NH NH S	
476	NH NH S	

No.	FORMULA	NMR or mass
477	NH NH NH NH NH NH NH NH NH NH NH NH NH N	
478	NH NH S	
479	2-(1-{[(cyclopropylmethyl)amino]carbonothioyl}piperidin-4-yl)-N-(2-morpholin-4-ylphenyl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
480	N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)pyridin-3-yl]-2-{1-[(2,2,2-trifluoroethyl)-sulfonyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	
481	2-{1-[(propylamino)carbonothioyl]piperidin-4-yl}-N-[2-pyrrolidin-1-yl-5-(trifluoromethyl)phenyl]-1,3-thiazole-4-carboxamide	
482	HN S N O HN F F	

No.	FORMULA	NMR or mass
483	O NH S	
484	O NH S	
485	2-(1-{[(2-methylprop-2-en-1-yl)amino]carbonothioyl}piperidin-4-yl)-N-[2-pyrrolidin-1-yl-5-(trifluoromethyl)phenyl]-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
486	O NH S	
487	NH S	
488	THE CONTRACTOR OF THE CONTRACT	
489	NH O	

No.	FORMULA	NMR or mass
490	NH NH S	
491	2-{1-[(butylamino)carbonothioyl]piperidin-4-yl}-N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)pyridin-3-yl]-1,3-thiazole-4-carboxamide	
492	HN S N O HN F	
493	S N N N N N N N N N N N N N N N N N N N	

No.	FORMULA	NMR or mass
494		
495		
496	F O N N N N N N N N N N N N N N N N N N	

No.	FORMULA	NMR or mass
497		
498	ON NO N	
499		
500	ON NO N	

No.	FORMULA	NMR or mass
501	O Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z	
502		
503		

No.	FORMULA	NMR or mass
504	N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)pyridin-3-yl]-2-[1-(2-methyl-3-phenyl-propanoyl)piperidin-4-yl]-1,3-thiazole-4-carboxamide	
505	F F O HN N O	
506		

No.	FORMULA	NMR or mass
507	ON NO N	
508		
509		
510	F F O O O O O O O O O O O O O O O O O O	

No.	FORMULA	NMR or mass
511		
512		
513	O HN O HN O N O N O N O N O N O N O N O	

No.	FORMULA	NMR or mass
514	F F S HN O HN O	
515	O HN O HN O	
516	O HN O HN O	
517	O HN O HN O	

No.	FORMULA	NMR or mass
518		
519	F F O N N N N N N N N N N N N N N N N N	
520		
521		

No.	FORMULA	NMR or mass
522		
523		
524	O S F F	
525	F F S N O O O O O O O O O O O O O O O O O O	

No.	FORMULA	NMR or mass
526	S H N N F	
527	S H N N F	
528	S H N N F	
529	S F F	

No.	FORMULA	NMR or mass
530	O N N N O O O O O O O O O O O O O O O O	
531	F F CI	
532	O N N N O O	
533	ON H N O	

No.	FORMULA	NMR or mass
534	S F N N N N N N N N N N N N N N N N N N	
535	S F O	
536	N N N N N N N N N N N N N N N N N N N	
537	O NH N S	

No.	FORMULA	NMR or mass
538	S S S S S S S S S S S S S S S S S S S	
539	S H N	
540	ON H N N O	
541	O N N O O O O O O O O O O O O O O O O O	

No.	FORMULA	NMR or mass
542	O ZH Z O O O O O O O O O O O O O O O O O	
543	F O N O CI	
544	ON NO STATE OF THE PROPERTY OF	
545	ON H S CI	

No.	FORMULA	NMR or mass
546	S N N N O	
547	F N N N N N N N N N N N N N N N N N N N	
548		
549		

No.	FORMULA	NMR or mass
550	2-(1-hex-2-ynoylpiperidin-4-yl)-N-(4-methoxybiphenyl-2-yl)-1,3-thiazole-4-carboxamide	•
551	2-(1-hex-2-ynoylpiperidin-4-yl)-N-(2-piperidin-1-ylphenyl)-1,3-thiazole-4-carboxamide	
552	N-(2-tert-butylphenyl)-2-(1-hex-2-ynoylpiperidin-4-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
553		
554		
. 555		
556	O N N N N N N N N N N N N N N N N N N N	

No.	FORMULA	NMR or mass
557	F F O N O O O O O O O O O O O O O O O O	
558	S N N N N N N N N N N N N N N N N N N N	
559	ON H N N N N N N N N N N N N N N N N N N	
560	S H N N N N N N N	

No.	FORMULA	NMR or mass
561	HN O	
562	N N N N N N N N N N N N N N N N N N N	
563	S F F	
564	HN N O	

No.	FORMULA	NMR or mass
565	HIN O	
566	HN N O	
567	N N N N N N N N N N N N N N N N N N N	
568		

No.	FORMULA	NMR or mass
569	O ZH Z Z	
570	F F O N O O O O O O O O O O O O O O O O	
571		
572		

No.	FORMULA	NMR or mass
573		
574		
575	F F O N N O O O O O O O O O O O O O O O	
576		

No.	FORMULA	NMR or mass
577	O N O N O N O N O N O N O N O N O N O N	
578		
579	N-(4-methoxybiphenyl-2-yl)-2-(1-pent-2-ynoylpiperidin-4-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
580	2-(1-pent-2-ynoylpiperidin-4-yl)-N-[2-pyrrolidin-1-yl-5-(trifluoromethyl)-phenyl]-1,3-thiazole-4-carboxamide	
581	N-(2-tert-butylphenyl)-2-(1-pent-2-ynoylpiperidin-4-yl)-1,3-thiazole-4-carboxamide	
582	Carboxamide O S S S S S S S S S S S S S S S S S S	

No.	FORMULA	NMR or mass
583	F F O O O O O O O O O O O O O O O O O O	
584	O N N O O	
585	NH N CI	
586	S N N N O O	

No.	FORMULA	NMR or mass
587	O NH O NH O O	
588	F F O N O CI	
589	O N N N C C N N N N N N N N N N N N N N	
590	O N N N O O	

No.	FORMULA	NMR or mass
591	O N H N O CI	
592	O NH NO O	
593	F F CI	
594	S H N N	

No.	FORMULA	NMR or mass
595	ON H N N CI	
596	S N N O	
597	N N N CI	
598	F F F N HN O	

No.	FORMULA	NMR or mass
599	HN O N O N O N O N O N O N O N O N O N O	
600	O N N O N O N O N O N O N O N O N O N O	
601	F F O N N N N N N N N N N N N N N N N N	
602		

No.	FORMULA	NMR or mass
603	N N O N O	
604	NH N	
605	O N N N N N N N N N N N N N N N N N N N	
606	F F O N N N N N N N N N N N N N N N N N	

No.	FORMULA	NMR or mass
607		
608	O N O N O	
609		
610		

No.	FORMULA	NMR or mass
611	F F N N N N N N N N N N N N N N N N N N	
612		
613	ON O	
614		

No.	FORMULA	NMR or mass
615		
616	O N O N O N O N O N O N O N O N O N O N	
617	S S S S S S S S S S S S S S S S S S S	
618	F F S S S S S S S S S S S S S S S S S S	

No.	FORMULA	NMR or mass
619		
620	O N N O	
621	O N O N O O O O O O O O O O O O O O O O	5°
622		

No.	FORMULA	NMR or mass
623	ON NO N	
624	S F F	
625	S F F F	
626	O N F F F	

No.	FORMULA	NMR or mass
627	O ZH LE	
628	STI ZO	
629	O N H F F	
630	S N N N N N N F	

No.	FORMULA	NMR or mass
631	F F O S F F	
632	O N H N F F	
633	S H N N F	
634		

No.	FORMULA	NMR or mass
635	F F O HN N	
636	O N N N N N N N N N N N N N N N N N N N	
637		
638	F F O HN N S	

No.	FORMULA	NMR or mass
639	THE STATE OF THE S	
640		
641	O N N N N N N N N N N N N N N N N N N N	
642	N N N N N N N N N N N N N N N N N N N	

No.	FORMULA	NMR or mass
643		
644	O Z Z S S S S S S S S S S S S S S S S S	
645		
646	S N N N N N N N N N N N N N N N N N N N	

No.	FORMULA	NMR or mass
647	ON NO N	
648	OH NH NH NH NH NH NH NH NH NH NH NH NH NH	
649	OH N H S	
650	OH NH S	

No.	FORMULA	NMR or mass
651	OH N N N N N N	
652		
653		
654		

No.	FORMULA	NMR or mass
655		
656		
657	2-(1-pent-4-enoylpiperidin-4-yl)-N-[4'-(trifluoromethoxy)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
658	N-(4'-fluorobiphenyl-2-yl)-2-(1-pent-4-enoylpiperidin-4-yl)-1,3-thiazole-4-carboxamide	
659	N-(4'-chlorobiphenyl-2-yl)-2-(1-pent-4-enoylpiperidin-4-yl)-1,3-thiazole-4-carboxamide	
660	O N N N N N N N N N N N N N N N N N N N	

No.	FORMULA	NMR or mass
661	O N O N O O N O O O O O O O O O O O O O	
662	2-(1-pent-4-enoylpiperidin-4-yl)-N-[3'-(trifluoromethyl)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
663	N-(4'-chloro-5-fluorobiphenyl-2-yl)-2-(1-pent-4-enoylpiperidin-4-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
664		
665	2-[1-(3-phenylpropanoyl)piperidin-4-yl]-N-[4'-(trifluoromethoxy)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
666	N-(4'-fluorobiphenyl-2-yl)-2-[1-(3-phenylpropanoyl)piperidin-4-yl]-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
667	N-(4'-chlorobiphenyl-2-yl)-2-[1-(3-phenylpropanoyl)piperidin-4-yl]-1,3-thiazole-4-carboxamide	
668		
669		

No.	FORMULA	NMR or mass
670	2-[1-(3-phenylpropanoyl)piperidin-4-yl]-N-[3'-(trifluoromethyl)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
671	N-(4'-chloro-5-fluorobiphenyl-2-yl)-2-[1-(3-phenylpropanoyl)piperidin-4-yl]-	
672	ethyl 4-[4-(4-{[(4'-ethylbiphenyl-2-yl)amino]carbonyl}-1,3-thiazol-2-yl)-piperidin-1-yl]-4-oxobutanoate	

No.	FORMULA	NMR or mass
673	ethyl 4-oxo-4-{4-[4-({[4'-(trifluoromethoxy)biphenyl-2-yl]amino}carbonyl)-1,3-thiazol-2-yl]piperidin-1-yl}butanoate	
674	ethyl 4-[4-(4-{[(4'-fluorobiphenyl-2-yl)amino]carbonyl}-1,3-thiazol-2-yl)-piperidin-1-yl]-4-oxobutanoate	

No.	FORMULA	NMR or mass
675	ethyl 4-[4-(4-{[(4'-chlorobiphenyl-2-yl)amino]carbonyl}-1,3-thiazol-2-yl)-piperidin-1-yl]-4-oxobutanoate	
676	ethyl 4-[4-(4-{[(4'-methylbiphenyl-2-yl)amino]carbonyl}-1,3-thiazol-2-yl)-piperidin-1-yl]-4-oxobutanoate	
677		

No.	FORMULA	NMR or mass
678	ethyl 4-oxo-4-{4-[4-({[3'-(trifluoromethyl)biphenyl-2-yl]amino}carbonyl)-1,3-thiazol-2-yl]piperidin-1-yl}butanoate	
679	ethyl 4-[4-(4-{[(4'-chloro-5-fluorobiphenyl-2-yl)amino]carbonyl}-1,3-thiazol-2-yl)piperidin-1-yl]-4-oxobutanoate	

No.	FORMULA	NMR or mass
680	2-{1-[(4-chlorophenoxy)acetyl]piperidin-4-yl}-N-[4'-(trifluoromethoxy)-biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
681	O N N O N O N O N O N O N O N O N O N O	

No.	FORMULA	NMR or mass
682	methyl 4-oxo-4-{4-[4-({[4'-(trifluoromethoxy)biphenyl-2-yl]amino}carbonyl)-1,3-thiazol-2-yl]piperidin-1-yl}butanoate	
683	methyl 4-[4-(4-{[(4'-fluorobiphenyl-2-yl)amino]carbonyl}-1,3-thiazol-2-yl)-piperidin-1-yl]-4-oxobutanoate	

No.	FORMULA	NMR or mass
684	methyl 4-[4-(4-{[(4'-chlorobiphenyl-2-yl)amino]carbonyl}-1,3-thiazol-2-yl)-piperidin-1-yl]-4-oxobutanoate	
685		
686		

No.	FORMULA	NMR or mass
687	methyl 4-oxo-4-{4-[4-({[3'-(trifluoromethyl)biphenyl-2-yl]amino}carbonyl)-1,3-thiazol-2-yl]piperidin-1-yl}butanoate	
688	methyl 4-[4-(4-{[(4'-chloro-5-fluorobiphenyl-2-yl)amino]carbonyl}-1,3-thiazol-2-yl)piperidin-1-yl]-4-oxobutanoate	

No.	FORMULA	NMR or mass
689	N N N N N N N N N N N N N N N N N N N	·
690	2-(1-butyrylpiperidin-4-yl)-N-[4'-(trifluoromethoxy)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
691	2-(1-butyrylpiperidin-4-yl)-N-(4'-fluorobiphenyl-2-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
692	2-(1-butyrylpiperidin-4-yl)-N-(4'-chlorobiphenyl-2-yl)-1,3-thiazole-4-carboxamide	
693		
694		

No.	FORMULA	NMR or mass
695	2-(1-butyrylpiperidin-4-yl)-N-[3'-(trifluoromethyl)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
696	2-(1-butyrylpiperidin-4-yl)-N-(4'-chloro-5-fluorobiphenyl-2-yl)-1,3-thiazole-4-carboxamide	·
697		

No.	FORMULA	NMR or mass
698	2-[1-(3-cyclopentylpropanoyl)piperidin-4-yl]-N-[4'-(trifluoromethoxy)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
699	2-[1-(3-cyclopentylpropanoyl)piperidin-4-yl]-N-(4'-fluorobiphenyl-2-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
700	N-(4'-chlorobiphenyl-2-yl)-2-[1-(3-cyclopentylpropanoyl)piperidin-4-yl]-1,3-thiazole-4-carboxamide	
701		
702		

No.	FORMULA	NMR or mass
703	2-[1-(3-cyclopentylpropanoyl)piperidin-4-yl]-N-[3'-(trifluoromethyl)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
704	N-(4'-chloro-5-fluorobiphenyl-2-yl)-2-[1-(3-cyclopentylpropanoyl)piperidin-4-yl]-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
705		
706	2-[1-(2-phenoxypropanoyl)piperidin-4-yl]-N-[4'-(trifluoromethoxy)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
707	N-(4'-fluorobiphenyl-2-yl)-2-[1-(2-phenoxypropanoyl)piperidin-4-yl]-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
708	N-(4'-chlorobiphenyl-2-yl)-2-[1-(2-phenoxypropanoyl)piperidin-4-yl]-1,3-thiazole-4-carboxamide	
709		
710		

No.	FORMULA	NMR or mass
711	2-[1-(2-phenoxypropanoyl)piperidin-4-yl]-N-[3'-(trifluoromethyl)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
712	N-(4'-chloro-5-fluorobiphenyl-2-yl)-2-[1-(ethylsulfonyl)piperidin-4-yl]-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
713	N-(4'-chloro-5-fluorobiphenyl-2-yl)-2-[1-(propylsulfonyl)piperidin-4-yl]-1,3-thiazole-4-carboxamide	
714	O N O N O N O N O N O N O N O N O N O N	
715	butyl 4-[4-({[4'-(trifluoromethoxy)biphenyl-2-yl]amino}carbonyl)-1,3-thiazol-2-yl]piperidine-1-carboxylate	

No.	FORMULA	NMR or mass
716	butyl 4-(4-{[(4'-fluorobiphenyl-2-yl)amino]carbonyl}-1,3-thiazol-2-yl)-piperidine-1-carboxylate	
717	butyl 4-(4-{[(4'-chlorobiphenyl-2-yl)amino]carbonyl}-1,3-thiazol-2-yl)-	
718	piperidine-1-carboxylate	

720 P HN S N N N N N N N N N N N N	No.	FORMULA	NMR or mass
butyl 4-[4-({[3'-(trifluoromethyl)biphenyl-2-yl]amino}carbonyl)-1,3-thiazol-2-yl]piperidine-1-carboxylate	719		·
721 HN	720	butyl 4-[4-({[3'-(trifluoromethyl)biphenyl-2-yl]amino}carbonyl)-1,3-thiazol-2-	
butyl 4-(4-{[(4'-chloro-5-fluorobiphenyl-2-yl)amino]carbonyl}-1,3-thiazol-2-yl)- piperidine-1-carboxylate	721	butyl 4-(4-{[(4'-chloro-5-fluorobiphenyl-2-yl)amino]carbonyl}-1,3-thiazol-2-yl)-	

No.	FORMULA	NMR or mass
722	but-3-en-1-yl 4-(4-{[(4'-ethylbiphenyl-2-yl)amino]carbonyl}-1,3-thiazol-2-yl)-piperidine-1-carboxylate	
723	but-3-en-1-yl 4-[4-({[4'-(trifluoromethoxy)biphenyl-2-yl]amino}carbonyl)-1,3-thiazol-2-yl]piperidine-1-carboxylate	
724	but-3-en-1-yl 4-(4-{[(4'-fluorobiphenyl-2-yl)amino]carbonyl}-1,3-thiazol-2-yl)-piperidine-1-carboxylate	

No.	FORMULA	NMR or mass
725	but-3-en-1-yl 4-(4-{[(4'-chlorobiphenyl-2-yl)amino]carbonyl}-1,3-thiazol-2-yl)-piperidine-1-carboxylate	
726	NH N	
727		

No.	FORMULA	NMR or mass
728	but-3-en-1-yl 4-[4-({[3'-(trifluoromethyl)biphenyl-2-yl]amino}carbonyl)-1,3-thiazol-2-yl]piperidine-1-carboxylate	
729	but-3-en-1-yl 4-(4-{[(4'-chloro-5-fluorobiphenyl-2-yl)amino]carbonyl}-1,3-thiazol-2-yl)piperidine-1-carboxylate	
730	N N N N N N N N N N N N N N N N N N N	

No.	FORMULA	NMR or mass
731	allyl 4-[4-({[4'-(trifluoromethoxy)biphenyl-2-yl]amino}carbonyl)-1,3-thiazol-2-yl]piperidine-1-carboxylate	
732	allyl 4-(4-{[(4'-fluorobiphenyl-2-yl)amino]carbonyl}-1,3-thiazol-2-yl)piperidine-1-carboxylate	
733	allyl 4-(4-{[(4'-chlorobiphenyl-2-yl)amino]carbonyl}-1,3-thiazol-2-yl)-piperidine-1-carboxylate	

No.	FORMULA	NMR or mass
734		
735		
736	allyl 4-[4-({[3'-(trifluoromethyl)biphenyl-2-yl]amino}carbonyl)-1,3-thiazol-2-yl]piperidine-1-carboxylate	

No.	FORMULA	NMR or mass
737	allyl 4-(4-{[(4'-chloro-5-fluorobiphenyl-2-yl)amino]carbonyl}-1,3-thiazol-2-yl)-piperidine-1-carboxylate	
738	2-methoxyethyl 4-[4-({[4'-(trifluoromethoxy)biphenyl-2-yl]amino}carbonyl)-1,3-thiazol-2-yl]piperidine-1-carboxylate	
739	2-methoxyethyl 4-(4-{[(4'-fluorobiphenyl-2-yl)amino]carbonyl}-1,3-thiazol-2-yl)piperidine-1-carboxylate	

No.	FORMULA	NMR or mass
740	2-methoxyethyl 4-(4-{[(4'-chlorobiphenyl-2-yl)amino]carbonyl}-1,3-thiazol-2-yl)piperidine-1-carboxylate	
741		
742		

No.	FORMULA	NMR or mass
743	2-methoxyethyl 4-(4-{[(4'-chloro-5-fluorobiphenyl-2-yl)amino]carbonyl}-1,3-thiazol-2-yl)piperidine-1-carboxylate	
744	N-pentyl-4-[4-({[4'-(trifluoromethoxy)biphenyl-2-yl]amino}carbonyl)-1,3-thiazol-2-yl]piperidine-1-carboxamide	

No.	FORMULA	NMR or mass
745	4-(4-{[(4'-fluorobiphenyl-2-yl)amino]carbonyl}-1,3-thiazol-2-yl)-N-pentyl-piperidine-1-carboxamide	
746	4-(4-{[(4'-chlorobiphenyl-2-yl)amino]carbonyl}-1,3-thiazol-2-yl)-N-pentyl-piperidine-1-carboxamide	
747	piperidine-1-carboxamide NH NH NS NH	

No.	FORMULA	NMR or mass
748	N N N N N N N N N N N N N N N N N N N	
749	N-pentyl-4-[4-({[3'-(trifluoromethyl)biphenyl-2-yl]amino}carbonyl)-1,3-thiazol-2-yl]piperidine-1-carboxamide	
750	4-(4-{[(4'-chloro-5-fluorobiphenyl-2-yl)amino]carbonyl}-1,3-thiazol-2-yl)-N-pentylpiperidine-1-carboxamide	

No.	FORMULA	NMR or mass
751	NH ON	
752	4-(4-{[(4'-chloro-5-fluorobiphenyl-2-yl)amino]carbonyl}-1,3-thiazol-2-yl)-N-ethylpiperidine-1-carboxamide	
753	N-allyl-4-[4-({[4'-(trifluoromethoxy)biphenyl-2-yl]amino}carbonyl)-1,3-thiazol-2-yl]piperidine-1-carboxamide	

No.	FORMULA	NMR or mass
754		
	N-allyl-4-(4-{[(4'-fluorobiphenyl-2-yl)amino]carbonyl}-1,3-thiazol-2-yl)- piperidine-1-carboxamide	
755	N-allyl-4-(4-{[(4'-chlorobiphenyl-2-yl)amino]carbonyl}-1,3-thiazol-2-yl)-piperidine-1-carboxamide	
756	NH NH ON	

No.	FORMULA	NMR or mass
757	N-allyl-4-(4-{[(4'-chloro-5-fluorobiphenyl-2-yl)amino]carbonyl}-1,3-thiazol-2-yl)piperidine-1-carboxamide	
758	ethyl N-{[4-(4-{[(4'-ethylbiphenyl-2-yl)amino]carbonyl}-1,3-thiazol-2-yl)-piperidin-1-yl]carbonyl}glycinate	

No.	FORMULA	NMR or mass
759	ethyl N-({4-[4-({[4'-(trifluoromethoxy)biphenyl-2-yl]amino}carbonyl)-1,3-thiazol-2-yl]piperidin-1-yl}carbonyl)glycinate	
760	ethyl N-{[4-(4-{[(4'-fluorobiphenyl-2-yl)amino]carbonyl}-1,3-thiazol-2-yl)-piperidin-1-yl]carbonyl}glycinate	
761	NH N	

No.	FORMULA	NMR or mass
762		
763	NH NH NH NH NH	
764	4-(4-{[(4'-chloro-5-fluorobiphenyl-2-yl)amino]carbonyl}-1,3-thiazol-2-yl)-N-propylpiperidine-1-carboxamide	

No.	FORMULA	NMR or mass
765	N-butyl-4-[4-({[4'-(trifluoromethoxy)biphenyl-2-yl]amino}carbonyl)-1,3-thiazol-2-yl]piperidine-1-carboxamide	
766	N-butyl-4-(4-{[(4'-fluorobiphenyl-2-yl)amino]carbonyl}-1,3-thiazol-2-yl)-piperidine-1-carboxamide	

No.	FORMULA	NMR or mass
767	N-butyl-4-(4-{[(4'-chlorobiphenyl-2-yl)amino]carbonyl}-1,3-thiazol-2-yl)-piperidine-1-carboxamide	
768	NH NH ON NH	
769	NH NH NH NH NH	

No.	FORMULA	NMR or mass
770	N-butyl-4-[4-({[3'-(trifluoromethyl)biphenyl-2-yl]amino}carbonyl)-1,3-thiazol-2-yl]piperidine-1-carboxamide	
771	N-butyl-4-(4-{[(4'-chloro-5-fluorobiphenyl-2-yl)amino]carbonyl}-1,3-thiazol-2-yl)piperidine-1-carboxamide	

No.	FORMULA	NMR or mass
772	N-(4'-fluorobiphenyl-2-yl)-2-(1-{[(2-methylprop-2-en-1-yl)amino]carbonothioyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	
773	N-(4'-chlorobiphenyl-2-yl)-2-(1-{[(2-methylprop-2-en-1-yl)amino]carbonothioyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
774	N-(4'-chloro-5-fluorobiphenyl-2-yl)-2-(1-{[(2-methylprop-2-en-1-yl)amino]-carbonothioyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	
775	2-{1-[(allylamino)carbonothioyl]piperidin-4-yl}-N-(4'-fluorobiphenyl-2-yl)-1,3-thiazole-4-carboxamide	
776	2-{1-[(allylamino)carbonothioyl]piperidin-4-yl}-N-(4'-chlorobiphenyl-2-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
777	2-{1-[(allylamino)carbonothioyl]piperidin-4-yl}-N-(4'-chloro-5-fluorobiphenyl-2-yl)-1,3-thiazole-4-carboxamide	
778	N-(4'-fluorobiphenyl-2-yl)-2-(1-{[(2-furylmethyl)amino]-carbonothioyl}-piperidin-4-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
779	N-(4'-chlorobiphenyl-2-yl)-2-(1-{[(2-furylmethyl)amino]carbonothioyl}-piperidin-4-yl)-1,3-thiazole-4-carboxamide	
780	N-(4'-chloro-5-fluorobiphenyl-2-yl)-2-(1-{[(2-furylmethyl)amino]carbonothioyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
781	methyl 2-({[4-(4-{[(4'-fluorobiphenyl-2-yl)amino]carbonyl}-1,3-thiazol-2-yl)-piperidin-1-yl]carbonothioyl}amino)butanoate	
782	methyl 2-{{[4-(4-{[(4'-chlorobiphenyl-2-yl)amino]carbonyl}-1,3-thiazol-2-yl)-piperidin-1-yl]carbonothioyl}amino)butanoate	

No.	FORMULA	NMR or mass
783	methyl 2-({[4-(4-{[(4'-chloro-5-fluorobiphenyl-2-yl)amino]carbonyl}-1,3-thiazol-2-yl)piperidin-1-yl]carbonothioyl}amino)butanoate	
784	ethyl N-{[4-(4-{[(4'-fluorobiphenyl-2-yl)amino]carbonyl}-1,3-thiazol-2-yl)-piperidin-1-yl]carbonothioyl}glycinate	

No.	FORMULA	NMR or mass
785	ethyl N-{[4-(4-{[(4'-chlorobiphenyl-2-yl)amino]carbonyl}-1,3-thiazol-2-yl)-piperidin-1-yl]carbonothioyl}glycinate	
786	ethyl N-{[4-(4-{[(4'-chloro-5-fluorobiphenyl-2-yl)amino]carbonyl}-1,3-thiazol-2-yl)piperidin-1-yl]carbonothioyl}glycinate	
787		

No.	FORMULA	NMR or mass
788	ethyl N-{[4-(4-{[(4'-fluorobiphenyl-2-yl)amino]carbonyl}-1,3-thiazol-2-yl)-piperidin-1-yl]carbonothioyl}alaninate	
789	ethyl N-{[4-(4-{[(4'-chlorobiphenyl-2-yl)amino]carbonyl}-1,3-thiazol-2-yl)-piperidin-1-yl]carbonothioyl}alaninate	

No.	FORMULA	NMR or mass
790	ethyl N-{[4-(4-{[(4'-chloro-5-fluorobiphenyl-2-yl)amino]carbonyl}-1,3-thiazol-2-yl)piperidin-1-yl]carbonothioyl}alaninate	
791	NH NH S	

No.	FORMULA	NMR or mass
792	2-{1-[(ethylamino)carbonothioyl]piperidin-4-yl}-N-(4'-fluorobiphenyl-2-yl)-1,3-thiazole-4-carboxamide	·
793	N-(4'-chlorobiphenyl-2-yl)-2-{1-[(ethylamino)carbonothioyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
794	N-(4'-chloro-5-fluorobiphenyl-2-yl)-2-{1-[(ethylamino)carbonothioyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	
795	NH NN NN NN NN NN NN NN NN NN NN NN NN N	
796	N-(4'-fluorobiphenyl-2-yl)-2-{1-[(propylamino)carbonothioyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
797	N-(4'-chlorobiphenyl-2-yl)-2-{1-[(propylamino)carbonothioyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	
798	N-(4'-chloro-5-fluorobiphenyl-2-yl)-2-{1-[(propylamino)carbonothioyl]-piperidin-4-yl}-1,3-thiazole-4-carboxamide	
799	2-{1-[(butylamino)carbonothioyl]piperidin-4-yl}-N-(4'-fluorobiphenyl-2-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
800	2-{1-[(butylamino)carbonothioyl]piperidin-4-yl}-N-(4'-chlorobiphenyl-2-yl)-1,3-thiazole-4-carboxamide	·
801	HN S N HN F 2-{1-[(butylamino)carbonothioyl]piperidin-4-yl}-N-(4'-chloro-5-fluorobiphenyl-	
802	2-ỳl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
803	N-(4'-fluorobiphenyl-2-yl)-2-{1-[(pentylamino)carbonothioyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	
804	N-(4'-chlorobiphenyl-2-yl)-2-{1-[(pentylamino)carbonothioyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMŔ or mass
805	N-(4'-chloro-5-fluorobiphenyl-2-yl)-2-{1-[(pentylamino)carbonothioyl]-piperidin-4-yl}-1,3-thiazole-4-carboxamide	
806	N-(4'-fluorobiphenyl-2-yl)-2-{1-[(isobutylamino)carbonothioyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
807	N-(4'-chlorobiphenyl-2-yl)-2-{1-[(isobutylamino)carbonothioyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	
808	N-(4'-chloro-5-fluorobiphenyl-2-yl)-2-{1-[(isobutylamino)carbonothioyl]-piperidin-4-yl}-1,3-thiazole-4-carboxamide	
809	N-(4'-fluorobiphenyl-2-yl)-2-(1-{[(3-methoxypropyl)amino]carbonothioyl}-piperidin-4-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
810	N-(4'-chlorobiphenyl-2-yl)-2-(1-{[(3-methoxypropyl)amino]-carbonothioyl}-piperidin-4-yl)-1,3-thiazole-4-carboxamide	
811	N-(4'-chloro-5-fluorobiphenyl-2-yl)-2-(1-{[(3-methoxypropyl)-amino]carbonothioyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	
812	O NH NH S	

No.	FORMULA	NMR or mass
813	methyl N-{[4-(4-{[(4'-fluorobiphenyl-2-yl)amino]carbonyl}-1,3-thiazol-2-yl)-piperidin-1-yl]carbonothioyl}glycinate	
814	methyl N-{[4-(4-{[(4'-chlorobiphenyl-2-yl)amino]carbonyl}-1,3-thiazol-2-yl)-piperidin-1-yl]carbonothioyl}glycinate	

No.	FORMULA	NMR or mass
815	methyl N-{[4-(4-{[(4'-chloro-5-fluorobiphenyl-2-yl)amino]carbonyl}-1,3-thiazol-2-yl)piperidin-1-yl]carbonothioyl}glycinate	
816	N-(4'-fluorobiphenyl-2-yl)-2-(1-{[(2-methoxyethyl)amino]-carbonothioyl}-piperidin-4-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
817	N-(4'-chlorobiphenyl-2-yl)-2-(1-{[(2-methoxyethyl)amino]-carbonothioyl}-piperidin-4-yl)-1,3-thiazole-4-carboxamide	
818.	The state of the s	
819	N-(4'-chloro-5-fluorobiphenyl-2-yl)-2-(1-{[(2-methoxyethyl)amino]-carbono-thioyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide N-(4'-chloro-5-fluorobiphenyl-2-yl)-1,3-thiazole-4-carboxamide N-(1-(1-(1-(1-(1-(1-(1-(1-(1-(1-(1-(1-(1-	

No.	FORMULA	NMR or mass
820	methyl N-{[4-(4-{[(4'-fluorobiphenyl-2-yl)amino]carbonyl}-1,3-thiazol-2-yl)-piperidin-1-yl]carbonothioyl}-beta-alaninate	
821	methyl N-{[4-(4-{[(4'-chlorobiphenyl-2-yl)amino]carbonyl}-1,3-thiazol-2-yl)-piperidin-1-yl]carbonothioyl}-beta-alaninate	

No.	FORMULA	NMR or mass
822	methyl N-{[4-(4-{[(4'-chloro-5-fluorobiphenyl-2-yl)amino]carbonyl}-1,3-thiazol-2-yl)piperidin-1-yl]carbonothioyl}-beta-alaninate	
823	N-(4'-fluorobiphenyl-2-yl)-2-(1-{[(1-methylbutyl)amino]-carbonothioyl}-piperidin-4-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
824	N-(4'-chlorobiphenyl-2-yl)-2-(1-{[(1-methylbutyl)amino]-carbonothioyl}-piperidin-4-yl)-1,3-thiazole-4-carboxamide	
825	N-(4'-chloro-5-fluorobiphenyl-2-yl)-2-(1-{[(1-methylbutyl)amino]-carbonothioyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
826	N-(4'-fluorobiphenyl-2-yl)-2-(1-{[(2-methylbutyl)amino]carbonothioyl}-piperidin-4-yl)-1,3-thiazole-4-carboxamide	
827	N-(4'-chlorobiphenyl-2-yl)-2-(1-{[(2-methylbutyl)amino]-carbonothioyl}-piperidin-4-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
828	N-(4'-chloro-5-fluorobiphenyl-2-yl)-2-(1-{[(2-methylbutyl)amino]-carbono-thioyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	
829	NH N O	
830	NH S O HN	

No.	FORMULA	NMR or mass
831	S N N N N N N N N N N N N N N N N N N N	
832	N-(4'-fluorobiphenyl-2-yl)-2-(1-{[(3-methylbutyl)amino]-carbonothioyl}-piperidin-4-yl)-1,3-thiazole-4-carboxamide	
833	N-(4'-chlorobiphenyl-2-yl)-2-(1-{[(3-methylbutyl)amino]-carbonothioyl}-piperidin-4-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
834	N-(4'-chloro-5-fluorobiphenyl-2-yl)-2-(1-{[(3-methylbutyl)amino]-carbono-thioyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	
835	N-(4'-ethylbiphenyl-2-yl)-2-(1-hexanoylpiperidin-4-yl)-1,3-thiazole-4-carboxamide	
836	2-(1-hexanoylpiperidin-4-yl)-N-[4'-(trifluoromethoxy)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
837	N-(4'-fluorobiphenyl-2-yl)-2-(1-hexanoylpiperidin-4-yl)-1,3-thiazole-4-	
	carboxamide	
838	N-(4'-chlorobiphenyl-2-yl)-2-(1-hexanoylpiperidin-4-yl)-1,3-thiazole-4-carboxamide	
839		

No.	FORMULA	NMR or mass
840		
841	2-(1-hexanoylpiperidin-4-yl)-N-[3'-(trifluoromethyl)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
842	N-(4'-chloro-5-fluorobiphenyl-2-yl)-2-(1-hexanoylpiperidin-4-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
843	NH NH O	
844	NH NH O	
845	F F O O O O O O O O O O O O O O O O O O	
846	F F S N O	

No.	FORMULA	NMR or mass
847	NH NH O	
848	NH NH O	
849	NH NH O	
850	NH NH S	

No.	FORMULA	NMR or mass
851	NH NH S	
852	F F O HN N N N N N N N N N N N N N N N N N	
853	NH N O	
854	NH NH O	

No.	FORMULA	NMR or mass
855	NH NO	
856	NH NO	
857	O H O H O	,
858	NH NH O	

No.	FORMULA	NMR or mass
859	N N N HN O	
860	NH NH O	
861	NH NH O	
862	NH NO	

No.	FORMULA	NMR or mass
863	F F O N S N O O	
864	NH NH O	
865	2-{1-[3-(3,4-difluorophenyl)propanoyl]piperidin-4-yl}-N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)pyridin-3-yl]-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
866	2-{1-[3-(3-chlorophenyl)propanoyl]piperidin-4-yl}-N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)pyridin-3-yl]-1,3-thiazole-4-carboxamide	
867	2-{1-[3-(3-chlorophenyl)propanoyl]piperidin-4-yl}-N-(2-piperidin-1-ylphenyl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
868	2-{1-[3-(3-chlorophenyl)propanoyl]piperidin-4-yl}-N-(2-morpholin-4-yl-phenyl)-1,3-thiazole-4-carboxamide	
869	2-{1-[3-(2-fluorophenyl)propanoyl]piperidin-4-yl}-N-(4-methoxybiphenyl-2-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
870	N-biphenyl-2-yl-2-{1-[3-(3-fluorophenyl)propanoyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	
871	N-N S	
872	NH NH O	

No.	FORMULA	NMR or mass
873	NH NO	
874	N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)pyridin-3-yl]-2-(1-hex-2-ynoylpiperidin-4-yl)-1,3-thiazole-4-carboxamide	
875	2-(1-hex-2-ynoylpiperidin-4-yl)-N-[2-pyrrolidin-1-yl-5-(trifluoromethyl)phenyl]-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
876	N-biphenyl-2-yl-2-(1-hex-2-ynoylpiperidin-4-yl)-1,3-thiazole-4-carboxamide	
877	NH NO	
878	N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)pyridin-3-yl]-2-{1-[(4-fluorophenoxy)-acetyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
879	NH N O	
880	NH NH O	
881	F F O N O OH	
882	NH NH OH	

No.	FORMULA	NMR or mass
883	NH NH OH	
884	NH NH OH	
885	NH N O	

No.	FORMULA	NMR or mass
886	2-(1-pent-2-ynoylpiperidin-4-yl)-N-(2-piperidin-1-ylphenyl)-1,3-thiazole-4-carboxamide	
887	N-biphenyl-2-yl-2-(1-pent-2-ynoylpiperidin-4-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
888	N-(2-morpholin-4-ylphenyl)-2-(1-pent-2-ynoylpiperidin-4-yl)-1,3-thiazole-4-carboxamide	
889	2-{1-[(3-chlorophenoxy)acetyl]piperidin-4-yl}-N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)pyridin-3-yl]-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
890	2-{1-[(3-chlorophenoxy)acetyl]piperidin-4-yl}-N-(2-piperidin-1-ylphenyl)-1,3-thiazole-4-carboxamide	
891	2-{1-[3-(2-chlorophenyl)propanoyl]piperidin-4-yl}-N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)pyridin-3-yl]-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
892	2-{1-[3-(2-chlorophenyl)propanoyl]piperidin-4-yl}-N-(2-morpholin-4-yl-phenyl)-1,3-thiazole-4-carboxamide	
893	phenyl)-1,3-thiazole-4-carboxamide HN O NH NO	
894	NH NH NO	

No.	FORMULA	NMR or mass
895	HN O NH N O	
896	HN O O S S S S S S S S S S S S S S S S S	
897	O HN O O	
898	N N N N N N N N N N N N N N N N N N N	

No.	FORMULA	NMR or mass
899	NH NH O	
900	NH NH O	
901	NH NH NO	
902	O NH NO	

No.	FORMULA	NMR or mass
903	No N	
904	F O N O O O O O O O O O O O O O O O O O	
905	NH NH O	
906	NH NHO	

No.	FORMULA	NMR or mass
907	ON SOH	
908	HO HO S	
909	H P S	
910	HO H	

No.	FORMULA	NMR or mass
911	HO HO O	
912	HO HO S	
913	NH NH O	
914	F F O HN N	

No.	FORMULA	NMR or mass
915	NH S N CI	
916	N N N S N CI	
917	F F CI CI N N O	

No.	FORMULA	NMR or mass
918	NH ONH ON NO CI	
919	NH ONS N CI	
920	NH S CI	

No.	FORMULA	NMR or mass
921	F F O N O O O O O O O O O O O O O O O O	
922	NH NO	
923	F O N N N N N N N N N N N N N N N N N N	

No.	FORMULA	NMR or mass
924	F F F O HN N O	
925	F F O HN N O	
926	N-(2-morpholin-4-ylphenyl)-2-{1-[(2,2,2-trifluoroethyl)sulfonyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
927	N-(2-tert-butylphenyl)-2-[1-(ethylsulfonyl)piperidin-4-yl]-1,3-thiazole-4-carboxamide	
928	N-(2-tert-butylphenyl)-2-[1-(propylsulfonyl)piperidin-4-yl]-1,3-thiazole-4-carboxamide	
929	N-(2-tert-butylphenyl)-2-[1-(butylsulfonyl)piperidin-4-yl]-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
930	N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)pyridin-3-yl]-2-{1-[(2-pyridin-2-ylethyl)-sulfonyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	
931	N-(2-tert-butylphenyl)-2-{1-[(2-pyridin-2-ylethyl)sulfonyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
932	N-(2-morpholin-4-ylphenyl)-2-{1-[(2-pyridin-2-ylethyl)sulfonyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	
933	NH N N N N N N N N N N N N N N N N N N	
934	F F S N N N N N N N N N N N N N N N N N	

No.	FORMULA	NMR or mass
935	NH NO O	·
936	F F O N O O O O O O O O O O O O O O O O	
937	NH NHO	
938	NH N O	

No.	FORMULA	NMR or mass
939	NH NH O	
940	NH NH O	
941	NH O NH O	
942	NH NH O	

No.	FORMULA	NMR or mass
943	NH NH O	
944	NH O S	
945	NH NH O	
946	NH NH O	

No.	FORMULA	NMR or mass
947	NH NHO	
948	NH NH S	
949	NH NH S	
950	NH NH S	

No.	FORMULA	NMR or mass
951	NH NH S	
952	NH NH S	
953	O DH S	
954	S NH N N N N N N N N N N N N N N N N N N	

No.	FORMULA	NMR or mass
955	NH O NH O	
956	NH S	
957	F P P P P P P P P P P P P P P P P P P P	
958	NH NH O	

No.	FORMULA	NMR or mass
959	NH NH O	
960	NH NH S	
961	NH NH S	
962	NH NH S	

No.	FORMULA	NMR or mass
963	NH NH S	
964	NH NH S	
965	NH NH S	
966	NH NH S	

No.	FORMULA	NMR or mass
967	NH NH S	
968	NH NH S	
969	NH NH S	
970	2-(1-{[(cyclopropylmethyl)amino]carbonothioyl}piperidin-4-yl)-N-(4-methoxy-biphenyl-2-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
971	N-biphenyl-2-yl-2-(1-{[(cyclopropylmethyl)amino]carbonothioyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	
972	NH N	
973	S S S S S S S S S S S S S S S S S S S	
974	NH NH N	

No.	FORMULA	NMR or mass
975	NH NH N	
976	NH NH N	
977	F F O HN N	
978	NH N N	

No.	FORMULA	NMR or mass
979	NH N	
980	NH N N	
981	N-[2-pyrrolidin-1-yl-5-(trifluoromethyl)phenyl]-2-[1-(3,3,3-trifluoropropyl)-piperidin-4-yl]-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
982	N-(2-piperidin-1-ylphenyl)-2-[1-(3,3,3-trifluoropropyl)piperidin-4-yl]-1,3-thiazole-4-carboxamide	
983	N-(2-morpholin-4-ylphenyl)-2-[1-(4,4,4-trifluorobutyl)piperidin-4-yl]-1,3-thiazole-4-carboxamide	
984	NH N N	

No.	FORMULA	NMR or mass
985	NH N N	
986	NH NY	
987	2-[1-(3-phenylpropyl)piperidin-4-yl]-N-[2-pyrrolidin-1-yl-5-(trifluoromethyl)-phenyl]-1,3-thiazole-4-carboxamide	
988	NH N N	

No.	FORMULA	NMR or mass
989	NH NH N	
990	NH NH N	
991	F F O HN S	
992	OH NH NH NN NN NN NN NN NN NN NN NN NN NN	

No.	FORMULA	NMR or mass
993	F F O HN OH	
994	OH NH N	
995	F F O HN O O	
996	NH NN N	

No.	FORMULA	NMR or mass
997	NH NH N	
998	NH N	
999	NH NH NN	

No.	FORMULA	NMR or mass
1000	2-{1-[(2Z)-3-pyridin-4-ylprop-2-en-1-yl]piperidin-4-yl}-N-[2-pyrrolidin-1-yl-5-(trifluoromethyl)phenyl]-1,3-thiazole-4-carboxamide	
1001	2-{1-[(4-chlorophenoxy)acetyl]piperidin-4-yl}-N-(4'-ethylbiphenyl-2-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1002	2-{1-[(4-chlorophenoxy)acetyl]piperidin-4-yl}-N-(4'-fluorobiphenyl-2-yl)-1,3-thiazole-4-carboxamide	
1003	N-(4'-chlorobiphenyl-2-yl)-2-{1-[(4-chlorophenoxy)acetyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1004	2-{1-[(4-chlorophenoxy)acetyl]piperidin-4-yl}-N-(4'-methylbiphenyl-2-yl)-1,3-thiazole-4-carboxamide	
1005	2-{1-[(4-chlorophenoxy)acetyl]piperidin-4-yl}-N-(5-methylbiphenyl-2-yl)-1,3-thiazole-4-carboxamide	
1006	2-{1-[(4-chlorophenoxy)acetyl]piperidin-4-yl}-N-[3'-(trifluoromethyl)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1007	N-(4'-chloro-5-fluorobiphenyl-2-yl)-2-[1-(2-phenoxypropanoyl)piperidin-4-yl]-1,3-thiazole-4-carboxamide	
1008	2-[1-(ethylsulfonyl)piperidin-4-yl]-N-[4'-(trifluoromethoxy)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1009	2-[1-(ethylsulfonyl)piperidin-4-yl]-N-(4'-fluorobiphenyl-2-yl)-1,3-thiazole-4-carboxamide	
1010	N-(4'-chlorobiphenyl-2-yl)-2-[1-(ethylsulfonyl)piperidin-4-yl]-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1011	2-[1-(ethylsulfonyl)piperidin-4-yl]-N-(4'-methylbiphenyl-2-yl)-1,3-thiazole-4-carboxamide	
1012	O=S=O N S N HN CI	
1013	N-(4'-fluorobiphenyl-2-yl)-2-[1-(propylsulfonyl)piperidin-4-yl]-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1014	N-(4'-chlorobiphenyl-2-yl)-2-[1-(propylsulfonyl)piperidin-4-yl]-1,3-thiazole-4-carboxamide	
1015	N-(4'-methylbiphenyl-2-yl)-2-[1-(propylsulfonyl)piperidin-4-yl]-1,3-thiazole-4-carboxamide	
1016	N-(5-methylbiphenyl-2-yl)-2-[1-(propylsulfonyl)piperidin-4-yl]-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1017	NH NO O	
1018	2-methoxyethyl 4-[4-({[3'-(trifluoromethyl)biphenyl-2-yl]amino}carbonyl)-1,3-thiazol-2-yl]piperidine-1-carboxylate	
1019	NH NH O	

No.	FORMULA	NMR or mass
1020	NH NH O	
1021	N-ethyl-4-[4-({[4'-(trifluoromethoxy)biphenyl-2-yl]amino}carbonyl)-1,3-thiazol-2-yl]piperidine-1-carboxamide	
1022	N-ethyl-4-(4-{[(4'-fluorobiphenyl-2-yl)amino]carbonyl}-1,3-thiazol-2-yl)-piperidine-1-carboxamide	

No.	FORMULA	NMR or mass
1023	4-(4-{[(4'-chlorobiphenyl-2-yl)amino]carbonyl}-1,3-thiazol-2-yl)-N-ethyl-piperidine-1-carboxamide	
1024	NH NH O	
1025	NH NH O	
1026	NH NH O	

No.	FORMULA	NMR or mass
1027	N-allyl-4-[4-({[3'-(trifluoromethyl)biphenyl-2-yl]amino}carbonyl)-1,3-thiazol-2-yl]piperidine-1-carboxamide	
1028	ethyl ({4-[4-({[4'-(trifluoromethoxy)biphenyl-2-yl]amino}carbonyl)-1,3-thiazol-2-yl]piperidin-1-yl}carbonyl)carbamate	
1029	2-yripiperidin-1-yricarbonyricarbamate	

No.	FORMULA	NMR or mass
1030	ethyl N-{[4-(4-{[(4'-chlorobiphenyl-2-yl)amino]carbonyl}-1,3-thiazol-2-yl)-piperidin-1-yl]carbonyl}glycinate	
1031	ethyl N-{[4-(4-{[(4'-chloro-5-fluorobiphenyl-2-yl)amino]carbonyl}-1,3-thiazol-2-yl)piperidin-1-yl]carbonyl}glycinate	

No.	FORMULA	NMR or mass
1032	N-propyl-4-[4-({[4'-(trifluoromethoxy)biphenyl-2-yl]amino}carbonyl)-1,3-thiazol-2-yl]piperidine-1-carboxamide	
1033	4-(4-{[(4'-fluorobiphenyl-2-yl)amino]carbonyl}-1,3-thiazol-2-yl)-N-propyl-piperidine-1-carboxamide	

No.	FORMULA	NMR or mass
1034	4-(4-{[(4'-chlorobiphenyl-2-yl)amino]carbonyl}-1,3-thiazol-2-yl)-N-propyl-piperidine-1-carboxamide	
1035	NH NH O	
1036	NH NH O	

No.	FORMULA	NMR or mass
1037	NH NH S	
1038	NH NH S	
1039	NH NH S	
1040	NH NH S	

No.	FORMULA	NMR or mass
1041	SH O	
1042	O NH N N S	
1043	NH O NH O	

No.	FORMULA	NMR or mass
1044	2-{1-[(ethylamino)carbonothioyl]piperidin-4-yl}-N-[4'-(trifluoromethoxy)-biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
1045	NH NH S	
1046	NH NH S	
1047	NH NH S	

No.	FORMULA	NMR or mass
1048	NH NH S	
1049	S S NH N N N N N N N N N N N N N N N N N	
1050	NH NH S	
1051	NH S N N O HN F	

No.	FORMULA	NMR or mass
1052	NH S	·
1053	2-{1-[(acetylamino)carbonothioyl]piperidin-4-yl}-N-[4'-(trifluoromethoxy)-biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
1054	NH NN N	

No.	FORMULA	NMR or mass
1055	N-(4'-chlorobiphenyl-2-yl)-2-[1-(2-methyl-3-phenylpropanoyl)piperidin-4-yl]-1,3-thiazole-4-carboxamide	
1056	N-(4'-chloro-5-fluorobiphenyl-2-yl)-2-[1-(2-methyl-3-phenylpropanoyl)-piperidin-4-yl]-1,3-thiazole-4-carboxamide	
1057	NH NO	

No.	FORMULA	NMR or mass
1058	methyl (3R)-3-methyl-4-oxo-4-{4-[4-({[4'-(trifluoromethoxy)biphenyl-2-yl]-amino}carbonyl)-1,3-thiazol-2-yl]piperidin-1-yl}butanoate	
1059	methyl (3R)-4-[4-(4-{[(4'-chlorobiphenyl-2-yl)amino]carbonyl}-1,3-thiazol-2-yl)piperidin-1-yl]-3-methyl-4-oxobutanoate	
1060	O HN N N O	

No.	FORMULA	NMR or mass
1061		
1062	NH NH O	
1063		

No.	FORMULA	NMR or mass
1064	NH NO	
1065	2-[1-(3-pyridin-3-ylpropanoyl)piperidin-4-yl]-N-[4'-(trifluoromethoxy)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
1066	N-(4'-chlorobiphenyl-2-yl)-2-[1-(3-pyridin-3-ylpropanoyl)piperidin-4-yl]-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1067	NH NO	
1068	N-(4'-chloro-5-fluorobiphenyl-2-yl)-2-[1-(3-pyridin-3-ylpropanoyl)piperidin-4-yl]-1,3-thiazole-4-carboxamide	
1069	NH O S F	

No.	FORMULA	NMR or mass
1070	2-{1-[3-(3,4-difluorophenyl)propanoyl]piperidin-4-yl}-N-[4'-(trifluoromethoxy)-biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
1071	N-(4'-chlorobiphenyl-2-yl)-2-{1-[3-(3,4-difluorophenyl)propanoyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1072	2-{1-[3-(3,4-difluorophenyl)propanoyl]piperidin-4-yl}-N-(5-methylbiphenyl-2-yl)-1,3-thiazole-4-carboxamide	
1073	2-{1-[3-(3,4-difluorophenyl)propanoyl]piperidin-4-yl}-N-[3'-(trifluoromethyl)-biphenyl-2-yl]-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1074	N-(4'-chloro-5-fluorobiphenyl-2-yl)-2-{1-[3-(3,4-difluorophenyl)propanoyl]-piperidin-4-yl}-1,3-thiazole-4-carboxamide	
1075	2-{1-[3-(3-chlorophenyl)propanoyl]piperidin-4-yl}-N-(4'-ethylbiphenyl-2-yl)-	
1076	N-(4'-chlorobiphenyl-2-yl)-2-{1-[3-(3-chlorophenyl)propanoyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1077	2-{1-[3-(3-chlorophenyl)propanoyl]piperidin-4-yl}-N-[3'-(trifluoromethyl)-biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
1078	N-(4'-ethylbiphenyl-2-yl)-2-{1-[3-(2-fluorophenyl)propanoyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1079	NH NH NH NH NH NH NH NH NH NH	
1080	CI NH O N N N	
1081	F NH O F O O	

No.	FORMULA	NMR or mass
1082	NH ON NEW YORK ON THE STATE OF	
1083	NH ON N S F	
1084	NH N	-

No.	FORMULA	NMR or mass
1085	2-{1-[(2-chlorophenoxy)acetyl]piperidin-4-yl}-N-(4'-ethylbiphenyl-2-yl)-1,3-thiazole-4-carboxamide	
1086	N-(4'-chlorobiphenyl-2-yl)-2-{1-[(2-chlorophenoxy)acetyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	
1087	2-{1-[(2-chlorophenoxy)acetyl]piperidin-4-yl}-N-(4'-methylbiphenyl-2-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1088	2-{1-[(2-chlorophenoxy)acetyl]piperidin-4-yl}-N-[3'-(trifluoromethyl)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	4
1089	NH NNO	

No.	FORMULA	NMR or mass
1090	2-{1-[(pyridin-4-ylthio)acetyl]piperidin-4-yl}-N-[4'-(trifluoromethoxy)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
1091	N-(4'-fluorobiphenyl-2-yl)-2-{1-[(pyridin-4-ylthio)acetyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1092	N-(4'-chlorobiphenyl-2-yl)-2-{1-[(pyridin-4-ylthio)acetyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	
1093	thiazole-4-carboxamide	
1094	NH N O	

No.	FORMULA	NMR or mass
1095	N-(4'-chlorobiphenyl-2-yl)-2-[1-(4-oxopentanoyl)piperidin-4-yl]-1,3-thiazole-4-carboxamide	
1096	N-(4'-ethylbiphenyl-2-yl)-2-{1-[(4-fluorophenoxy)acetyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	
1097		

No.	FORMULA	NMR or mass
1098	S N O HN	
1099		
1100	S O HN HN F	
1101	NH NO	

No.	FORMULA	NMR or mass
1102	N-(4'-chlorobiphenyl-2-yl)-2-[1-(5-oxohexanoyl)piperidin-4-yl]-1,3-thiazole-4-carboxamide	
1103	NH NH N	
1104	2-[1-(5-oxohexanoyl)piperidin-4-yl]-N-[3'-(trifluoromethyl)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1105	NH NH N	
1106		
1107	2-{1-[3-(2-furyl)propanoyl]piperidin-4-yl}-N-[3'-(trifluoromethyl)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1108	2-{1-[(3-chlorophenoxy)acetyl]piperidin-4-yl}-N-(4'-ethylbiphenyl-2-yl)-1,3-thiazole-4-carboxamide	
1109	2-{1-[(3-chlorophenoxy)acetyl]piperidin-4-yl}-N-[4'-(trifluoromethoxy)-biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
1110	N-(4'-chlorobiphenyl-2-yl)-2-{1-[(3-chlorophenoxy)acetyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	,

No.	FORMULA	NMR or mass
1111	2-{1-[(3-chlorophenoxy)acetyl]piperidin-4-yl}-N-[3'-(trifluoromethyl)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
1112	NH CI	
1113	N-(4'-chlorobiphenyl-2-yl)-2-{1-[3-(2-chlorophenyl)propanoyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1114	2-{1-[3-(2-chlorophenyl)propanoyl]piperidin-4-yl}-N-[3'-(trifluoromethyl)-biphenyl-2-yl]-1,3-thiazole-4-carboxamide	.**
1115	2-{1-[3-(4-chlorophenyl)propanoyl]piperidin-4-yl}-N-(4'-ethylbiphenyl-2-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1116	N-(4'-chlorobiphenyl-2-yl)-2-{1-[3-(4-chlorophenyl)propanoyl]piperidin-4-yl}-	
	N-(4'-chlorobiphenyl-2-yl)-2-{1-[3-(4-chlorophenyl)propanoyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	
1117	HN O NH NO	
1118		

No.	FORMULA	NMR or mass
1119	NH NO	
1120	N-(4'-chlorobiphenyl-2-yl)-2-{1-[(ethylthio)acetyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	
1121	NH NO	

No.	FORMULA	NMR or mass
1122	2-{1-[(ethylthio)acetyl]piperidin-4-yl}-N-[3'-(trifluoromethyl)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
1123	N-(4'-chloro-5-fluorobiphenyl-2-yl)-2-{1-[(ethylthio)acetyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	
1124	NH NO	

No.	FORMULA	NMR or mass
1125	2-{1-[(4E)-hex-4-enoyl]piperidin-4-yl}-N-[4'-(trifluoromethoxy)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
1126	N-(4'-chlorobiphenyl-2-yl)-2-{1-[(4E)-hex-4-enoyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	
1127	2-{1-[(4E)-hex-4-enoyl]piperidin-4-yl}-N-[3'-(trifluoromethyl)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1128	N-(4'-chloro-5-fluorobiphenyl-2-yl)-2-{1-[(4E)-hex-4-enoyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	
1129	NH N O	
1130	N-(4'-chlorobiphenyl-2-yl)-2-{1-[4-(dimethylamino)-4-oxobutanoyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1131	NH NO	
1132	2-(1-hex-5-enoylpiperidin-4-yl)-N-[4'-(trifluoromethoxy)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
1133	N-(4'-chlorobiphenyl-2-yl)-2-(1-hex-5-enoylpiperidin-4-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1134	2-(1-hex-5-enoylpiperidin-4-yl)-N-[3'-(trifluoromethyl)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
1135	N-(4'-chloro-5-fluorobiphenyl-2-yl)-2-(1-hex-5-enoylpiperidin-4-yl)-1,3-thiazole-4-carboxamide	
1136	NH NH NO	

No.	FORMULA	NMR or mass
1137	N-(4'-chlorobiphenyl-2-yl)-2-[1-(3-ethoxypropanoyl)piperidin-4-yl]-1,3-thiazole-4-carboxamide	
1138	NH NO	
1139	O N N N N N N N N N N N N N N N N N N N	

No.	FORMULA	NMR or mass
1140	NH NH O	
1141	2-{1-[(methylthio)acetyl]piperidin-4-yl}-N-[4'-(trifluoromethoxy)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
1142	S N N N N N N N N N N N N N N N N N N N	

No.	FORMULA	NMR or mass
1143	N-(4'-chlorobiphenyl-2-yl)-2-{1-[(methylthio)acetyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	
1144	2-{1-[(methylthio)acetyl]piperidin-4-yl}-N-[3'-(trifluoromethyl)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
1145	N-(4'-chloro-5-fluorobiphenyl-2-yl)-2-{1-[(methylthio)acetyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1146	2-(1-{[(2-methylprop-2-en-1-yl)amino]carbonothioyl}piperidin-4-yl)-N-[4'-(trifluoromethoxy)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
1147	H S S	
1148	NH NH S	

No.	FORMULA	NMR or mass
1149	2-(1-{[(2-methylprop-2-en-1-yl)amino]carbonothioyl}piperidin-4-yl)-N-[3'-(trifluoromethyl)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
1150	2-{1-[(allylamino)carbonothioyl]piperidin-4-yl}-N-[4'-(trifluoromethoxy)-biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
1151	NH NH S	

No.	FORMULA	NMR or mass
1152	NH S	·
1153	2-{1-[(allylamino)carbonothioyl]piperidin-4-yl}-N-[3'-(trifluoromethyl)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
1154	2-(1-{[(2-furylmethyl)amino]carbonothioyl}piperidin-4-yl)-N-[4'-(trifluoromethoxy)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1155	NH NH S	
1156	2-(1-{[(2-furylmethyl)amino]carbonothioyl}piperidin-4-yl)-N-[3'-(trifluoromethyl)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
1157	methyl 2-[({4-[4-({[4'-(trifluoromethoxy)biphenyl-2-yl]amino}carbonyl)-1,3-thiazol-2-yl]piperidin-1-yl}carbonothioyl)amino]butanoate	

No.	FORMULA	NMR or mass
1158	NH N N N N O	
1159	NH NH N N N N N N N N N N N N N N N N N	
1160	methyl 2-[({4-[4-({[3'-(trifluoromethyl)biphenyl-2-yl]amino}carbonyl)-1,3-thiazol-2-yl]piperidin-1-yl}carbonothioyl)amino]butanoate	

No.	FORMULA	NMR or mass
1161	ethyl N-({4-[4-({[4'-(trifluoromethoxy)biphenyl-2-yl]amino}carbonyl)-1,3-thiazol-2-yl]piperidin-1-yl}carbonothioyl)glycinate	
1162	NH NH S	
1163	NH NH S	

No.	FORMULA	NMR or mass
1164	ethyl N-({4-[4-({[3'-(trifluoromethyl)biphenyl-2-yl]amino}carbonyl)-1,3-thiazol-2-yl]piperidin-1-yl}carbonothioyl)glycinate	
1165	ethyl N-({4-[4-({[4'-(trifluoromethoxy)biphenyl-2-yl]amino}carbonyl)-1,3-thiazol-2-yl]piperidin-1-yl}carbonothioyl)alaninate	
1166	thiazoi-z-yijpiperidin-1-yijcarbonothioyi)alaninate	

No.	FORMULA	NMR or mass
1167	NH NH N N N N N N N N N N N N N N N N N	
1168	ethyl N-({4-[4-({[3'-(trifluoromethyl)biphenyl-2-yl]amino}carbonyl)-1,3-thiazol-2-yl]piperidin-1-yl}carbonothioyl)alaninate	
1169	NH NH S	

No.	FORMULA	NMR or mass
1170	NH NH S	
1171	2-{1-[(ethylamino)carbonothioyl]piperidin-4-yl}-N-[3'-(trifluoromethyl)-biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
1172	2-{1-[(propylamino)carbonothioyl]piperidin-4-yl}-N-[4'-(trifluoromethoxy)-biphenyl-2-yl]-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1173	NH NH S	
1174	NH NH S	
1175	2-{1-[(propylamino)carbonothioyl]piperidin-4-yl}-N-[3'-(trifluoromethyl)-biphenyl-2-yl]-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1176	2-{1-[(butylamino)carbonothioyl]piperidin-4-yl}-N-[4'-(trifluoromethoxy)-biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
1177	NH NH S	
1178	NH NH S	

No.	FORMULA	NMR or mass
1179	2-{1-[(butylamino)carbonothioyl]piperidin-4-yl}-N-[3'-(trifluoromethyl)-biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
1180	2-{1-[(pentylamino)carbonothioyl]piperidin-4-yl}-N-[4'-(trifluoromethoxy)-biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
1181	NH NH S	

No.	FORMULA	NMR or mass
1182	NH S	
1183	2-{1-[(pentylamino)carbonothioyl]piperidin-4-yl}-N-[3'-(trifluoromethyl)-biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
1184	2-{1-[(isobutylamino)carbonothioyl]piperidin-4-yl}-N-[4'-(trifluoromethoxy)-biphenyl-2-yl]-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1185	NH NH S	
1186	NH NH S	
1187	HN S N N N N N N N N N N N N N N N N N N	

No.	FORMULA	NMR or mass
1188	2-(1-{[(3-methoxypropyl)amino]carbonothioyl}piperidin-4-yl)-N-[4'-(trifluoromethoxy)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
1189	NH S	
1190	NH NH N	

No.	FORMULA	NMR or mass
1191	2-(1-{[(3-methoxypropyl)amino]carbonothioyl}piperidin-4-yl)-N-[3'-(trifluoromethyl)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
1192	methyl N-({4-[4-({[4'-(trifluoromethoxy)biphenyl-2-yl]amino}carbonyl)-1,3-thiazol-2-yl]piperidin-1-yl}carbonothioyl)glycinate	
1193	NH NH S	

No.	FORMULA	NMR or mass
1194	O NH S	
1195	methyl N-({4-[4-({[3'-(trifluoromethyl)biphenyl-2-yl]amino}carbonyl)-1,3-thiazol-2-yl]piperidin-1-yl}carbonothioyl)glycinate	
1196	2-(1-{[(2-methoxyethyl)amino]carbonothioyl}piperidin-4-yl)-N-[4'-(trifluoro-methoxy)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1197	NH NH S	
1198	NH NH S	
1199	methyl N-({4-[4-({[4'-(trifluoromethoxy)biphenyl-2-yl]amino}carbonyl)-1,3-thiazol-2-yl]piperidin-1-yl}carbonothioyl)-beta-alaninate	

No.	FORMULA	NMR or mass
1200	NH NH S	
1201	NH NH S	
1202	HN S S S S S S S S S S S S S S S S S S S	

No.	FORMULA	NMR or mass
1203	2-(1-{[(1-methylbutyl)amino]carbonothioyl}piperidin-4-yl)-N-[4'-(trifluoro-methoxy)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
1204	NH N N N N N N N N N N N N N N N N N N	
1205	NH N N N N N N N N N N N N N N N N N N	

No.	FORMULA	NMR or mass
1206	2-(1-{[(1-methylbutyl)amino]carbonothioyl}piperidin-4-yl)-N-[3'-(trifluoromethyl)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
1207	2-(1-{[(2-methylbutyl)amino]carbonothioyl}piperidin-4-yl)-N-[4'-(trifluoro-methoxy)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
1208	NH NH NN S	

No.	FORMULA	NMR or mass
1209	NH NH S	
1210	2-(1-{[(2-methylbutyl)amino]carbonothioyl}piperidin-4-yl)-N-[3'-(trifluoro-methyl)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
1211	NH S N N N N N N N N N N N N N N N N N N	

No.	FORMULA	NMR or mass
1212	NH N N H	
1213	NH N	
1214	NH S N HN F F	
1215	2-(1-{[(3-methylbutyl)amino]carbonothioyl}piperidin-4-yl)-N-[4'-(trifluoro-methoxy)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1216	NH NH S	
1217	NH NH S	
1218	HN S N N N N N N N N N N N N N N N N N N	

No.	FORMULA	NMR or mass
1219	N-(4'-chlorobiphenyl-2-yl)-2-(1-pent-4-en-1-ylpiperidin-4-yl)-1,3-thiazole-4-carboxamide	
1220	NH NH N	
1221	N-(4'-chloro-5-fluorobiphenyl-2-yl)-2-(1-pent-4-en-1-ylpiperidin-4-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1222	N-[4'-(trifluoromethoxy)biphenyl-2-yl]-2-[1-(3,3,3-trifluoropropyl)piperidin-4-yl]-1,3-thiazole-4-carboxamide	
1223	N-(4'-fluorobiphenyl-2-yl)-2-[1-(3,3,3-trifluoropropyl)piperidin-4-yl]-1,3-thiazole-4-carboxamide	
1224	N-(4'-chlorobiphenyl-2-yl)-2-[1-(3,3,3-trifluoropropyl)piperidin-4-yl]-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1225	N-(4'-chloro-5-fluorobiphenyl-2-yl)-2-[1-(3,3,3-trifluoropropyl)piperidin-4-yl]-1,3-thiazole-4-carboxamide	
1226	N-(4'-chlorobiphenyl-2-yl)-2-[1-(2-methylpentyl)piperidin-4-yl]-1,3-thiazole-4-carboxamide	
1227	2-[1-(2-ethylhexyl)piperidin-4-yl]-N-[4'-(trifluoromethoxy)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1228	2-[1-(2-ethylhexyl)piperidin-4-yl]-N-(4'-fluorobiphenyl-2-yl)-1,3-thiazole-4-carboxamide	
1229	N-(4'-chlorobiphenyl-2-yl)-2-[1-(2-ethylhexyl)piperidin-4-yl]-1,3-thiazole-4-carboxamide	
1230	NH N N	

No.	FORMULA	NMR or mass
1231	2-[1-(2-ethylhexyl)piperidin-4-yl]-N-[3'-(trifluoromethyl)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
1232	N-(4'-chloro-5-fluorobiphenyl-2-yl)-2-[1-(2-ethylhexyl)piperidin-4-yl]-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1233	2-[1-(3-phenylpropyl)piperidin-4-yl]-N-[4'-(trifluoromethoxy)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
1234	NH NH N	
1235	OH NH N	

No.	FORMULA	NMR or mass
1236	2-[1-(5-hydroxypentyl)piperidin-4-yl]-N-[4'-(trifluoromethoxy)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
1237	N-(4'-fluorobiphenyl-2-yl)-2-[1-(5-hydroxypentyl)piperidin-4-yl]-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1238	N-(4'-chlorobiphenyl-2-yl)-2-[1-(5-hydroxypentyl)piperidin-4-yl]-1,3-thiazole-4-carboxamide	
1239	OH NH	
1240	OH NH NH NN N	

No.	FORMULA	NMR or mass
1241	2-[1-(5-hydroxypentyl)piperidin-4-yl]-N-[3'-(trifluoromethyl)biphenyl-2-yl]-1,3-thiazole-4-carboxamie	
1242	HO NO HE	
	N-(4'-chloro-5-fluorobiphenyl-2-yl)-2-[1-(5-hydroxypentyl)piperidin-4-yl]-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1243	NH N N	
1244	methyl 6-[4-(4-{[(4'-chloro-5-fluorobiphenyl-2-yl)amino]carbonyl}-1,3-thiazol-2-yl)piperidin-1-yl]hexanoate	
1245	NH NH N	

No.	FORMULA	NMR or mass
1246	2-{1-[(2Z)-3-(2-furyl)prop-2-en-1-yl]piperidin-4-yl}-N-[4'-(trifluoromethoxy)-biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
1247	N-(4'-fluorobiphenyl-2-yl)-2-{1-[(2Z)-3-(2-furyl)prop-2-en-1-yl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1248	N-(4'-chlorobiphenyl-2-yl)-2-{1-[(2Z)-3-(2-furyl)prop-2-en-1-yl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	
1249	NH N O	
1250	NH N O	

}

No.	FORMULA	NMR or mass
1251	2-{1-[(2Z)-3-(2-furyl)prop-2-en-1-yl]piperidin-4-yl}-N-[3'-(trifluoromethyl)-biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
1252	N-(4'-chloro-5-fluorobiphenyl-2-yl)-2-{1-[(2Z)-3-(2-furyl)prop-2-en-1-yl]-piperidin-4-yl}-1,3-thiazole-4-carboxamide	
1253	piperidin-4-yi)-1,3-tillazole-4-carboxamide	

No.	FORMULA	NMR or mass
1254	2-{1-[(6-methylpyridin-2-yl)methyl]piperidin-4-yl}-N-[4'-(trifluoromethoxy)-biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
1255	N-(4'-fluorobiphenyl-2-yl)-2-{1-[(6-methylpyridin-2-yl)methyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1256	N-(4'-chlorobiphenyl-2-yl)-2-{1-[(6-methylpyridin-2-yl)methyl]piperidin-4-yl}-	
1257	1,3-thiazole-4-carboxamide	
1258	2-{1-[(6-methylpyridin-2-yl)methyl]piperidin-4-yl}-N-[3'-(trifluoromethyl)-biphenyl-2-yl]-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1259	N-(4'-chloro-5-fluorobiphenyl-2-yl)-2-{1-[(6-methylpyridin-2-yl)methyl]-piperidin-4-yl}-1,3-thiazole-4-carboxamide	
1260	NH NH N	
1261	2-[1-(pyridin-3-ylmethyl)piperidin-4-yl]-N-[4'-(trifluoromethoxy)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1262	N-(4'-fluorobiphenyl-2-yl)-2-[1-(pyridin-3-ylmethyl)piperidin-4-yl]-1,3-thiazole-4-carboxamide	
1263	N-(4'-chlorobiphenyl-2-yl)-2-[1-(pyridin-3-ylmethyl)piperidin-4-yl]-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1264	2-[1-(pyridin-3-ylmethyl)piperidin-4-yl]-N-[3'-(trifluoromethyl)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
1265	N-(4'-chloro-5-fluorobiphenyl-2-yl)-2-[1-(pyridin-3-ylmethyl)piperidin-4-yl]-1,3-thiazole-4-carboxamide	
1266	NH NH NN N	

No.	FORMULA	NMR or mass
1267	2-[1-(quinolin-2-ylmethyl)piperidin-4-yl]-N-[4'-(trifluoromethoxy)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
1268	N-(4'-fluorobiphenyl-2-yl)-2-[1-(quinolin-2-ylmethyl)piperidin-4-yl]-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1269	N-(4'-chlorobiphenyl-2-yl)-2-[1-(quinolin-2-ylmethyl)piperidin-4-yl]-1,3-thiazole-4-carboxamide	
1270	NH N	
1271	NH N N N N N N N N N N N N N N N N N N	

No.	FORMULA	NMR or mass
1272	2-[1-(quinolin-2-ylmethyl)piperidin-4-yl]-N-[3'-(trifluoromethyl)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
1273	2-[1-(N-acetyl-beta-alanyl)piperidin-4-yl]-N-[4'-(trifluoromethoxy)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
1274	HN	

No.	FORMULA	NMR or mass
1275	HN N	
1276	O N O O O O O O O O O O O O O O O O O O	
1277	N N N N N N N N N N N N N N N N N N N	
1278		

No.	FORMULA	NMR or mass
1279	O N O OH	
1280	F F OH	
1281	O N S	
1282	NH O N S	
1283		

No.	FORMULA	NMR or mass
1284	F F	
1285		
1286		
1287	NH S	

No.	FORMULA	NMR or mass
1288		
1289	O NH S S	
1290	CI NO	
1291	CI NOH	

No.	FORMULA	NMR or mass
1292	O N S	
1293		
1294		
1295		

No.	FORMULA	NMR or mass
1296	O N O O O O O O O O O O O O O O O O O O	
1297		
1298		
1299		

No.	FORMULA	NMR or mass
1300	S N N N N N N N N N N N N N N N N N N N	
1301	S N	
1302	S N	
1303	HO N OH	

No.	FORMULA	NMR or mass
1304	S OH	
1305	HO NOH	
1306	S OH	
1307	о то	
1308	O O O O O O O O O O O O O O O O O O O	

No.	FORMULA	NMR or mass
1309	S-OH P-F	
1310		
1311	S N N N N N N N N N N N N N N N N N N N	
1312	S H N OH	

No.	FORMULA	NMR or mass
1313	S N O N O N O N O N O N O N O N O N O N	
1314	S N OH	
1315		
1316	S N N N N N N N N N N N N N N N N N N N	

No.	FORMULA	NMR or mass
1317	S N	
1318	HN S	
1319	S S S S S S S S S S S S S S S S S S S	
1320	HN S CI	

No.	FORMULA	NMR or mass
1321	HN S	
1322	HN D C	
1323	O N OH	
1324	O N OH	

No.	FORMULA	NMR or mass
1325	OH NH	
1326		
1327	OH N N N N N N N N N N N N N N N N N N N	
1328		

No.	FORMULA	NMR or mass
1329		
1330		
1331		
1332	F F O N H	

No.	FORMULA	NMR or mass
1333		
1334		
1335		
1336		

No.	FORMULA	NMR or mass
1337		
1338		
1339		
1340		

No.	FORMULA	NMR or mass
1341		
1342		
1343		
1344	HN N O N S	

No.	FORMULA	NMR or mass
1345		
1346		
1347		
1348		

No.	FORMULA	NMR or mass
1349		
1350		
1351	HN DO NO DO	
1352		

No.	FORMULA	NMR or mass
1353	4-(2-{1-[2-(benzyloxy)benzoyl]piperidin-4-yl}-1,3-thiazol-4-yl)-2,6-di-tert-butylphenol	
1354	F F F OH N H	
1355	F F F O N H	
1356	F F F S O N	

No.	FORMULA	NMR or mass
1357	F F F CI	
1358	O N O N O N O N O N O N O N O N O N O N	
1359	CI	
1360	CI N N H	

No.	FORMULA	NMR or mass
1361	O N N N N N N N N N N N N N N N N N N N	
1362		
1363		
1364		

No.	FORMULA	NMR or mass
1365	OH N N N N N N N N N N N N N N N N N N N	
1366		
1367	F F O N N N N N N N N N N N N N N N N N	
1368	N-(4'-fluorobiphenyl-2-yl)-2-[1-(2-methyl-3-phenylpropanoyl)piperidin-4-yl]-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1369	NH NO	
1370	methyl (3R)-4-[4-(4-{[(4'-fluorobiphenyl-2-yl)amino]carbonyl}-1,3-thiazol-2-yl)piperidin-1-yl]-3-methyl-4-oxobutanoate	
1371	O H O NH O	

No.	FORMULA	NMR or mass
1372	methyl (3R)-4-[4-(4-{[(4'-chloro-5-fluorobiphenyl-2-yl)amino]carbonyl}-1,3-thiazol-2-yl)piperidin-1-yl]-3-methyl-4-oxobutanoate	
1373		
1374	O ZH Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z	

No.	FORMULA	NMR or mass
1375	N-(4'-fluorobiphenyl-2-yl)-2-[1-(3-pyridin-3-ylpropanoyl)piperidin-4-yl]-1,3-thiazole-4-carboxamide	
1376	NH NO O	
1377	N N N N N N N N N N N N N N N N N N N	

No.	FORMULA	NMR or mass
1378	2-{1-[3-(3,4-difluorophenyl)propanoyl]piperidin-4-yl}-N-(4'-fluorobiphenyl-2-yl)-1,3-thiazole-4-carboxamide	·
1379	2-{1-[3-(3,4-difluorophenyl)propanoyl]piperidin-4-yl}-N-(4'-methylbiphenyl-2-yl)-1,3-thiazole-4-carboxamide	
1380	2-{1-[3-(3-chlorophenyl)propanoyl]piperidin-4-yl}-N-[4'-(trifluoromethoxy)-biphenyl-2-yl]-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1381	2-{1-[3-(3-chlorophenyl)propanoyl]piperidin-4-yl}-N-(4'-fluorobiphenyl-2-yl)-1,3-thiazole-4-carboxamide	
1382	2-{1-[3-(3-chlorophenyl)propanoyl]piperidin-4-yl}-N-(5-methylbiphenyl-2-yl)-	
1383	N-(4'-chloro-5-fluorobiphenyl-2-yl)-2-{1-[3-(3-chlorophenyl)propanoyl]-piperidin-4-yl}-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1384	2-{1-[3-(2-fluorophenyl)propanoyl]piperidin-4-yl}-N-[4'-(trifluoromethoxy)-biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
1385	2-{1-[3-(2-fluorophenyl)propanoyl]piperidin-4-yl}-N-(4'-methylbiphenyl-2-yl)-1,3-thiazole-4-carboxamide	
1386	2-{1-[3-(2-fluorophenyl)propanoyl]piperidin-4-yl}-N-(5-methylbiphenyl-2-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1387	2-{1-[3-(2-fluorophenyl)propanoyl]piperidin-4-yl}-N-[3'-(trifluoromethyl)-biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
1388	2-{1-[3-(3-fluorophenyl)propanoyl]piperidin-4-yl}-N-[4'-(trifluoromethoxy)-	
1389	biphenyl-2-yl]-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1390	2-{1-[(2-chlorophenoxy)acetyl]piperidin-4-yl}-N-[4'-(trifluoromethoxy)-biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
1391	NH N O	
1392	N N N N N N N N N N N N N N N N N N N	

No.	FORMULA	NMR or mass
1393	N-(4'-chloro-5-fluorobiphenyl-2-yl)-2-{1-[(pyridin-4-ylthio)acetyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	·
1394	N-(4'-ethylbiphenyl-2-yl)-2-(1-hex-2-ynoylpiperidin-4-yl)-1,3-thiazole-4-carboxamide	
1395	S N N N N N N N N N N N N N N N N N N N	

No.	FORMULA	NMR or mass
1396	O NH O NH O	
1397	N-(4'-chloro-5-fluorobiphenyl-2-yl)-2-[1-(4-oxopentanoyl)piperidin-4-yl]-1,3-thiazole-4-carboxamide	
1398	NH S O F	

No.	FORMULA	NMR or mass
1399	N-(4'-chlorobiphenyl-2-yl)-2-{1-[(4-fluorophenoxy)acetyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	
1400	N-(4'-chloro-5-fluorobiphenyl-2-yl)-2-{1-[(4-fluorophenoxy)acetyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	
1401	The strategy of the strategy o	

No.	FORMULA	NMR or mass
1402		
1403	S N N N N N N N N N N N N N N N N N N N	
1404	2-[1-(5-oxohexanoyl)piperidin-4-yl]-N-[4'-(trifluoromethoxy)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1405	N-(4'-fluorobiphenyl-2-yl)-2-[1-(5-oxohexanoyl)piperidin-4-yl]-1,3-thiazole-4-carboxamide	
1406	NH NO	
1407	O Y Y O HN F	

No.	FORMULA	NMR or mass
1408	N-(4'-fluorobiphenyl-2-yl)-2-{1-[3-(2-furyl)propanoyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	
1409	NH N O	
1410	N-(4'-chloro-5-fluorobiphenyl-2-yl)-2-{1-[3-(2-furyl)propanoyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1411	N-(4'-ethylbiphenyl-2-yl)-2-(1-pent-2-ynoylpiperidin-4-yl)-1,3-thiazole-4-carboxamide	
1412	2-{1-[(3-chlorophenoxy)acetyl]piperidin-4-yl}-N-(5-methylbiphenyl-2-yl)-1,3-thiazole-4-carboxamide	
1413	N-(4'-chloro-5-fluorobiphenyl-2-yl)-2-{1-[(3-chlorophenoxy)acetyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1414	2-{1-[3-(2-chlorophenyl)propanoyl]piperidin-4-yl}-N-[4'-(trifluoromethoxy)-biphenyl-2-yl]-1,3-thiazole-4-carboxamide	·
1415	2-{1-[3-(2-chlorophenyl)propanoyl]piperidin-4-yl}-N-(4'-fluorobiphenyl-2-yl)-1,3-thiazole-4-carboxamide	
1416	NH CI	

No.	FORMULA	NMR or mass
1417	2-{1-[3-(2-chlorophenyl)propanoyl]piperidin-4-yl}-N-(5-methylbiphenyl-2-yl)-1,3-thiazole-4-carboxamide	
1418	N-(4'-chloro-5-fluorobiphenyl-2-yl)-2-{1-[3-(2-chlorophenyl)propanoyl]-piperidin-4-yl}-1,3-thiazole-4-carboxamide	
1419		

No.	FORMULA	NMR or mass
1420	2-{1-[3-(4-chlorophenyl)propanoyl]piperidin-4-yl}-N-[3'-(trifluoromethyl)-biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
1421	N-(4'-chloro-5-fluorobiphenyl-2-yl)-2-{1-[3-(4-chlorophenyl)propanoyl]-piperidin-4-yl}-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1422	2-{1-[4-(methylamino)-4-oxobutanoyl]piperidin-4-yl}-N-[4'-(trifluoromethoxy)-biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
1423	HN O	
1424	2-{1-[4-(methylamino)-4-oxobutanoyl]piperidin-4-yl}-N-[3'-(trifluoromethyl)-biphenyl-2-yl]-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1425	N-(4'-chloro-5-fluorobiphenyl-2-yl)-2-{1-[4-(methylamino)-4-oxobutanoyl]-piperidin-4-yl}-1,3-thiazole-4-carboxamide	
1426	2-{1-[(ethylthio)acetyl]piperidin-4-yl}-N-(4'-fluorobiphenyl-2-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1427	N-(4'-fluorobiphenyl-2-yl)-2-{1-[(4E)-hex-4-enoyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	
1428	NH N	
1429	2-{1-[4-(dimethylamino)-4-oxobutanoyl]piperidin-4-yl}-N-[4'-(trifluoromethoxy)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1430	2-{1-[4-(dimethylamino)-4-oxobutanoyl]piperidin-4-yl}-N-(4'-fluorobiphenyl-2-yl)-1,3-thiazole-4-carboxamide	
1431	NH NHO	
1432	NH NH N	

No.	FORMULA	NMR or mass
1433	2-{1-[4-(dimethylamino)-4-oxobutanoyl]piperidin-4-yl}-N-[3'-(trifluoromethyl)-biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
1434	N-(4'-fluorobiphenyl-2-yl)-2-(1-hex-5-enoylpiperidin-4-yl)-1,3-thiazole-4-carboxamide	
1435	NH NH NO	

No.	FORMULA	NMR or mass
1436	2-[1-(3-ethoxypropanoyl)piperidin-4-yl]-N-[4'-(trifluoromethoxy)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
1437	2-[1-(3-ethoxypropanoyl)piperidin-4-yl]-N-(4'-fluorobiphenyl-2-yl)-1,3-thiazole-4-carboxamide	
1438	NH NO	

s

No.	FORMULA	NMR or mass
1439	N-(4'-chloro-5-fluorobiphenyl-2-yl)-2-[1-(3-ethoxypropanoyl)piperidin-4-yl]-1,3-thiazole-4-carboxamide	
1440	N-(4'-chlorobiphenyl-2-yl)-2-{1-[2-hydroxy-4-(methylthio)butanoyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	
1441	NH N O	

No.	FORMULA	NMR or mass
1442	2-{1-[(2R)-2-hydroxy-3-phenylpropanoyl]piperidin-4-yl}-N-[4'-(trifluoromethoxy)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
1443	N-(4'-chlorobiphenyl-2-yl)-2-{1-[(2R)-2-hydroxy-3-phenylpropanoyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1444	NH N	
1445	N-(4'-fluorobiphenyl-2-yl)-2-(1-pent-4-en-1-ylpiperidin-4-yl)-1,3-thiazole-4-carboxamide	
1446	NH N N	

No.	FORMULA	NMR or mass
1447	2-(1-pent-4-en-1-ylpiperidin-4-yl)-N-[3'-(trifluoromethyl)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
1448	N-(4'-ethylbiphenyl-2-yl)-2-[1-(3,3,3-trifluoropropyl)piperidin-4-yl]-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1449	N-(4'-methylbiphenyl-2-yl)-2-[1-(3,3,3-trifluoropropyl)piperidin-4-yl]-1,3-thiazole-4-carboxamide	,
1450	N-[3'-(trifluoromethyl)biphenyl-2-yl]-2-[1-(3,3,3-trifluoropropyl)piperidin-4-yl]-1,3-thiazole-4-carboxamide	
1451	N-(4'-fluorobiphenyl-2-yl)-2-[1-(2-methylpentyl)piperidin-4-yl]-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1452	NH N N	
1453	NH NH NS	
1454	NH N N	
1455	NH N N	

No.	FORMULA	NMR or mass
1456	NH N N	
1457	2-[1-(3-phenylpropyl)piperidin-4-yl]-N-[3'-(trifluoromethyl)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
1458	N-(4'-chloro-5-fluorobiphenyl-2-yl)-2-[1-(3-phenylpropyl)piperidin-4-yl]-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1459	methyl 6-{4-[4-({[4'-(trifluoromethoxy)biphenyl-2-yl]amino}carbonyl)-1,3-thiazol-2-yl]piperidin-1-yl}hexanoate	
1460	methyl 6-[4-(4-{[(4'-fluorobiphenyl-2-yl)amino]carbonyl}-1,3-thiazol-2-yl)-piperidin-1-yl]hexanoate	
1461	NH NN N	

No.	FORMULA	NMR or mass
1462	methyl 6-{4-[4-({[3'-(trifluoromethyl)biphenyl-2-yl]amino}carbonyl)-1,3-thiazol-2-yl]piperidin-1-yl}hexanoate	
1463	N-(4'-chloro-5-fluorobiphenyl-2-yl)-2-{1-[(2Z)-3-pyridin-4-ylprop-2-en-1-yl]-piperidin-4-yl}-1,3-thiazole-4-carboxamide	
1464	NH NN N	

No.	FORMULA	NMR or mass
1465	NH N	
1466	N-(4'-chloro-5-fluorobiphenyl-2-yl)-2-[1-(quinolin-2-ylmethyl)piperidin-4-yl]-1,3-thiazole-4-carboxamide	
1467	2-[1-(N-acetyl-beta-alanyl)piperidin-4-yl]-N-(4'-fluorobiphenyl-2-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1468	2-[1-(N-acetyl-beta-alanyl)piperidin-4-yl]-N-(4'-chlorobiphenyl-2-yl)-1,3-thiazole-4-carboxamide	
1469	2-[1-(N-acetyl-beta-alanyl)piperidin-4-yl]-N-(4'-chloro-5-fluorobiphenyl-2-yl)-1,3-thiazole-4-carboxamide	
1470	NH NH NH N	

No.	FORMULA	NMR or mass
1471	-s NH NH N	
1472	NH NH NH	·
1473	NH NO	
1474	NH NH NH NH NO	

No.	FORMULA	NMR or mass
1475	F F S S S S S S S S S S S S S S S S S S	
1476	NH NO	
1477	NH NH O	
1478	NH O S O S O S O S O S O S O S O S O S O	

No.	FORMULA	NMR or mass
1479	N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)pyridin-3-yl]-2-(1-{[(methylsulfonyl)-methyl]sulfonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	
1480	F O N S O S O S S O S O S S O	·
1481	2-(1-{[(methylsulfonyl)methyl]sulfonyl}piperidin-4-yl)-N-(2-piperidin-1-yl-phenyl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1482	N-(2-tert-butylphenyl)-2-(1-{[(methylsulfonyl)methyl]sulfonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	
1483	N-biphenyl-2-yl-2-(1-{[(methylsulfonyl)methyl]sulfonyl}piperidin-4-yl)-1,3-	
1484	thiazole-4-carboxamide NH NH S N S O II II O O	

No.	FORMULA	NMR or mass
1485	NH N	
1486	N N N N N N N N N N N N N N N N N N N	
1487	F F O HN N	
1488	NH N N	

No.	FORMULA	NMR or mass
1489	NH N N	
1490	NH NH N	
1491	NH NH N	
1492	NH NH NO	

No.	FORMULA	NMR or mass
1493	N N N S N O S N O S N O S N O O S N O O O O	
1494	NH N O	
1495	NH NH O	
1496	NH N	

No.	FORMULA	NMR or mass
1497	F O HN N F	
1498	2-{1-[3-(2-fluorophenyl)propanoyl]piperidin-4-yl}-N-(2-piperidin-1-ylphenyl)-1,3-thiazole-4-carboxamide	
1499	N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)pyridin-3-yl]-2-{1-[3-(3-fluorophenyl)-propanoyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1500	E F	
1501	N-(4-methoxybiphenyl-2-yl)-2-{1-[2,2,3,4,4,6,6,6-octafluoro-3,5,5-tris-(trifluoromethyl)hexanoyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	
1502	N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)pyridin-3-yl]-2-{1-[2,2,3,4,4,6,6,6-octa-fluoro-3,5,5-tris(trifluoromethyl)hexanoyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1503	2-{1-[2,2,3,4,4,6,6,6-octafluoro-3,5,5-tris(trifluoromethyl)hexanoyl]piperidin-4-yl}-N-[2-pyrrolidin-1-yl-5-(trifluoromethyl)phenyl]-1,3-thiazole-4-carboxamide	
1504		

No.	FORMULA	NMR or mass
1505	N-(2-tert-butylphenyl)-2-{1-[2,2,3,4,4,6,6,6-octafluoro-3,5,5-tris(trifluoro-methyl)hexanoyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	
1506	CF ₃ CF ₃ O N N H	
1507	CF ₃ CF ₃ O N N N N N N N N N N N N N N N N N N	

No.	FORMULA	NMR or mass
1508	2-{1-[(2-chlorophenoxy)acetyl]piperidin-4-yl}-N-(2-piperidin-1-ylphenyl)-1,3-thiazole-4-carboxamide	
1509	N-(4-methoxybiphenyl-2-yl)-2-{1-[(pyridin-4-ylthio)acetyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	
1510	2-(1-hex-2-ynoylpiperidin-4-yl)-N-(2-morpholin-4-ylphenyl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1511	2-[1-(4-oxopentanoyl)piperidin-4-yl]-N-[2-pyrrolidin-1-yl-5-(trifluoromethyl)-phenyl]-1,3-thiazole-4-carboxamide	
1512	NH NHO	
1513	NH NHO	
1514	NH ON NN ON NN NN NN NN NN NN NN NN NN NN	

No.	FORMULA	NMR or mass
1515	NH NO OH	
1516	N N N OH	
1517	NH NO	
1518		

No.	FORMULA	NMR or mass
1519	2-{1-[3-(4-chlorophenyl)propanoyl]piperidin-4-yl}-N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)pyridin-3-yl]-1,3-thiazole-4-carboxamide	
1520	ON S NH NO	
1521	NH NH O	

No.	FORMULA	NMR or mass
1522	F F O N S S S S S S S S S S S S S S S S S S	
	2-{1-[3-(4-oxo-2-thioxo-1,3-thiazolidin-3-yl)propanoyl]piperidin-4-yl}-N-[2-pyrrolidin-1-yl-5-(trifluoromethyl)phenyl]-1,3-thiazole-4-carboxamide	
1523	S S S S S S S S S S S S S S S S S S S	
1524	NH NO	
1525	NH NHO	

No.	FORMULA	NMR or mass
1526	NH NO	
1527	N N N O O O O O O O O O O O O O O O O O	
1528	NH NH O	
1529	NH NH NH O	

No.	FORMULA	NMR or mass
1530	N-(4-methoxybiphenyl-2-yl)-2-{1-[(2,2,2-trifluoroethyl)sulfonyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	
1531	N-[2-pyrrolidin-1-yl-5-(trifluoromethyl)phenyl]-2-{1-[(2,2,2-trifluoroethyl)-sulfonyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	
1532	N-(2-piperidin-1-ylphenyl)-2-{1-[(2,2,2-trifluoroethyl)sulfonyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1533	N-(2-tert-butylphenyl)-2-{1-[(2,2,2-trifluoroethyl)sulfonyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	
1534	N-biphenyl-2-yl-2-{1-[(2,2,2-trifluoroethyl)sulfonyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	
1535	F O N N N N N N N N N N N N N N N N N N	

No.	FORMULA	NMR or mass
1536	2-[1-(ethylsulfonyl)piperidin-4-yl]-N-(2-piperidin-1-ylphenyl)-1,3-thiazole-4-carboxamide	
1537	N-biphenyl-2-yl-2-[1-(ethylsulfonyl)piperidin-4-yl]-1,3-thiazole-4-	
1538	N-(4-methoxybiphenyl-2-yl)-2-[1-(propylsulfonyl)piperidin-4-yl]-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1539	2-[1-(propylsulfonyl)piperidin-4-yl]-N-[2-pyrrolidin-1-yl-5-(trifluoromethyl)-phenyl]-1,3-thiazole-4-carboxamide	
1540	N-(2-piperidin-1-ylphenyl)-2-[1-(propylsulfonyl)piperidin-4-yl]-1,3-thiazole-4-carboxamide	
1541	N-biphenyl-2-yl-2-[1-(propylsulfonyl)piperidin-4-yl]-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1542	2-[1-(butylsulfonyl)piperidin-4-yl]-N-(4-methoxybiphenyl-2-yl)-1,3-thiazole-4-carboxamide	
1543	2-[1-(butylsulfonyl)piperidin-4-yl]-N-[2-pyrrolidin-1-yl-5-(trifluoromethyl)-phenyl]-1,3-thiazole-4-carboxamide	
1544	2-[1-(butylsulfonyl)piperidin-4-yl]-N-(2-piperidin-1-ylphenyl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1545	N-biphenyl-2-yl-2-[1-(butylsulfonyl)piperidin-4-yl]-1,3-thiazole-4-carboxamide	
1546	2-[1-(butylsulfonyl)piperidin-4-yl]-N-(2-morpholin-4-ylphenyl)-1,3-thiazole-4-carboxamide	
1547	2-{1-[(2-pyridin-2-ylethyl)sulfonyl]piperidin-4-yl}-N-[2-pyrrolidin-1-yl-5-(trifluoromethyl)phenyl]-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1548	N-(2-piperidin-1-ylphenyl)-2-{1-[(2-pyridin-2-ylethyl)sulfonyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	
1549	N-biphenyl-2-yl-2-{1-[(2-pyridin-2-ylethyl)sulfonyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	
1550	NH NO O	

No.	FORMULA	NMR or mass
1551	NH NH O	
1552	F F O HN O O	
1553	NH O NHO	
1554	NH NH O	

No.	FORMULA	NMR or mass
1555	NH NH O	
1556	NH NH NH N	
1557	NH NH O	
1558	NH NH S	

No.	FORMULA	NMR or mass
1559	NH NH S	
1560	NH NH S	
1561	NH NH S	
1562	N N N NH NH S	

No.	FORMULA	NMR or mass
1563	F F O NH S	
1564	NH NH S	
1565	NH NH S	
1566	NH NH S	

No.	FORMULA	NMR or mass
1567	NH NH S	
1568	NH NH O	
1569	NH O NH O	
1570	NH NH S	

No.	FORMULA	NMR or mass
1571	NH NH S	
1572	F F N NH S	
1573	NH NH NH S	
1574	NH NH S	

No.	FORMULA	NMR or mass
1575	NH NH S	
1576	NH NH S	
1577	NH N N N O	
1578	NH NH NH NH NH NH NH NH NH NH NH NH NH N	

No.	FORMULA	NMR or mass
1579	2-{1-[(acetylamino)carbonothioyl]piperidin-4-yl}-N-[2-pyrrolidin-1-yl-5-(trifluoromethyl)phenyl]-1,3-thiazole-4-carboxamide	
1580	S N N N N N N N N N N N N N N N N N N N	
1581	NH N	
1582	NH N N N O	

No.	FORMULA	NMR or mass
1583	S NH NH O	
1584	E H N N N N N N N N N N N N N N N N N N	
1585	NH NH NN N	
1586	S S S S S S S S S S S S S S S S S S S	

No.	FORMULA	NMR or mass
1587	N-(2-piperidin-1-ylphenyl)-2-[1-(4,4,4-trifluorobutyl)piperidin-4-yl]-1,3-thiazole-4-carboxamide	
1588	NH N N	
1589	NH NH NH NNH NNH NNH NNH NNH NNH NNH NN	
1590	F F O N N N N N N N N N N N N N N N N N	

No.	FORMULA	NMR or mass
1591	NH NH N	
1592	NH N N	
1593	NH N	
1594	NH NH NH N	·
1595	NH N N	

No.	FORMULA	NMR or mass
1596	NH NH NS	
1597	NH NH NN N	
1598	NH NH NN N	
1599	NH N N	
1600	NH NH N	

No.	FORMULA	NMR or mass
1601	2-{1-[3-(methylthio)propyl]piperidin-4-yl}-N-[2-pyrrolidin-1-yl-5-(trifluoromethyl)phenyl]-1,3-thiazole-4-carboxamide	
1602	NH N	
1603	NH N N	
1604	NH NH N	

No.	FORMULA	NMR or mass
1605	NH N N	
1606	N N N N N N N N N N N N N N N N N N N	
1607	F F S N S	
1608	NH NH N	
1609	NH N N	

No.	FORMULA	NMR or mass
1610	NH NH N	
1611	NH NH S	
1612	NH N N	
1613	N N N N N N N N N N N N N N N N N N N	
1614	F O N N N N N N N N N N N N N N N N N N	

No.	FORMULA	NMR or mass
1615	NH NH N	
1616	NH NH N	
1617	NH N N	
1618	NH NH NN N	
1619	NH NH NN N	

No.	FORMULA	NMR or mass
1620	NH N N	
1621	NH N N	
1622	N N N O O NH N N N N N N N N N N N N N N	
1623	F F O HN N O	

No.	FORMULA	NMR or mass
1624	NH NH N	
1625	NH N N	
1626	NH N N	
1627	NH NH NH	
1628	NH N N	

No.	FORMULA	NMR or mass
1629	N N N N N N N N N N N N N N N N N N N	
1630	NH N N N	
1631	NH N N N N N N N N N N N N N N N N N N	
1632	NH N N N N N N N N N N N N N N N N N N	
1633	NH N N	

No.	FORMULA	NMR or mass
1634	NH N N N N N N N N N N N N N N N N N N	
1635	N N N N N N N N N N N N N N N N N N N	
1636	F F O HN N N	
1637	NH NH NN N	
1638	NH N N	

No.	FORMULA	NMR or mass
1639	NH N N N N N N N N N N N N N N N N N N	
1640	NH NH N	
1641	NH NH N	
1642	N N N N N N N N N N N N N N N N N N N	·

No.	FORMULA	NMR or mass
1643	F F O N N N N N N N N N N N N N N N N N	
1644	N N N N N N N N N N N N N N N N N N N	
1645	NH NN N	
1646	NH NN N	
1647	NH NH NN N	

No.	FORMULA	NMR or mass
1648	N N N N N N N N N N N N N N N N N N N	
1649	F F S N N	
1650	NH NN N	
1651	NH NH N	

No.	FORMULA	NMR or mass
1652	NH NH NN N	
1653		
1654	NH NH O	

No.	FORMULA	NMR or mass
1655	methyl (3R)-3-methyl-4-oxo-4-{4-[4-({[3'-(trifluoromethyl)biphenyl-2-yl]-amino}carbonyl)-1,3-thiazol-2-yl]piperidin-1-yl}butanoate	
1656	NH NO	
1657	2-{1-[(pyridin-2-ylthio)acetyl]piperidin-4-yl}-N-[4'-(trifluoromethoxy)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1658	N-(4'-fluorobiphenyl-2-yl)-2-{1-[(pyridin-2-ylthio)acetyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	
1659	N-(4'-chlorobiphenyl-2-yl)-2-{1-[(pyridin-2-ylthio)acetyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	
1660	NH NH NH O	

No.	FORMULA	NMR or mass
1661	NH NS	·
1662	2-{1-[(pyridin-2-ylthio)acetyl]piperidin-4-yl}-N-[3'-(trifluoromethyl)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
1663	N-(4'-chloro-5-fluorobiphenyl-2-yl)-2-{1-[(pyridin-2-ylthio)acetyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1664	2-{1-[3-(3-chlorophenyl)propanoyl]piperidin-4-yl}-N-(4'-methylbiphenyl-2-yl)-1,3-thiazole-4-carboxamide	
1665	2-{1-[3-(3-fluorophenyl)propanoyl]piperidin-4-yl}-N-(4'-methylbiphenyl-2-yl)-1,3-thiazole-4-carboxamide	
1666	2-{1-[3-(3-fluorophenyl)propanoyl]piperidin-4-yl}-N-[3'-(trifluoromethyl)-biphenyl-2-yl]-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1667	N-(4'-chloro-5-fluorobiphenyl-2-yl)-2-{1-[3-(3-fluorophenyl)propanoyl]-piperidin-4-yl}-1,3-thiazole-4-carboxamide	
1668	N-(4'-ethylbiphenyl-2-yl)-2-{1-[2,2,3,4,4,6,6,6-octafluoro-3,5,5-tris(trifluoro-methyl)hexanoyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1669	2-{1-[2,2,3,4,4,6,6,6-octafluoro-3,5,5-tris(trifluoromethyl)hexanoyl]piperidin-4-yl}-N-[4'-(trifluoromethoxy)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
1670	N-(4'-fluorobiphenyl-2-yl)-2-{1-[2,2,3,4,4,6,6,6-octafluoro-3,5,5-tris(trifluoromethyl)hexanoyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1671	N-(4'-chlorobiphenyl-2-yl)-2-{1-[2,2,3,4,4,6,6,6-octafluoro-3,5,5-tris(trifluoro-methyl)hexanoyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	
1672	N-(4'-methylbiphenyl-2-yl)-2-{1-[2,2,3,4,4,6,6,6-octafluoro-3,5,5-tris(trifluoro-methyl)hexanoyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1673	N-(5-methylbiphenyl-2-yl)-2-{1-[2,2,3,4,4,6,6,6-octafluoro-3,5,5-tris(trifluoro-methyl)hexanoyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	
1674	2-{1-[2,2,3,4,4,6,6,6-octafluoro-3,5,5-tris(trifluoromethyl)hexanoyl]piperidin-4-yl}-N-[3'-(trifluoromethyl)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1675	N-(4'-chloro-5-fluorobiphenyl-2-yl)-2-{1-[2,2,3,4,4,6,6,6-octafluoro-3,5,5-tris(trifluoromethyl)hexanoyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	
1676	NH NHO	
1677	2-{1-[3-(2-thienyl)propanoyl]piperidin-4-yl}-N-[4'-(trifluoromethoxy)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1678	N-(4'-fluorobiphenyl-2-yl)-2-{1-[3-(2-thienyl)propanoyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	
1679	N-(4'-chlorobiphenyl-2-yl)-2-{1-[3-(2-thienyl)propanoyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	
1680	NH NO	

No.	FORMULA	NMR or mass
1681	NH N O	
1682	2-{1-[3-(2-thienyl)propanoyl]piperidin-4-yl}-N-[3'-(trifluoromethyl)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
1683		

No.	FORMULA	NMR or mass
1684	2-{1-{(2-chlorophenoxy)acetyl]piperidin-4-yl}-N-(4'-fluorobiphenyl-2-yl)-1,3-thiazole-4-carboxamide	
1685	2-{1-[(2-chlorophenoxy)acetyl]piperidin-4-yl}-N-(5-methylbiphenyl-2-yl)-1,3-thiazole-4-carboxamide	
1686	N-(4'-chloro-5-fluorobiphenyl-2-yl)-2-{1-[(2-chlorophenoxy)acetyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1687	2-(1-hex-2-ynoylpiperidin-4-yl)-N-[4'-(trifluoromethoxy)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
1688	N-(4'-fluorobiphenyl-2-yl)-2-(1-hex-2-ynoylpiperidin-4-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1689	N-(4'-chlorobiphenyl-2-yl)-2-(1-hex-2-ynoylpiperidin-4-yl)-1,3-thiazole-4-carboxamide	
1690	2-(1-hex-2-ynoylpiperidin-4-yl)-N-(4'-methylbiphenyl-2-yl)-1,3-thiazole-4-carboxamide	
1691	2-(1-hex-2-ynoylpiperidin-4-yl)-N-(5-methylbiphenyl-2-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1692	2-(1-hex-2-ynoylpiperidin-4-yl)-N-[3'-(trifluoromethyl)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
1693	N-(4'-chloro-5-fluorobiphenyl-2-yl)-2-(1-hex-2-ynoylpiperidin-4-yl)-1,3-thiazole-4-carboxamide	
1694	2-[1-(4-oxopentanoyl)piperidin-4-yl]-N-[4'-(trifluoromethoxy)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1695	NH NO	
1696	2-[1-(4-oxopentanoyl)piperidin-4-yl]-N-[3'-(trifluoromethyl)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
1697	2-{1-[(4-fluorophenoxy)acetyl]piperidin-4-yl}-N-[4'-(trifluoromethoxy)-biphenyl-2-yl]-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1698	NH ON N= N= N= N= N= N= N= N= N= N= N= N= N=	
1699	NH O S N O F	
1700	F HN P	

No.	FORMULA	NMR or mass
1701	S N N HN	
1702	NH NO	
1703	OH O N N N N N N N N N N N N N N N N N N	

No.	FORMULA	NMR or mass
1704	N-(4'-fluorobiphenyl-2-yl)-2-[1-(2-hydroxyhexanoyl)piperidin-4-yl]-1,3-thiazole-4-carboxamide	
1705	N-(4'-chlorobiphenyl-2-yl)-2-[1-(2-hydroxyhexanoyl)piperidin-4-yl]-1,3-thiazole-4-carboxamide	
1706	NH NOO	

No.	FORMULA	NMR or mass
1707	OH OO OO	
1708	2-[1-(2-hydroxyhexanoyl)piperidin-4-yl]-N-[3'-(trifluoromethyl)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
1709	N-(4'-chloro-5-fluorobiphenyl-2-yl)-2-[1-(2-hydroxyhexanoyl)piperidin-4-yl]-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1710	N-(4'-fluorobiphenyl-2-yl)-2-(1-pent-2-ynoylpiperidin-4-yl)-1,3-thiazole-4-carboxamide	
1711	N-(4'-chlorobiphenyl-2-yl)-2-(1-pent-2-ynoylpiperidin-4-yl)-1,3-thiazole-4-carboxamide	
1712	N-(4'-methylbiphenyl-2-yl)-2-(1-pent-2-ynoylpiperidin-4-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1713	2-(1-pent-2-ynoylpiperidin-4-yl)-N-[3'-(trifluoromethyl)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
1714	N-(4'-chloro-5-fluorobiphenyl-2-yl)-2-(1-pent-2-ynoylpiperidin-4-yl)-1,3-thiazole-4-carboxamide	
1715	2-{1-[(3-chlorophenoxy)acetyl]piperidin-4-yl}-N-(4'-fluorobiphenyl-2-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1716	2-{1-[(3-chlorophenoxy)acetyl]piperidin-4-yl}-N-(4'-methylbiphenyl-2-yl)-1,3-thiazole-4-carboxamide	
1717	2-{1-[3-(4-chlorophenyl)propanoyl]piperidin-4-yl}-N-(4'-methylbiphenyl-2-yl)-1,3-thiazole-4-carboxamide	
1718	N-(4'-fluorobiphenyl-2-yl)-2-{1-[4-(methylamino)-4-oxobutanoyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1719	NH NH O	
1720	NH NH O	
1721	2-{1-[3-(4-oxo-2-thioxo-1,3-thiazolidin-3-yl)propanoyl]piperidin-4-yl}-N-[4'-(trifluoromethoxy)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1722	N-(4'-fluorobiphenyl-2-yl)-2-{1-[3-(4-oxo-2-thioxo-1,3-thiazolidin-3-yl)-propanoyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	
1723	N-(4'-chlorobiphenyl-2-yl)-2-{1-[3-(4-oxo-2-thioxo-1,3-thiazolidin-3-yl)-propanoyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	
1724	NH NO	

No.	FORMULA	NMR or mass
1725	NH NH O	
1726	2-{1-[3-(4-oxo-2-thioxo-1,3-thiazolidin-3-yl)propanoyl]piperidin-4-yl}-N-[3'-(trifluoromethyl)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
1727		

No.	FORMULA	NMR or mass
1728	NH NO	ı
1729	O N N N N N N N N N N N N N N N N N N N	
	N-(4'-chloro-5-fluorobiphenyl-2-yl)-2-{1-[4-(dimethylamino)-4-oxobutanoyl]-piperidin-4-yl}-1,3-thiazole-4-carboxamide	
1730	NH NO	

No.	FORMULA	NMR or mass
1731	NH NH O	,
1732	OH O Z HZ O HZ F F	
	2-{1-[2-hydroxy-4-(methylthio)butanoyl]piperidin-4-yl}-N-[4'-(trifluoro-methoxy)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
1733	N-(4'-fluorobiphenyl-2-yl)-2-{1-[2-hydroxy-4-(methylthio)butanoyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1734	NH NO OH	
1735	NH NO	
1736	2-{1-[2-hydroxy-4-(methylthio)butanoyl]piperidin-4-yl}-N-[3'-(trifluoromethyl)-biphenyl-2-yl]-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1737	N-(4'-chloro-5-fluorobiphenyl-2-yl)-2-{1-[2-hydroxy-4-(methylthio)butanoyl]-piperidin-4-yl}-1,3-thiazole-4-carboxamide	
1738	HO H	
1739	N-(4'-fluorobiphenyl-2-yl)-2-{1-[(2R)-2-hydroxy-3-phenylpropanoyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1740	HO HO S	
1741	HO HO NO	•
1742	2-{1-[(2R)-2-hydroxy-3-phenylpropanoyl]piperidin-4-yl}-N-[3'-(trifluoro-methyl)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1743	N-(4'-chloro-5-fluorobiphenyl-2-yl)-2-{1-[(2R)-2-hydroxy-3-phenylpropanoyl]-piperidin-4-yl}-1,3-thiazole-4-carboxamide	
1744	N-(4'-chloro-5-fluorobiphenyl-2-yl)-2-{1-[(4-chlorophenoxy)acetyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1745	N-(4'-ethylbiphenyl-2-yl)-2-(1-{[(methylsulfonyl)methyl]sulfonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	
1746	2-(1-{[(methylsulfonyl)methyl]sulfonyl}piperidin-4-yl)-N-[4'-(trifluoromethoxy)-biphenyl-2-yl]-1,3-thiazole-4-carboxamide	,
1747		

No.	FORMULA	NMR or mass
1748		
1749	N-(4'-methylbiphenyl-2-yl)-2-(1-{[(methylsulfonyl)methyl]sulfonyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	
1750	NH S S S S S S S S S S S S S S S S S S S	

No.	FORMULA	NMR or mass
1751		
	2-(1-{[(methylsulfonyl)methyl]sulfonyl}piperidin-4-yl)-N-[3'-(trifluoromethyl)-biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
1752	N-(4'-chloro-5-fluorobiphenyl-2-yl)-2-(1-{[(methylsulfonyl)methyl]sulfonyl}-piperidin-4-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1753	N-(4'-ethylbiphenyl-2-yl)-2-{1-[(2,2,2-trifluoroethyl)sulfonyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	
	F F	
1754	F O S O HZ	
	2-{1-[(2,2,2-trifluoroethyl)sulfonyl]piperidin-4-yl}-N-[4'-(trifluoromethoxy)-biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
1755	N-(4'-fluorobiphenyl-2-yl)-2-{1-[(2,2,2-trifluoroethyl)sulfonyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1756	NH O S N S N S S S S S S S S S S S S S S S	
	N-(4'-chlorobiphenyl-2-yl)-2-{1-[(2,2,2-trifluoroethyl)sulfonyl]piperidin-4-yl}- 1,3-thiazole-4-carboxamide	
1757	N-(4'-methylbiphenyl-2-yl)-2-{1-[(2,2,2-trifluoroethyl)sulfonyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	
1758	N-(5-methylbiphenyl-2-yl)-2-{1-[(2,2,2-trifluoroethyl)sulfonyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1759	2-{1-[(2,2,2-trifluoroethyl)sulfonyl]piperidin-4-yl}-N-[3'-(trifluoromethyl)-biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
1760	N-(4'-chloro-5-fluorobiphenyl-2-yl)-2-{1-[(2,2,2-trifluoroethyl)sulfonyl]-piperidin-4-yl}-1,3-thiazole-4-carboxamide	
1761	N-(4'-ethylbiphenyl-2-yl)-2-[1-(ethylsulfonyl)piperidin-4-yl]-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1762	O N N N N N N N N N N N N N N N N N N N	
	/ 2-[1-(ethylsulfonyl)piperidin-4-yl]-N-(5-methylbiphenyl-2-yl)-1,3-thiazole-4-carboxamide	
1763		·
	F F HN	
	2-[1-(ethylsulfonyl)piperidin-4-yl]-N-[3'-(trifluoromethyl)biphenyl-2-yl]-1,3- thiazole-4-carboxamide	
1764	NH O N N N N N N N N N N N N N N N N N N	
	N-(4'-ethylbiphenyl-2-yl)-2-[1-(propylsulfonyl)piperidin-4-yl]-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1765	2-[1-(propylsulfonyl)piperidin-4-yl]-N-[4'-(trifluoromethoxy)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
1766	thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1767	2-[1-(propylsulfonyl)piperidin-4-yl]-N-[3'-(trifluoromethyl)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
1768	2-[1-(butylsulfonyl)piperidin-4-yl]-N-(4'-ethylbiphenyl-2-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1769	2-[1-(butylsulfonyl)piperidin-4-yl]-N-[4'-(trifluoromethoxy)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
1770	2-[1-(buty sulfonyl)piperidin-4-yl]-N-(4'-fluorobiphenyl-2-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1771	2-[1-(butylsulfonyl)piperidin-4-yl]-N-(4'-chlorobiphenyl-2-yl)-1,3-thiazole-4-carboxamide	
1772	2-[1-(butylsulfonyl)piperidin-4-yl]-N-(4'-methylbiphenyl-2-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1773	2-[1-(butylsulfonyl)piperidin-4-yl]-N-(5-methylbiphenyl-2-yl)-1,3-thiazole-4-carboxamide	
1774	2-[1-(buty su fony)piperidin-4-yl]-N-[3'-(trifluoromethyl)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	·

No.	FORMULA	NMR or mass
1775	O—S=O HN S N E 2-[1-(butylsulfonyl)piperidin-4-yl]-N-(4'-chloro-5-fluorobiphenyl-2-yl)-1,3-thiazole-4-carboxamide	
1776	N-(4'-ethylbiphenyl-2-yl)-2-{1-[(2-pyridin-2-ylethyl)sulfonyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1777	2-{1-[(2-pyridin-2-ylethyl)sulfonyl]piperidin-4-yl}-N-[4'-(trifluoromethoxy)-biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
1778	N-(4'-fluorobiphenyl-2-yl)-2-{1-[(2-pyridin-2-ylethyl)sulfonyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1779	N-(4'-chlorobiphenyl-2-yl)-2-{1-[(2-pyridin-2-ylethyl)sulfonyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	
1780	N-(4'-methylbiphenyl-2-yl)-2-{1-[(2-pyridin-2-ylethyl)sulfonyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1781	N-(5-methylbiphenyl-2-yl)-2-{1-[(2-pyridin-2-ylethyl)sulfonyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	
1782	2-{1-[(2-pyridin-2-ylethyl)sulfonyl]piperidin-4-yl}-N-[3'-(trifluoromethyl)-biphenyl-2-yl]-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1783	N-(4'-chloro-5-fluorobiphenyl-2-yl)-2-{1-[(2-pyridin-2-ylethyl)sulfonyl]-	
1784	N-ethyl-4-[4-({[3'-(trifluoromethyl)biphenyl-2-yl]amino}carbonyl)-1,3-thiazol-2-yl]piperidine-1-carboxamide	
1785	NH NH O	

No.	FORMULA	NMR or mass
1786	ethyl {[4-(4-{[(4'-fluorobiphenyl-2-yl)amino]carbonyl}-1,3-thiazol-2-yl)-piperidin-1-yl]carbonyl}carbamate	
1787	ethyl {[4-(4-{[(4'-chlorobiphenyl-2-yl)amino]carbonyl}-1,3-thiazol-2-yl)-piperidin-1-yl]carbonyl}carbamate	
1788	piperidiri- 1-yijcarboniyi,carbaniate	

No.	FORMULA	NMR or mass
1789	ethyl ({4-[4-({[3'-(trifluoromethyl)biphenyl-2-yl]amino}carbonyl)-1,3-thiazol-2-yl]piperidin-1-yl}carbonyl)carbamate	
1790	ethyl {[4-(4-{[(4'-chloro-5-fluorobiphenyl-2-yl)amino]carbonyl}-1,3-thiazol-2-yl)piperidin-1-yl]carbonyl}carbamate	

No.	FORMULA	NMR or mass
1791	ethyl N-({4-[4-({[3'-(trifluoromethyl)biphenyl-2-yl]amino}carbonyl)-1,3-thiazol-2-yl]piperidin-1-yl}carbonyl)glycinate	
1792	NH NH O	·
1793	N-propyl-4-[4-({[3'-(trifluoromethyl)biphenyl-2-yl]amino}carbonyl)-1,3-thiazol-	
	N-propyl-4-[4-({[3'-(trifluoromethyl)biphenyl-2-yl]amino}carbonyl)-1,3-thiazol-2-yl]piperidine-1-carboxamide	

No.	FORMULA	NMR or mass
1794	NH NH S	
1795	2-(1-{[(methoxymethyl)amino]carbonothioyl}piperidin-4-yl)-N-[4'-(trifluoromethoxy)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
1796	N-(4'-fluorobiphenyl-2-yl)-2-(1-{[(methoxymethyl)amino]carbonothioyl}-piperidin-4-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1797	N-(4'-chlorobiphenyl-2-yl)-2-(1-{[(methoxymethyl)-amino]carbonothioyl}-piperidin-4-yl)-1,3-thiazole-4-carboxamide	
1798	NH NH S	
1799	NH NH S	

No.	FORMULA	NMR or mass
1800	2-(1-{[(methoxymethyl)amino]carbonothioyl}piperidin-4-yl)-N-[3'-(trifluoromethyl)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
1801	N-(4'-chloro-5-fluorobiphenyl-2-yl)-2-(1-{[(methoxymethyl)amino]carbono-thioyl}piperidin-4-yl)-1,3-thiazole-4-carboxamide	
1802	NH NH O	-

No.	FORMULA	NMR or mass
1803	ethyl ({4-[4-({[4'-(trifluoromethoxy)biphenyl-2-yl]amino}carbonyl)-1,3-thiazol-2-yl]piperidin-1-yl}carbonothioyl)carbamate	
1804	ethyl {[4-(4-{[(4'-fluorobiphenyl-2-yl)amino]carbonyl}-1,3-thiazol-2-yl)-piperidin-1-yl]carbonothioyl}carbamate	

No.	FORMULA	NMR or mass
1805	ethyl {[4-(4-{[(4'-chlorobiphenyl-2-yl)amino]carbonyl}-1,3-thiazol-2-yl)-piperidin-1-yl]carbonothioyl}carbamate	
1806	NH NH O	
1807		

No.	FORMULA	NMR or mass
1808	ethyl {[4-(4-{[(4'-chloro-5-fluorobiphenyl-2-yl)amino]carbonyl}-1,3-thiazol-2-yl)piperidin-1-yl]carbonothioyl}carbamate	
1809	NH NH S	·
1810	HN S N N N N N N N N N N N N N N N N N N	

No.	FORMULA	NMR or mass
1811	2-(1-{[(2E)-but-2-en-1-ylamino]carbonothioyl}piperidin-4-yl)-N-(4'-fluoro-biphenyl-2-yl)-1,3-thiazole-4-carboxamide	
1812	2-(1-{[(2E)-but-2-en-1-ylamino]carbonothioyl}piperidin-4-yl)-N-(4'-chlorobiphenyl-2-yl)-1,3-thiazole-4-carboxamide	·
1813	NH NH S	

No.	FORMULA	NMR or mass
1814	NH S	
1815	2-(1-{[(2E)-but-2-en-1-ylamino]carbonothioyl}piperidin-4-yl)-N-[3'-(trifluoromethyl)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
1816	2-(1-{[(2E)-but-2-en-1-ylamino]carbonothioyl}piperidin-4-yl)-N-(4'-chloro-5-fluorobiphenyl-2-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1817	NH N N N N O	
1818	2-{1-[(acetylamino)carbonothioyl]piperidin-4-yl}-N-(4'-fluorobiphenyl-2-yl)-1,3-thiazole-4-carboxamide	
1819	2-{1-[(acetylamino)carbonothioyl]piperidin-4-yl}-N-(4'-chlorobiphenyl-2-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1820	NH N N N N N N N N N N N N N N N N N N	
1821	SH NH O	·
1822	2-{1-[(acetylamino)carbonothioyl]piperidin-4-yl}-N-[3'-(trifluoromethyl)-biphenyl-2-yl]-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1823	2-{1-[(acetylamino)carbonothioyl]piperidin-4-yl}-N-(4'-chloro-5-fluoro-biphenyl-2-yl)-1,3-thiazole-4-carboxamide	
1824	S S S S S S S S S S S S S S S S S S S	
1825	2-{1-[2-methyl-2-(methyldithio)propyl]piperidin-4-yl}-N-[4'-(trifluoromethoxy)-biphenyl-2-yl]-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1826	N-(4'-fluorobiphenyl-2-yl)-2-{1-[2-methyl-2-(methyldithio)propyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	
1827	N-(4'-chlorobiphenyl-2-yl)-2-{1-[2-methyl-2-(methyldithio)propyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	
1828	NH NN N	

No.	FORMULA	NMR or mass
1829	NH NH NN N	
1830	2-{1-[2-methyl-2-(methyldithio)propyl]piperidin-4-yl}-N-[3'-(trifluoromethyl)-biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
1831	N-(4'-chloro-5-fluorobiphenyl-2-yl)-2-{1-[2-methyl-2-(methyldithio)propyl]-piperidin-4-yl}-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1832	2-(1-pent-4-en-1-ylpiperidin-4-yl)-N-[4'-(trifluoromethoxy)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	-
1833	N-(5-methylbiphenyl-2-yl)-2-[1-(3,3,3-trifluoropropyl)piperidin-4-yl]-1,3-thiazole-4-carboxamide	
1834	NH N N	

No.	FORMULA	NMR or mass
1835	2-[1-(2-methylbutyl)piperidin-4-yl]-N-[4'-(trifluoromethoxy)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
1836	N-(4'-fluorobiphenyl-2-yl)-2-[1-(2-methylbutyl)piperidin-4-yl]-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1837	N-(4'-chlorobiphenyl-2-yl)-2-[1-(2-methylbutyl)piperidin-4-yl]-1,3-thiazole-4-carboxamide	
1838	NH NN N	
1839	NH NN N	

No.	FORMULA	NMR or mass
1840	2-[1-(2-methylbutyl)piperidin-4-yl]-N-[3'-(trifluoromethyl)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
1841	N-(4'-chloro-5-fluorobiphenyl-2-yl)-2-[1-(2-methylbutyl)piperidin-4-yl]-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1842	NH N N	
1843	2-[1-(2-methylpentyl)piperidin-4-yl]-N-[4'-(trifluoromethoxy)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
1844	NH N N	

No.	FORMULA	NMR or mass
1845	2-[1-(2-methylpentyl)piperidin-4-yl]-N-[3'-(trifluoromethyl)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
1846	N-(4'-chloro-5-fluorobiphenyl-2-yl)-2-[1-(2-methylpentyl)piperidin-4-yl]-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1847	NH N	
1848	2-(1-propylpiperidin-4-yl)-N-[4'-(trifluoromethoxy)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
1849	Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z	

No.	FORMULA	NMR or mass
1850	N-(4'-chlorobiphenyl-2-yl)-2-(1-propylpiperidin-4-yl)-1,3-thiazole-4-carboxamide	
1851	NH N N	
1852	NH N N	

No.	FORMULA	NMR or mass
1853	2-(1-propylpiperidin-4-yl)-N-[3'-(trifluoromethyl)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
1854	N-(4'-chloro-5-fluorobiphenyl-2-yl)-2-(1-propylpiperidin-4-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1855	N N N N N N N N N N N N N N N N N N N	
	N-(4'-fluorobiphenyl-2-yl)-2-[1-(3-phenylpropyl)piperidin-4-yl]-1,3-thiazole-4-carboxamide	
1856	N-(4'-chlorobiphenyl-2-yl)-2-[1-(3-phenylpropyl)piperidin-4-yl]-1,3-thiazole-4-carboxamide	
1857	NH NH N	

No.	FORMULA	NMR or mass
1858	2-{1-[3-(methylthio)propyl]piperidin-4-yl}-N-[4'-(trifluoromethoxy)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
1859	N-(4'-fluorobiphenyl-2-yl)-2-{1-[3-(methylthio)propyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1860	N-(4'-chlorobiphenyl-2-yl)-2-{1-[3-(methylthio)propyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	
1861	NH NH N	
1862	NH N N	

No.	FORMULA	NMR or mass
1863	2-{1-[3-(methylthio)propyl]piperidin-4-yl}-N-[3'-(trifluoromethyl)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
1864	N-(4'-chloro-5-fluorobiphenyl-2-yl)-2-{1-[3-(methylthio)propyl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1865	NH N N	
1866	2-(1-butylpiperidin-4-yl)-N-[4'-(trifluoromethoxy)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
1867	2-(1-butylpiperidin-4-yl)-N-(4'-fluorobiphenyl-2-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1868	2-(1-butylpiperidin-4-yl)-N-(4'-chlorobiphenyl-2-yl)-1,3-thiazole-4-	
1869	2-(1-butylpiperidin-4-yl)-N-(4'-chlorobiphenyl-2-yl)-1,3-thiazole-4-carboxamide	
1870	NH N N	

No.	FORMULA	NMR or mass
1871	2-(1-butylpiperidin-4-yl)-N-[3'-(trifluoromethyl)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
1872	2-(1-butylpiperidin-4-yl)-N-(4'-chloro-5-fluorobiphenyl-2-yl)-1,3-thiazole-4-carboxamide	
1873	NH N N	

No.	FORMULA	NMR or mass
1874	2-(1-pentylpiperidin-4-yl)-N-[4'-(trifluoromethoxy)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
1875	N-(4'-fluorobiphenyl-2-yl)-2-(1-pentylpiperidin-4-yl)-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1876	N-(4'-chlorobiphenyl-2-yl)-2-(1-pentylpiperidin-4-yl)-1,3-thiazole-4-carboxamide	
1877	NH NH N	
1878	NH NH N	

No.	FORMULA	NMR or mass
1879	2-(1-pentylpiperidin-4-yl)-N-[3'-(trifluoromethyl)biphenyl-2-yl]-1,3-thiazole-4-carboxamide	
1880	N-(4'-chloro-5-fluorobiphenyl-2-yl)-2-(1-pentylpiperidin-4-yl)-1,3-thiazole-4-carboxamide	ζ

No.	FORMULA	NMR or mass
1881	NH N N	
1882	methyl 6-[4-(4-{[(4'-chlorobiphenyl-2-yl)amino]carbonyl}-1,3-thiazol-2-yl)-piperidin-1-yl]hexanoate	
	piperidin-1-yiji iexarioate	·
1883	NH N N	

No.	FORMULA	NMR or mass
1884	N N N N N N N N N N N N N N N N N N N	
1885	2-{1-[(2Z)-3-pyridin-4-ylprop-2-en-1-yl]piperidin-4-yl}-N-[4'-(trifluoromethoxy)biphenyl-2-yl]-1,3-thiazole-4-carboxamide N N-(4'-fluorobiphenyl-2-yl)-2-{1-[(2Z)-3-pyridin-4-ylprop-2-en-1-yl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	

No.	FORMULA	NMR or mass
1886	S Z HN	
	N-(4'-chlorobiphenyl-2-yl)-2-{1-[(2Z)-3-pyridin-4-ylprop-2-en-1-yl]piperidin-4-yl}-1,3-thiazole-4-carboxamide	
1887	NH N N	
1888	NH N N	

No.	FORMULA	NMR or mass
1889	Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z	
1890	NH N N	
1891	NH NH NO	

No.	FORMULA	NMR or mass
1892	NH NO O	
1893	NH NNO	
1894		

No.	FORMULA	NMR or mass
1895	F F O N O N O N O N O N O N O N O N O N	ES+ 604,4
1896	F F O O O O O O O O O O O O O O O O O O	ES+ 632,4
1897	F F O N N N N N N N N N N N N N N N N N	ES+ 618,4

No.	FORMULA	NMR or mass
1898	F F O N N N N N N N N N N N N N N N N N	ES+ 662,4
1899	F F O N N N O N O N O N O N O N O N O N	ES+ 648,4
1900	F F O N N N N N N N N N N N N N N N N N	ES+ 488,3

No.	FORMULA	NMR or mass
1901	F F O NH S NH	ES+ 502,2
1902	F F O N N N N N N N N N N N N N N N N N	ES+ 603,3
1903	F F O N N N N N N N N N N N N N N N N N	ES+617,4

No.	FORMULA	NMR or mass
1904	F F S	ES- 616,3

5

10

15

20

25

30

BIOLOGICAL EXPERIMENTAL SECTION BIOLOGICAL ACTIVITY TESTS

Analysis of the inhibition of MTP activity

The inhibition of the activity of microsomal triglyceride transfer protein (MTP) was tested by using the following operating protocol.

The inhibition of MTP activity with a compound can be quantified by observing the inhibition of the transfer of a labelled triglyceride, from a donor particle to an acceptor particle, in the presence of MTP. The procedure for the preparation of MTP is based on the method by Wetterau and Zilversmit (*Biochem. Biophys. Acta* (1986) **875**, 610). A few grams of golden hamster liver are taken and then rinsed several times in a 250 mM sucrose solution at 0°C. All the following steps proceed at +4°C. A homogenate at a concentration of 50% in 250 mM sucrose is prepared using a Teflon mill and then centrifuged for 10 minutes at 10 000×g at +4°C. The supernatant is then centrifuged at 105 000×g for 75 minutes at +4°C. The supernatant is discarded and the microsomal pellet is taken up in 3 ml (per g of starting liver) of Tris/HCl 150 mM pH 8.0. 1-ml aliquot fractions are stored at -80°C until the time of use.

After thawing a fraction of microsomes (1 ml), 12 ml of refrigerated Tris/HCl 50 mM, KCl 50 mM, MgCl₂ 5 mM pH 7.4 buffers and 1.2 ml of deoxycholate (0.54% in water) are added. After incubation for 30 minutes at +4°C with gentle agitation, the suspension is centrifuged at 105 000×g for 75 minutes. The supernatant comprising the soluble MTP is dialysed against Tris/HCl 150 mM, NaCl 40 mM, EDTA 1 mM, 0.02% sodium azide pH 7.4 buffer (5 times one litre over 2-3 days). The MTP is stored at +4°C, is stable for at least 30 days and is used in unmodified form in the test.

The donor particles (liposomes) are prepared from 208 μ L of L-phosphatidylcholine at a concentration of 10 mg/ml in chloroform, and 480 μ L of [3H]-triolein at a concentration of 0.5 mCi/ml in toluene. After stirring, the solution is evaporated under nitrogen, taken up in 6 ml of Tris/HCl 50 mM, KCl 50 mM, MgCl₂ 5 mM pH 7.4 buffer and incubated in an ultrasound bath for 30 minutes at

room temperature. The liposomes are stored at +4°C and sonicated again for 10 minutes before each use.

The acceptor particles are biotinylated low density lipoproteins (LDL-biot). These particles are supplied by the company Amersham.

The reaction mixture is prepared in untreated ½ well white plates (Corning Costar) by addition, in the following order, of: 5 μ L of HEPES 50 mM, NaCl 150 mM, BSA 0.1% (w/v), 0.05% sodium azide (w/v), pH 7.4 buffer; 5 μ L of liposomes; 5 μ L of LDL-biot; 5 μ L of test products in DMSO; 5 μ L of MTP. After incubation for 18-24 hours at 37°C, the reaction is stopped by adding 100 μ L of Amersham SPA (Scintillation Proximity Assay) beads coupled to streptavidin, and the radioactivity is counted using a Top Count (Packard) machine at least one hour later. The inhibition of the transfer of the triglycerides with a compound is reflected by a reduction in the transferred radioactivity. The percentage of inhibition for a given compound is determined relative to controls that do not comprise compounds in the reaction mixture.

The results are expressed in terms of the IC_{50} , i.e. the concentration that allows a 50% inhibition of MTP. These results are summarized in Table A below for a number of representative compounds of the invention.

TABLE A

~	J	L	ı

5

10

15

Example	IC ₅₀ (nM)
1	51
3	57
4	720
5	660
6	385
7	926
8	892
9 .	58
10	167

5

10

15

20

Analysis of the secretion of apo B in the HepG2 human cell line:

The activity of a compound according to the invention can be evaluated by measuring the inhibition of apo B secretion in HepG2 cells.

The HepG2 cells (ECACC – No. 85011430) are used as model in the study of the in vitro hepatic secretion of lipoproteins (Dixon J. and Ginsberg H., *J. Lipid. Res.*, 1993, **34**,167-179).

The HepG2 cells are cultured in Dulbecco's modified Eagle's medium comprising 10% foetal calf serum (DMEM and FBS - Gibco) in 96-well plates under an atmosphere of 5% carbon dioxide for 24 hours (about 70% confluence).

The test compounds are dissolved at a concentration of 2 or 10 mM in dimethyl sulfoxide (DMSO). Serial dilutions (1:3.16) are made in DMSO and are added (1:200 – Robot Multimek Beckman) to the growth medium (200 μ L) and then finally incubated for 24 hours in the various wells containing the HepG2 cells.

The 24-hour culture supernatant diluted to 1:5 (phosphate-buffered saline: PBS comprising 1% bovine serum albumin) is tested according to a sandwich-ELISA method specific for human apo B.

The results are expressed in terms of IC_{50} , i.e. the concentration that produces a 50% inhibition of apo B secretion in the HepG2 cells.

These results are collated in Table B below for a number of representative compounds of the invention.

TABLE B

Example	IC ₅₀ (nM)
1	20
3	12
4	307
5	286
6	288
9	7